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Abstract
In developmental toxicity studies, multiple levels of correlation exist between multi-
ple outcomes of interest, complicating the estimation of models and risk assessment for
data collected from these studies. The ﬁrst chapter describes these multiple layers of cor-
relation, the problems that arise from them, and provides a detailed literature review of
the statistical methodology developed in order to address these problems.
The second chapter presents a method for modeling death and malformation out-
comes based on the bivariate Plackett-Dale distribution. The method deﬁnes three as-
sociation parameters to describe all litter-level correlations, and then derives bivariate
Plackett-Dale distributions based on these three associations. A pseudolikelihood based
on the probability mass functions of these distributions is used as a basis for estimating
the model parameters for death and malformation as well as the three association pa-
rameters. The model relaxes the conditional independence assumption and, unlike meth-
ods assuming an underlying latent normal distribution, allows for assuming death and
malformation following a Bernoulli distribution. The method is applied to two different
datasets and compared to other methods. The third chapter examines the small sample
behavior of the proposed model in chapter two with simulations. A comparison to other
methods, as well as an examination of the robustness of the model to misspeciﬁcation of
second order parameters is also presented.
The fourth chapter proposes a method for joint risk estimation for the proposed
iiimodel as well as for Carey’s method, an approach to modeling the data without assum-
ing conditional independence but with no development for joint risk estimation. These
methods were compared to methods that do assume conditional independence with the
two data sets used in chapter two, as well as with simulations.
Finally, the ﬁfth chapter summarizes the work presented and its speciﬁc contribution
to the ﬁeld of analysis of developmental toxicity data. The advantages and limitations of
the proposed model are discussed, as well as and possible avenues for future research.
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11.1 Introduction
Controlled animal studies play an important role in determining safe doses for environ-
mental toxic substances, drugs, and other chemical agents. Unlike studies that determine
efﬁcacy of treatments, studies that determine the toxicity of a substance cannot use hu-
man subjects. Thus, animal studies are often the only method where experimental data
can be obtained to assess toxicity. Along with other information, a proper analysis of ex-
perimental data can be helpful to regulators who need to decide on an acceptable dose
of the substance in question. These assays can range from studies for determining risk of
various types of cancer, an area where much of the early work in dose-response modeling
and risk assessment was developed, to studies for various non-cancer related toxicities
such as developmental and neurotoxicities.
In developmental toxicology studies, female animals (rodents or rabbits) are mated,
and then exposed to speciﬁc doses of the toxin under study. Although sample sizes may
vary by study, it is recommended at least 20 pregnant animals (dams) are assigned to
each dose group, and the study have at least three dose-groups in addition to a control
group (Kimmel and Price, 1990) (United States Environmental Protection Agency, 1991).
During gestation some embryos are resorbed back into the uterus while others mature
but do not survive gestation. These two embryolethality outcomes are known as resorp-
tions and fetal deaths, respectively. Fetuses that survive gestation are at risk for adverse
events including low birth weight and skeletal, visceral, and external malformations. Be-
fore natural birth, the dams are sacriﬁced and uterine contents are examined. The main
endpoints of interest are typically the number of embryolethalities, and for fetuses that
would be born, number of malformed fetuses (along with what kind of malformation)
and fetal weights and lengths. Table 1.1 exhibits summary data by dose from a develop-
mental toxicity data of Ethylene Glycol (EG) in rats reported by Price, Kimmel, Tyl, and
Marr (Price et al., 1985).
The trends observed in this study are consistent with what is seen in many develop-
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3mental toxicology assays. As is shown in Table 1.1, as dosage increases, the number of
implants tends to remain the same, due to dose being assigned after mating, while the
embryolethality rate tends to increase. Accordingly, litter size tends to decrease as dose
increases. Note that the standard deviation of litter size also tends to increase with dose,
illustrating litter response heterogeneity. For the live outcomes, malformation rate in-
creases while fetal weight decreases as dose increases. Note, also, that at the highest dose
of the study, standard deviation is signiﬁcantly larger for fetal weights, again indicating
more heterogeneity at the higheset dose level.
Developmental toxicity data can have complexities that make proper analysis chal-
lenging. First, the observed endpoints are clustered into litters, and animals from the
same litters tend to be correlated. Second, among living fetuses, different outcomes from
the same fetus may also be correlated. Third, live outcomes, such as fetal weight and
malformations, have a hierarchical relationship with death, which further complicates
the interpretation of the data. Calculating a proper safe dose needs to involve taking
into account both intra-litter and inter-outcome correlations, as well as the hierarchical
relationship between live fetal outcomes and number of dead fetuses in a given litter.
Figure 4.1 shows the relationships between the various commonly measured outcomes in
developmental toxicity.
1.2 Risk Assessment
Historically, the NOAEL (No Observed Adverse Effect Level) played an important role
in determining safes doses of toxins (Catalano and Ryan, 1994). The NOAEL is deﬁned
as the largest dose in a toxicology experiment in which no statistically signiﬁcant adverse
effect is observed. The NOAEL has several weaknesses that make it unattractive for de-
velopmental toxicology. First, NOAEL studies are restricted to actual doses from the
experiment, so a NOAEL may not even exist for a particular study. Second, the NOAEL
approach to ﬁnding safe doses encourages small sample size studies. Since the NOAEL
is determined by testing for a difference between adverse effects in the control group and
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Figure 1.1: Outcomes in Developmental Toxicity
the dose groups, small sample studies with low power are less likely to detect a statisti-
cally signiﬁcant difference at lower dose groups, leading, paradoxically, to higher accept-
able doses. Perhaps the most damning weakness for the NOAEL approach is it does not
provide any corresponding estimate of associated risk (Crump, 1984).
For these reasons, the NOAEL has been mostly abandoned in favor of the Bench-
mark Dose (BMD) method, ﬁrst proposed by Crump (Crump, 1984). Instead of using
an ANOVA-like approach where hypothesis tests are the major tool for determining safe
doses, Crump proposes ﬁtting a quantitative, continuous dose-response model to the ex-
perimental data, for example, in the form of p(dose) = f(0 + 1dose) where f is a link
function that ensures p(dose) is bounded between 0 and 1. Popular dose-response models
that have been used in developmental toxicology studies include the probit model, the
logit model, extreme-value model, and Weibull model:
Probit: p(dose) = (0 + 1dose)
Logit : p(dose) =
1
1 + exp[ (0 + 1dose)]
Extreme-Value : p(dose) = 1   exp[ exp(0 + 1dose)]
Weibull : p(dose) = 1   exp[ (0 + 1dose
)]
5When working with binary outcomes such as malformations or fetal deaths, the BMD is
deﬁned as the dose that corresponds to a pre-speciﬁed risk above background, known as
the Benchmark Dose (BMR). For example, if we were interested in an extra risk (BMR)
of 0:1, the BMD is the dose that solves r(dose) =
p(dose) p(0)
1 p(0) = 0:1, where p(dose) is the
probability of an adverse event at the speciﬁed dose, deﬁned by the dose-response model.
Alternatively, one can deﬁne the BMD using an additional risk function, in which case the
BMD solves p(dose)   p(0) = 0:1. Extra risk is sometimes preferred over additional risk
because, extra risk can be interpreted as the added risk of an adverse event out of those
not affected had they not received a dose.
Toxicologists are often also interested in continuous outcomes such as fetal weight.
For these endpoints, determining what outcomes constitute an adverse event is not as
clear as for binary endpoints. In this situation, a cut-off value is usually determined based
on the estimated mean and standard deviation of the control group. Given that, in the
case of fetal weight, an abnormally low outcome is cause for concern, the cut-off of point,
wc can follow the formula: wc = w(0)   k  sd(0) where sd(0) is the estimated standard
deviation for the control group and k is an arbitrary chosen threshold, generally ranging
from 1.5 to 3. Alternatively, a cutoff can be determined by a low percentile (for example,
1%) of the control group distribution. Once the cut-off is determined, probability of an
adverse event is deﬁned as p(w < wc) (Gaylor et al., 1998).
Because a relationship betwen the dose and outcome is speciﬁed, a BMD should exist
in every experiment and is not limited to the experimental doses. More importantly, a
conﬁdence interval can be placed on the BMD so that a 95% lower bound, called the
BMDL.95, can be calculated. Because a safe dose will be determined by the BMD’s lower
bound, this approach encourages larger sample size studies.
There are multiple methods for calculating the BMDL.95. One intuitive approach
is to let BMDL:95 = BMD   1:645
p
var(BMD). However, this approach allows for
nonsensical negative BMDLs. Kimmel and Gaylor propose calculating the dose that
corresponds an excess risk of 0.1 for the 95% upper conﬁdence bound of the dose-
6response curve (Kimmel and Gaylor, 1988). This translates to ﬁnding the dose that
solves ^ r(dose) + 1:645se(^ r(dose)) = 0:1, where se(^ r(dose)) is obtained using the delta
method. However this method is not invariant under parameter transformations. An-
other method, preferred by several authors, is to calculate conﬁdence bounds based on
likelihood ratio statistics. Let lmax be the unrestricted maximized log-likelihood and l1
the log-likelihood under some constraint. The dose that satisﬁes 2(lmax   l1) = 1:6452
and minimizes the BMD is a BMDL.95. This method is preferred since it is invariant un-
der transformations. However, it can only be used when a full likelihood distribution is
assumed.
The methods described above only use information from a single adverse outcome to
determine the safe dose. However, it is also important to consider the joint risk from mul-
tiple outcomes. Traditionally, when multiple outcomes are of interest, BMDs or NOAELs
are calculated for each outcome and the smallest of these doses is chosen as the safe dose.
In the case where adverse outcome are highly correlated, this approach is reasonable.
However, in general, this approach is not satisfactory. For example, consider a case where
there are two outcomes of interest, malformation and fetal weight. If two separate models
are ﬁt and two BMDs are calculated, one for each outcome, and the malformation BMD
is chosen as the ”more conservative” BMD, then the BMD may not take into account
the additional toxic effects the substance poses to fetal weight. If the two outcomes are
highly correlated, this additional toxic effect may be small. However, if the two outcomes
are nearly independent, this additional toxic effect may be quite large, and ignoring this
effect will lead to underestimating the safe dose (Ryan, 1992).
A more accurate approach would be to calculate a BMD based on the combined risk
of all outcomes, while still allowing separate descriptions of dose-response relationships
for each outcome. That is, instead of calculating a BMD for each outcome and choos-
ing the most conservative, it is more advantageous to be able calculate one BMD where
p(dose) is the probability of any adverse outcome at the speciﬁed dose (for example, the
probability of malformation or low fetal weight). Note that, in order to have a formula
7for the joint probability, p(dose), it is necessary to clearly deﬁne the correlations of the
multiples responses, in some cases within and between animals.
1.3 Methods for Accommodating Litter Effects
The litter effect is an ever present issue in the analysis of developmental toxicology data
and much of the early statistical work in this area focused on this problem. Outcomes
from fetuses of the same dam tend to be correlated, and this correlation must be taken
into account for a valid analysis. An analysis ignoring the litter effect will tend to un-
derestimate variances, and thus, lead to misleadingly low p-values. Willliams proposed
a famous model in which fetuses from the same dam share the same probability of mal-
formation, but malformation probability would differ by dam (Williams, 1975). For dam
k, let nk be the number of live fetuses and Mk be the number of malformations. The so
called beta-binomial model is a hierarchical model where Mkjnk;pk  Binomial(nk;pk)
and pk  Beta((dose);(dose)), so
P(Mk = yjnk) =

Mk
y

B((dose) + y;nk + (dose)   y)
B((dose);(dose))
The model assumes that intra-litter correlation is always positive. In the setting of devel-
opmental toxicity, it is expected that fetuses from the same litter will have similar out-
comes, so this is considered a reasonable assumption.
For the purposes of parameter estimation, it is advantageous to reparameterize
the model parameters to (dose) =
(dose)
(dose)+(dose) and (dose) = 1
(dose)+(dose). Here,
E[Mk] = nk(dose) and V ar[Mk] = nk(dose)(1   (dose))(1 + (nk   1)
(dose)
1+(dose)). Un-
der this reparameterization, the intra-litter correlation for litter k is m(dose) =
(dose)
1+(dose).
Note that (1+(nk  1) 
1+) is an inﬂation factor to the binomial variance which takes into
account the extra-variation induced by the intra-litter correlation.
Also, underthisreparameterization, theprobabilityofobservingamalformationfora
fetusinlitterk is(dose). Whileitispossibletoestimateseparatelyforeachdosegroup,
8a more useful approach, in terms of risk assessment, is to ﬁt a dose-response model by
letting  = f(0 + 1dose). Then, through maximum likelihood estimation, 0 and 1 (as
well as (dose)) can be estimated to calculate a BMD and its associated BMDL.
Other notable extensions to the binomial model include the correlated binomial
model (Kupper and Haseman, 1978) which allowed for negative intra-litter correlation,
and the multiplicative binomial model (Altham, 1978). The correlated binomial model
assumes that the correlation parameter is bounded, and these bounds are a function of
nk and pk. Indeed, in the case of binary data, it is impossible to have a correlation of  1,
except for the special case when n = 2. A perfect negative correlation implies one ob-
served malformation in a litter implies all other fetuses will not be malformed, while one
observed non-malformation corresponds to all other observations being malformations.
This logic is contradictory in the case where litter size is greater than 2.
Many other extensions to handle correlated binary data exist but only a handful of
important models will be described in this section. Ochi and Prentice, instead of gen-
eralizing the binomial model, took the approach of using the multivariate normal dis-
tribution, exploiting its ﬂexible correlation structure (Ochi and Prentice, 1984). They as-
sume that malformations from litter k are determined by latent variables, ~ mk, that fol-
low a multivariate normal distribution with mean k1n and variance-covariance matrix
2
k((1 k)Ink+kJnk) where 2
k is the variance of the latent variable and k is the common
intra-litter correlation. Without loss of generality, the threshold that ~ mjk needs to surpass
for a malformation to be observed is assigned to be 0.
These assumptions lead to the correlated-probit model among the observable out-
comes:
P(Mk = y) =

nk
y
Z
A
n( ~ mkjk;k;k)d ~ mk
where A = (mkj(~ mjk > 0;j  y) [ (~ mjk  0;j > y)).
The area of integration, A, reﬂects that in order to observe y malformations, y of nk latent
variablesmustexceed0andtheremainingnk y latentvariablesmustbelessthany. Note
that the above likelihood formulation contains an nk dimensional integral, making it dif-
9ﬁcult to compute the ﬁrst and second derivatives of the log likelihood necessary for esti-
mating the regression parameters. Ochi and Prentice re-express the log likelihood deriva-
tives in a form where the approximation of Mendell and Elston can be used (Mendell and
Elston, 1974). Also, note that the correlation parameter in this model does not have addi-
tional constraints like the correlated-binomial model, because the model is based on the
continuous normal distribution.
The Ochi-Prentice model is an important contribution to developmental toxicology
methodology in that it introduces the concept of using latent variables to model binary
outcomes. For many toxicologists, the concept of a quantal outcome being deﬁned by
whether an occult latent variable crosses a threshold is attractive from a biological the-
ory perspective. However, given the computation complexity of the model and the the
existence of simpler, more intuitive models based on the binomial distribution, the latent
variable approach may seem unnecessary. Yet, the use of latent variables becomes a com-
mon feature in later models that incorporate both binary and continuous outcomes, since
the latent formulation of a binary outcome can serve as a link between binary and contin-
uous outcomes. These models are discussed in more detail in the mixed outcome section
of the paper.
Rai and Van Ryzin (Rai and Van Ryzin, 1985), instead of developing a model based
on classical statistical distributions, attempted to develop a more biologically motivated
model based on the one-hit dose-response model, a concept borrowed from early car-
cinogenicity studies where the one-hit model was an established and popular method for
cancer modeling and low-dose extrapolation. Biologically, the model assumes that only
one ”hit” or one genetic mutation from a toxic insult is necessary to begin the cascade
to change a normal cell to a cancer cell. The dose-response model Rai and Van Ryzin
propose is as follows:
P(mjk = 1jdose;nk) = (1   e
 (0+1dose))e
( nk(0+1dose))
where dose  0;nk  0;0  0;1  0 and 0 + 1dose  0 for all dk. The ﬁrst factor,
(1   e (0+1dose)), can be interpreted as the probability of a toxic event occurring in dam
10k at the speciﬁed dose, such that its offspring may be affected as well, and the second
factor, e( nk(0+1dose)), can be interpreted as the conditional probability of a fetus from
dam k experiencing an adverse event given that dam k experienced a toxic event where
the litter size for dam k is nk. Instead of taking into account the litter effect through the
likelihood, Rai and Van Ryzin include litter size as part of the dose-response model as
an ad-hoc method for handling the litter effect. Unfortunately, others have shown that
this method does not account for all of the extra-binomial variation inherent in the data
and, in general, does not ﬁt the observed data well (Carr and Portier, 1991). Because the
approach of ﬁtting biologically motivated models have not successfully produced good
ﬁtting models, further research in developmental toxicity models is motivated less from
biological theory and more on statistical ﬂexibility.
All of the methods mentioned above specify a likelihood model for the outcome.
Thus if the assumed likelihood model is misspeciﬁed, resulting parameters can be bi-
ased. Liang and Zeger’s generalized estimating equations (GEE) (Liang and Zeger, 1986),
an extension of the quasi-likelihood method (Wedderburn, 1974), makes it possible to es-
timate regression model parameters without having to correctly specify the distributions
and correlations of the various outcomes. For this reason, the GEE has been a popular al-
ternative to likelihood methods in many areas, including non-cancer toxicology studies.
With GEEs, the following estimating equations:
U() =
K X
k=1
D
T
kV
 1
k (mk   k) = 0
are solved for , where mk is the outcome vector (in this case, say, malformation) for
litter k, k is the mean vector for the outcomes (in this case, the vector of malformation
probabilities p(dosek)1nk ), Dk =
@jk
@ , and Vk = A
1
2
kR()A
1
2
k is the working covariance
matrix for mk where Ak = diag[var(mjk)], R() is the assumed correlation matrix for
mjk and  is the parameter characterizing the correlation. When working with binary
outcomes such as malformations, var(mjk) = p(dosek)(1   p(dosek))]. In developmental
toxicity, where it is reasonable to assume fetuses within a litter are equally correlated, a
compound symmetry structure is usually chosen for R(). That is, R() = (1 )I+J.
11If this is the correct correlation structure, then the covariance estimator for ^  is ^ ;N =
PK
k=1 DT
kV
 1
k Dk
 1
. However, one can also use the sandwich estimator:
^ ;R =
 
K X
k=1
D
T
kV
 1
k Dk
! 1

 
K X
k=1
D
T
kV
 1
k (mk   k)(mk   k)
TV
 1
k Dk
! 
K X
k=1
D
T
kV
 1
k Dk
! 1
(1.1)
which is a consistent estimator, regardless of whether R() is correctly speciﬁed.
Like the likelihood methods discussed above (not including the Rai-Van Ryzin
model), there is a great degree of ﬂexibility in terms of choosing a dose-response model.
In general, one can ﬁt any model that follows the form: k = p(mk) = f(X), where X
is the nk  p matrix of covariates for mk (including, of course, dose) and  is the p  1
vector of regression parameters. Note that the likelihood models described above are all
litter-level models since they treat the number of malformations as the outcome of in-
terest. Thus, if one were to add additional covariates to the dose-response model, the
new covariates would also have to be at the litter-level. By ﬁtting a mean model where
the outcomes are the binary malformation status of each fetus instead of the malforma-
tion count, we are free to allow fetus-speciﬁc covariates, such as sex, to be included in
the model. Furthermore, the GEE approach using the sandwich estimator is a popular
method, since it is robust to variance misspeciﬁcation and can include a wider range of
covariates.
However, the fact that minimal assumptions need to be made to use GEEs also poses
a slight disadvantage in terms of quantitative risk assessment. Speciﬁcally, BMD calcu-
lations that require the likelihood cannot be completed since no likelihood is speciﬁed in
this approach.
121.4 Multiple Binary Outcomes
In non-cancer studies, toxicologists are almost always interested in more than one type of
adverse outcome. For example, there may be interest in probability of death in addition to
probability of malformation, or in different kinds of malformations (e.g. skeletal, visceral,
andexternal). Thepossibleinter-outcomecorrelationsfurthercomplicatesanalysesinthis
scenario.
Ryan and Lefkopoulou proposed a robust method, using GEEs, to model multiple
binary outcomes (Lefkpoulou et al., 1989). Letting Mik be the number of malformations
of type i from dam k and pik be the probability of fetus from litter k has a malformation of
type i, they specify themoments for Mik as E[Mik] = nkpik and V ar[Mik] = nkpik(1 pik)
where  is a dispersion parameter which takes into account the extra-binomial variation
due to the litter effect. Then the following GEEs are used to solve for the logistic regres-
sion model logit(pik) = i + Xk:
U(i;) =
K X
k=1
D
T
kV
 1
k (Mk   nkpk) = 0
where DT
k is the matrix of mean derivatives,
@pk
@k, Mk is the vector of counts for each type
of outcome, pk is the vector of probabilities for each type of outcome, nk is the the number
of fetuses in dam k and K is the number of dams in the study. Vk = NkA
1=2
k R()A
1=2
k
where Ak = diag[pik(1   pik)] and R() is the matrix characterizing the correlation be-
tween the multiple outcomes within one fetus. Note that the variance matrix contains
two parameters to account for two different types of correlation: , which describes the
intra-fetus correlation between the various outcomes, and , the dispersion parameter for
V ar[Mik], which is related to the correlation of two fetuses in the same litter on the same
outcome (k =
 1
nk 1).
Note that in this particular mean model, there is a unique i for each response, but
only a single . Thus, the model assumes that the dose-response curves for each response
are parallel, but with different intercepts. In other words, this mean model allows for
13the estimation of one parameter to describe the common dose effect of across all out-
comes. This assumption, that dose affects all outcomes in the same way, makes testing
for an overall dose effect relatively simple since there is only a singe degree of freedom
used for estimating the dose effect. However, for some data sets, this assumption may
be too restrictive and a more ﬂexible model such as logit(pik) = i + Xki, where dose
is assumed to have a separate effect on each outcome, may be more appropriate. In-
deed, being able to separately quantify the dose-response for each outcome is of interest
to many toxicologists, especially since it is possible that some outcomes may be signif-
icantly more sensitive to dose than others. In cases where only a small proportion of
the outcomes are sensitive to the toxin, an analysis assuming a common dose effect may
misleadingly conclude that the toxin has no overall effect when in fact some outcomes of
interest are affected by the toxin while others are unaffected. Also note that, unlike the
GEE approach described earlier, this method treats the outcome of interest as malforma-
tion counts. Thus, including fetus-level covariates is not possible.
Using GEEs to handle multiple outcomes and the litter effect is advantageous since
the method gives robust parameter estimates that are not biased from mis-specifying
the covariance matrix, and minimal assumptions are required. However, because this
method does not specify how to characterize the joint probability of multiple outcomes,
it cannot be used to calculate a joint BMD, even though the correlation parameters can be
easily estimated through method of moments.
1.5 Mixed Outcomes
The way toxic substances negatively affect fetal development is not limited to causing
deaths and malformations. A low fetal weight from a fetus without the presence of a mal-
formation can still indicate that a substance has a harmful effect and may be a sensitive
outcome of toxicity, especially at low doses. Thus, in the interest of utilizing all available
information to assess risk, toxicologists are also interested in fetal weights. However, the
fact that fetal weight is a continuous outcome, and known to be correlated with binary
14outcomes like malformation status, presents an analytic complication (Ryan et al., 1991).
The simplest approach to this problem is to dichotomize the continuous outcomes by
choosing an arbitrary cutpoint and deﬁning an outcome below that cutpoint as an ad-
verse event. This allows the use of methods developed for multiple binary outcomes.
However, this approach essentially ignores that fetal weight is measured on a continuous
scale and thus leads to a loss of information, both in terms of statistical efﬁciency and in
terms of losing the ability to quantify how dose directly affects fetal weight. Thus, the
models presented in this section maintain fetal weight as a continuous outcome while
still accounting for the litter effect and inter-outcome correlation.
A common feature of the models described below is that they all circumvent deﬁning
the joint probability of malformation and fetal weight. Instead, they rely on the fact that
the joint likelihood can be expressed as the product of the marginal distribution of one
variable and the conditional distribution of the other variable. For example, the joint den-
sity of fetal weight and malformation, fm;w(m;w), can be expressed as fmjw(mjw)fw(w),
the product of conditional probability of malformation given weight and the marginal
density of weight. Using this factorization allows for separately modeling mean and mal-
formation based on simpler likelihood models while also taking into account that the two
outcome are correlated.
One such model, proposed by Catalano and Ryan (Catalano and Ryan, 1992) assumes
theunderlyingdistributionfortheoutcomesisamultivariatenormal, muchliketheOchi-
Prentice model. Malformation, the observed binary outcome, is assumed to be deter-
mined by a latent variable ~ m which follows the normal distribution. By taking this latent
variable approach, it is possible to characterize the intra-outcome and inter-outcome cor-
relations between these types of outcomes. More speciﬁcally, the proposed model is:
wjk = 0 + 1dk + wjk
~ mjk = 0 + 1dk + mjk
where wjk is the fetal weight and ~ mjk is the latent variable for malformation for the j-th
15fetus in litter k, and
jk =

wjk
mjk

 N

0
0

;

2
w wm
wm 2
m

where 2
w is the variance for wjk, 2
m is the variance for ~ mjk, and  is the correlation be-
tween wjk and ~ mjk on the same fetus. A result of this formulation is that ~ mjkjwjk;dk 
N(0 + 1dk + (
1
2)(wjk   (0 + 1dk));2
m(1   2)) which leads to the result:
P(mjk = 1jwjk;dk) = 
 
0 + 1dk + (
1
2)(wjk   (0 + 1dk))
p
2
m(1   2)
!
In order for all coefﬁcient parameters to be estimable, the model must be reparameterized
to
P(mjk = 1jmjk;dk) = (

0 + 

1dk + 

2(wjk   (0 + 1dk)):
Of course, for the model to have practical use, it must be extended to also address
intra-litter correlation. Fortunately, the multivariate normal makes including this cor-
relation structure relatively easy to do. In Catalano-Ryan’s extended model, the latent
variable follows a multivariate normal with the following moments:
E

wk
~ mk

=

1 dk1 0 0
0 0 1 dk1

0
B
B
@
0
1
0
1
1
C
C
A
and
V ar

wk
~ mk

=

2
w[(1   w)I + wJ] wm[(   wmI + wmJ]
wm[(   wmI + wmJ] 2
m[(1   m)I + mJ]

where wm is the correlation between wjk and ~ mjk , w is the intra-litter correlation for fetal
weight, and w is the intra-litter correlation for the latent variables for malformation.
Thus, the conditional distribution for malformations is ~ mkjwk  N(wk;2
mk)
16where
wjk = 0 + 1dk +
m
w
(
 + (Nk   1)wm
1 + (Nk   1)w
) ewk +
m
w
(
   wm
1   w
)(ewjk    ewk)
ewjk = mjk   (0 + 1dk)
 ewk =  mk   (0 + 1dk)
k = [(1   w)  
(   wm)2
1   w
]I + [m  
(1   m)(2 + (Nk   1)2
wm)   (   mw)2
(1   w)(1 + (Nk   1)w)
]J
After reparameterizing the model to ensure estimability, the model becomes
E[mjkjwk] = (
0 + 
1dk + 
2 ewk + 
3(ewjk    ewk)). Note that ewjk is the fetus-speciﬁc
residual of the weight model and  ewk is the average of the litter weight residuals. Thus,
according to this model, both individual fetal weight and average litter weight affect the
probability of malformation. More speciﬁcally, when the average litter weight is lower
than expected (^ ewjk is negative), a fetus of that litter is more likely to be malformed. Simi-
larly, when the weight of a fetus is lower than the average weight for that litter (ewjk  ^ wjk
is negative), the fetus will also have a higher malformation rate. Thus, these two ad-
ditional parameters reﬂect the inherent correlation between malformation rate and fetal
weight within a fetus, as well as intra-litter correlation.
Catalano and Ryan propose using two sets of estimating equations to estimate pa-
rameters:
K X
k=1
X
T
kV
 1
wk(wk   Xk) = 0
K X
k=1
@E[mkjwk]
@
V
 1
mk(mk   E[mkjwk]) = 0
Note that ^  obtained from solving the ﬁrst estimating equation, substitutes  in E[mkjwk]
for the second estimating equation without iteration.
While the model’s latent formulation has an intuitive appeal, it also has some disad-
vantages. For instance, the regression parameters for the malformation model are con-
ditional on fetal weight. Thus, the  parameters in this model do not have a marginal
interpretation because of the nonlinear link function. Without a model that characterizes
17marginal risk for malformation, it is not possible to calculate a univariate BMD for that
response.
Fitzmaurice and Laird (Fitzmaurice and Laird, 1995) propose a similar model that
reverses the role of weight and malformation conditioning in terms of characterizing
the joint density. In the Fitzmaurice-Laird model, mj follows a Bernoulli distribution
and wj follows a normal distribution, conditional on malformation status. That is,
mj  Bernoulli(pj) and wjjmj  N(Xj + (mj   pj);2), where logit(pj) = Xj and
 is the parameter from a regression of wj on mj. Thus, in this model, the joint distri-
bution is characterized as fmj;wj(mj;wj) = fwjjmj(wjjmj)fmj(m), deﬁned by the marginal
distribution of malformation status and conditional distribution of fetal weight, whereas
the Catalano-Ryan model deﬁnes the joint density as the product of the marginal distribu-
tion of fetal weight and conditional distribution of malformation status. The advantage of
the Fitzmaurice-Laird model is, since E[wjjmj] = Xj+(mj pj);E[wj] = E[E[wjjmj]] =
Xj. Thus, both  and  parameters have a marginal interpretation in this setting.
In the clustered setting, the mean models are as follows:
logit(pk) = Xk
E[wjkjmk] = Xjk + 1(mjk   pjk) + 2
nk X
j=1
(mjk   pjk)
and the following GEEs are used to solve for  and 2 = (;1;2):
K X
k=1
 
@E[mk]
@
@E[mk]
@2
@E[wkjmk]
@
@E[wkjmk]
@2
!T
V ar
 1

mk
wkjmk

mk   E[mk]
wk   E[wkjmk]

= 0
which can be expressed as:
K X
k=1

XTpmk(1   pmk)Ink  (1 + 2)XTpmk(1   pmk)Ink
0 WT


V 1
mk 0
0 V
 1
wkjmk

mk   pk
wk   E[wkjmk]

= 0
where Wk = (W1k;W2k;:::;Wjk;:::;Wnkk), and Wjk = (Xjk;mjk   pjk;
Pnk
j=1(mjk  
pjk)) (Fitzmaurice and Laird, 1995). Note that, while the malformation model only de-
18pends on , the weight model is conditional on pmk and therefore on  as well as 2,
which is why
@E[mk]
@2 is 0 while
@E[wkjmk]
@2 is not, leading to a non-symmetric matrix for DT.
In order to calculate a joint BMD, it is necessary to characterize joint risk through a
likelihood and to estimate the parameters that characterize the correlation between the
outcomes. The Fitzmaurice-Laird model only deﬁnes likelihoods for the malformation
and weight conditional on malformation. Furthermore, the model accounts for corre-
lation between fetal weight and malformation through the parameters 1 and 2 in the
conditional weight model but these parameters do not directly estimate the correlation
between weight and malformation. On the other hand, the Catalano-Ryan model does
specify the joint probability, but the correlation parameter, , which describes the rela-
tionship between fetal weight and malformation is not directly estimated. Thus, neither
method can be used calculate a joint BMD.
Regan and Catalano (Regan and Catalano, 1999) propose a method which retains esti-
mation of the inter-outcome correlation but also takes advantage of the robust properties
of GEE. Like the Catalano-Ryan model, the distribution of w and m are determined by
the distribution of w and latent variable ~ m which follow a bivariate normal distribution.
Without loss of generality, ~ mjk is further standardized so that m = 1. Thus, the density
function for the weight and latent malformation variable is
f(wjk; ~ mjk) =
1
2w
p
1   2
exp
 
 1
2(1   2)
"
wjk   w
w
2
  2

wjk   w
w

(~ mjk   m) + (~ mjk   m)
2
#!
where m = m=w, the mean of the standardized ~ mjk. From this density, it can be shown
that f(wjk;mjk) = (mjwjk)mjk[1   (mjwjk)(1 mjk)]f(wjk) where mjwjk =
m+
wjk w
w p
1 2 .
Also note that, in addition to mean weight and malformation, weight variance and inter-
outcome correlation can also be modeled as dose-dependent. Previously proposed mod-
els have assumed these parameters to be non-dose-dependent. However, in developmen-
tal toxicity data, it is often the case that the negative correlation between malformation
and fetal weight grows stronger, and that fetal weight variance increases, as dose in-
19creases (Chen and Gaylor, 1992).
Therefore, the dose response components in this model are as follows:
mjk = XT
jk jk = e
XT
jk
 1
e
XT
jk
+1
wjk = XT
jk log(2
wjk) = XT
jk
To account for clustering, the parameters are estimated using the the following GEE
which uses a working covariance matrix to allow for the possible misspeciﬁcation of
correlation:
K X
k=1
0
B B
B
@
@E[mkjwk]
@ 0 0
@E[mkjwk]
@ 0 0
@E[mkjwk]
@
E[wk]
@ 0
@E[mkjwk]
@ 0
E[sk]
@
1
C C
C
A
0
@
Vmk Vwmk 0
Vwmk Vwk 0
0 0 Vsk
1
A
 1 0
@
mk   (mjwk)
wk   wk
sk   2
wk
1
A = 0
where
sjk = (wjk   w)
2
Vwk = 
1=2
wk [(1   w)Inj + wJnk]
1=2
wk
Vmk = 
1=2
mk[(1   m)Imj + mJnk]
1=2
mk
VSk = 
1=2
sk [(1   m)Imj + mJnk]
1=2
sk =m
Vwmk = 
1=2
wk [ wmInk + wmJnk]
1=2
mk=
1=2
m
and
mk = diag[(mjwjk)(1   (mjwjk))]
wk = diag[
2
wjk]
sk = diag[2
4
wjk]
and m is a scale parameter. Method of moments estimation is used to calculate estimates
for the correlation parameters w, m and wm, as well as m.
Regan and Catalano use the assumed joint likelihood model for risk assessment. Be-
cause the inter-outcome correlation is also estimated, a joint BMD can be calculated. Let
20us assume that a malformation or a fetal weight lower than the cutpoint wc is considered
an adverse event. Then,
p(dose) = P(adverse event at dose) = 1   P((mjk = 1) \ (wjk > wc)) =
1  
Z m(d)
 1
Z 1
wc
2(wjk;mjkjw = w(dose); ~ m = 0;w = w; ~ m = 1; = )dwjkd~ mjk
where 2 is the bivariate normal density function and w, w, and  are functions of dose.
This formula reduces to
(m(dose)) + 2

 m(dose);
wc   w(dose)
w(dose)
j(dose)

where  and 2 are the cumulative distribution functions for the standard univariate and
standard bivariate normal distribution, respectively. This joint risk formulation can be
used to calculate a joint BMD and associated BMDL.
Molenberghs, Geys, and Buyse (Molenberghs et al., 2001) propose an entirely differ-
ent model, based on the Plackett-Dale distribution rather than a latent bivariate normal
distribution. Let Fwk(x) = cumulative distribution function for wk and let Fmk(y) = cumu-
lative distribution function for mk . Under the Plackett-Dale model, the joint cumulative
distribution function for mk and wk is
Fwk;mk =
(
1+(Fwk+Fmk)( k 1) S(Fwk;Fmk; k)
2( k 1)  k 6= 1
FwkFmk  k = 1
where
S(Fwk;Fmk; k) =
q
[1 + ( k   1)(Fwk + Fmk)]2 + 4 k(1    k)FwkFmk
 k, known as the global cross-ratio, deﬁnes the dependence structure of wk and mk,
 k =
Fwk;mk(1   Fwk   Fmk + Fwk;mk)
(Fwk   Fwk;mk)(Fmk   Fwk;mk)
and is used to derive the above joint cumulative density function.
From this deﬁnition, the joint density function is derived to be
fwk;mk(w;0) =
(
fwk(w)
2 [1  
1+Fwk(w)( k 1) Fmk(0)( k+1)
S(Fwk(w);Fmk(0); k ]  k 6= 1
fwk(w)(1   pk)  k = 1
fwk;mk(w;1) = fwk(w)   fwk;mk(w;0)
21To account for clustering, a pseudo-likelihood score function, pl =
PK
k=1
PJ
j=1 ln(fwjk;mjk(w;m)), rather than a full likelihood score function, is used
for computational simplicity and stability.
Letting jk = (jk;2
jk;jk; jk)T, the vector of parameters of interest, we can charac-
terize the dose response model as
jk =
0
B B
@
jk
ln(2
jk)
logit(pjk)
ln( jk)
1
C C
A = Xjk
Estimates for  can be obtained from solving the following score-based estimating func-
tion:
U() =
K X
k=1
Uk() =
K X
k=1
nk X
j=1

@k
@
T 
@k
@k
 T 
@ln(fwjk;mjk(x;y))
@i

= 0
The dependence structure for the two outcomes is deﬁned by the global cross-cut
ratio,  k. Thus, this approach allows for great ﬂexibility in choice of marginal distribu-
tions. The global cross-ratio can be interpreted as the odds-ratio comparing malformation
odds and fetal weight odds, where fetal weight is thought of as a dichotomized variable
using an unestimated cut point, wc. That is, when  k = 1, the two outcome are indepen-
dent, when  k > 0, there is a positive correlation between weight and malformation, and
when  k < 0, there is a negative correlation. Thus, the model’s characterization of the
association is completely different than that of the probit model, which uses a correlation
parameter from a multivariate normal distribution.
Again, assuming observing a malformation or a fetal weight lower than the cutpoint
wc isconsideredanadverseevent, theprobabilityofanadverseeventcanbecharacterized
as
P(w < wc [ m = 1jdose) = p(m = 1jdose) + p(w < wcjdose)   p(m = 1 \ w < wcjdose)
= p(m = 1jdose) + Fw;m(wc;0j (dose)):
Using this formulation of the joint risk, a joint BMD can be calculated (Geys et al., 2001).
221.6 Hierarchical Outcomes
The models described above have mostly focused on outcomes from live fetuses, namely,
fetal weight and malformation or multiple types of malformations. Another important
outcome that toxicologists consider is early prenatal loss and fetal death, often collec-
tively termed embryolethality. The addition of death as an outcome of interest presents a
new statistical challenge because of the hierarchical relationship between death and live
outcomes in the litter. In particular, being able to observe malformation status and fetal
weight is conditional on the fetus being alive at the time of sacriﬁce. Say we are only in-
terested in deaths and malformations as outcomes. Within a dam, one can easily estimate
p(d) with Dk=nk and, similarly, p(mj d) with Mk=lk, where Dk and Mk are the number of
deaths and malformations observed respectively, nk is the number of implants in dam k
and lk = nk   Dk is the number of live fetuses (litter size) for dam k. However, it is more
difﬁcult to characterize the joint risk of both death and malformation. Similarly, any risk
statement we can make on fetal malformation is conditional on those fetuses surviving
gestation. Many methods obviate this road block by assuming conditional independence:
that d and m;wjd are independent. This assumption simpliﬁes the construction of joint
risk from multiple outcomes to P(d)P(m;wj d). The calculation may be appropriate for
univariate unclustered hierarchical outcomes because observing a death in one animal
would not inform the malformation rate or fetal weight for a different animal. However,
this logic breaks down in litter data where death rate of a litter is expected to inform the
malformation status and fetal weights of animals in the same litter.
For an example of a hierarchical model that assumes conditional independence, Cata-
lano, Ryan and Scharfstein (Catalano et al., 1994) present a method to model the dose
response for two hierarchical binary outcomes. In their approach, two dose-response
models are ﬁtted: one for death and one for malformation, with the malformation model
being conditional the fetus surviving the gestation period. Letting pd(dose) be the proba-
bility of death at the speciﬁed dose and pm(dose) be the probability of malformation, two
23sets of GEEs are solved simultaneously:
K X
k=1
nk X
j=1
@pd(dose)
@d
V
 1
djk(djk   pd(dose)1nk) = 0
K X
k=1
nk Dk X
j=1
@pm(dose)
@m
V
 1
mjk(mjk   pm(dose)1nk Dk) = 0
where Vdjk and Vmjk are the assumed covariance matrices for death and malforma-
tions, respectively, d and m are the parameters from the death and malformation dose-
response model, and djk is a length nk vector indicating death for fetuses from dam jk
while mjk is a length nk   Dk vector indicating malformations for live fetuses from dam
jk.
In order to perform a risk assessment analysis, they deﬁne an adverse event as either
observing a death or malformation. Assuming conditional independence, P(d [ m) =
1   P( d \  m) = 1   P( d)P( mj d) = 1   (1   P(d))(1   P(mj d)). Thus, since they assume d
and mj d are fully independent, they can ﬁt a model with death as the outcome of interest
where number of implants is considered the denominator, while also ﬁtting a separate
model treating malformations as the outcome of interest where number living fetuses is
considered the denominator, to calculate the overall probability of an adverse event. This
probability can then be used to calculate a BMD. Catalano, Scharfstein, et al. extend this
approach to include fetal weight as an outcome of interest by modeling the live outcomes
(malformations and weight) together using the Catalano-Ryan probit model (Catalano
et al., 1993).
Another example of a model that incorporates lethality as an outcome is the Dirichlet-
trinomialmodel(Chenetal.,1991), whichextendsthebeta-binomialmodeltoincludetwo
binary outcomes, malformation and death, by replacing the binomial with a trinomial
and beta with a Dirichlet distribution. The resulting, more general, hierarchical model
can be also used for calculating a joint BMD. Note that the assumption of conditional
independence is implicit in the likelihood formulation. However, both of these papers
ignore the inter-outcome litter effects that may be present in the hierarchical outcomes.
24In situations without clustered data, conditional independence is a reasonable as-
sumption. One would expect that outcomes from one animal would not inform the like-
lihood for a live fetus from another animal. However, when fetuses are clustered into
litters, as in developmental or other animal studies involving litter data, it is possible that
knowing the death experience of a given litter can affect the malformation rate and fetal
weight distribution of the remaining live outcomes in the same litter. In particular, one
might expect that a litter with a high death rate could also have a high malformation rate
and a lower fetal weight distribution for the live fetuses. In practice, and somewhat con-
tradictory to the conditional independence assumption that many models employ, litter
size is often included as a covariate in regression models for live-outcomes as an ad-hoc
method for taking into account the possibility that death rate may affect malformation
rates and fetal weights (Chen, 1993).
Christensen (Christensen, 2004) formalizes this ad hoc approach and extends the
Ochi-Prentice model by including fetal death as a variable in such a way that it does
not assume conditional independence. Essentially, three possible outcomes, no adverse
event, malformation, and death are treated as ordinal events. In Christensen’s model, two
threshold parameters, m and d, are used to deﬁne how the latent variable relates to the
observed outcomes. Letting ~ yjk be the latent variable for fetus j from dam k, if ~ yjk < m,
then no adverse event is observed for that fetus, if m < ~ yjk < d, then a malformation
is observed for the fetus and if ~ yjk > d, a fetal death is observed. Like the Ochi-Prentice
model, ~ yk, the vector denoting the latent variables for the fetuses from dam k, follows a
multivariate normal distribution with mean 1n and variance 2((1 )In +Jn). Letting
Hk denote the number of healthy fetuses from litter k, the joint distribution of the three
outcomes from litter k can be expressed as:
P(Hk;Mk;Dk) /
Z
B
n(~ zkj0;1;)d~ zk
25where
~ zk = ~ yk   1nk
B = (~ zkj(~ zk <  m;k  Hk) [ (m  ~ zjk <  d;Hk < k < Hk + Mk)
[ (~ zjk   d;j > Hk + Mk)))
m = m   
d = d   
m and d are standardized cutpoints.
From this formulation, it follows that the probablity of death is (d) and probability
of malformation is (m)   (d). Using the above likelihood, the model speciﬁcation is
as follows:
 = f(X1)
m =  m + 0 + f(X1) = 

m(Xmm) + f(X1)
D =  D + 0 + f(X1) = 

d(Xdd) + f(X1)
 = g(X2)
where g() can either be the identity function or Fisher’s Z-transformation.
In order to compute MLE’s for the parameters of interest, it is necessary to take
derivatives of the log-likelihood. The derivatives of the log-likelihood with respect to
 and  can be quite complicated as they involve differentiating the following integrals:
Z
B
nk X
j=1
~ zjkn(~ zkj0;1;)d~ zk
Z
B
nk X
j=1
nk X
j0=1
~ zjk~ zj0kn(~ zkj0;1;)d~ zk:
As in the Ochi-Prentice model, moment generating functions are used to express the
integrals as the product of univariate normal density function and a (n-1)-dimensional
26multivariate normal integral, conditional on one of the two thresholds. Using this
method, we can calculate the ﬁrst and second derivatives of interest for the likelihood.
As with the Ochi-Prentice model, approximations developed by Mendell and El-
ston (Mendell and Elston, 1974) are used to carry out the calculations. Using this method,
the joint risk of the outcomes of a litter:
P(~ z1 <  m;:::; ~ zMk <  m; ~ zMk+1 <  d;:::; ~ zMk+Dk <  d) =

Mk
k=1P(~ zk <  mj~ zk <  m;:::; ~ zk 1 <  m)

Mk+Dk
j=Mk+1P(~ zj <  dj~ z <  m;:::; ~ zMk <  ; ~ zMk+1 <  d;:::; ~ zj 1 <  d)
can be approximated by 
Mj
j=1(qj)
Mj+Dj
k=Mj+1(uj).
For the ﬁrst product, wj = 1;wj + 1 = (wj   awjrj)=j;rj = (rj 2   1)=2
j 1 + 1;wj =
 (wj)=(wj) and 2
j = 1   r2
jawj(awj   wj) for j = 1;:::;Mk. For the second product, uj
must be calculated in two stages. First, for u1;:::;uMk+1, u1 =  d and us+1 = ut wwsrt=s,
where aws;rs, and 2
s are the same as above. For uMj+1;:::;uMj+Dj;us +1 = (us  ausrs)=s
where rs = (rs 1   1)=2
s 1 + 1, aus =  (us)=(us), and  = 1   r2
saus(aus   us).
Christensen also extends this model to include fetal weight by assuming fetal weight
and the latent variable follow a multivariate normal distribution. In this case, regression
models can be speciﬁed for all parameters of interest: fetal weight mean and variance,
both litter-effect correlations, and the inter-outcome correlation.
The likelihood for this model can be extremely complicated, and even using approx-
imation techniques to make certain calculations more tractable, the method can be com-
putationally intensive, sensitive to starting values, and unstable with certain outcome
data patterns. Also, as a likelihood method, it is not robust to model misspeciﬁcation.
However, it is one of the ﬁrst models that allows joint risk assessment without assuming
conditional independence.
As mentioned above, it is common practice to adjust the live-outcome models by the
litter’s death rate or litter size to informally take into account the conditional indepen-
dence in the observed data. While Christensen’s model formally incorporates conditional
27dependence into his model, its complexity makes it unappealing for many researchers.
Carey (Carey, 2006) develops a model which relaxes the conditional independence as-
sumption but also retains the simplicity and accessibility of the more commonly used
ad-hoc methods. Essentially, Carey uses adjustment covariates for conditional models
that are derived from a proper likelihood model that does not assume conditional inde-
pendence.
Unlike Christensen’s method, Carey’s likelihood uses two latent variables, one for
deathandoneformalformation, denotedas ~ dand ~ mrespectively. Thetwolatentvariables
and fetal weight follow a multivariate normal distribution. More speciﬁcally, for the k-th
litter:
0
@
~ dk
wk
~ mk
1
A  N
0
@
0
@
d
w
m
1
A;
0
@
d dw dm
dw w wm
dm wm m
1
A
1
A
where
d = (~ 0 + ~ 1dosek)1nk
w = (0 + 1dosek)1lk
m = (~ 0 + ~ 1dosek)1lk
d = 
2
d((1   d)Ink + dJnk)
w = 
2
w((1   w)Ilk + wJlk)
m = 
2
m((1   m)Ilk + mJlk)
dw = 
T
wd = wdwdJnklk
dm = 
T
md = mdmdJnklk
wm = 
T
mw = wmwmJlk
and lk denotes the number of live fetuses while nk denotes the number of implants in
litter k.
As weight is observed only when death does not occur for a fetus, it may be of
greater interest to consider wjd. Similarly, the conditional distribution mjd;w may be
28more attractive than the marginal distribution of malformation. Unlike the marginal dis-
tributions, the conditional distributions wjd and mjw;d both take into account the death
outcomes of the litter and therefore may inform how death from the litter relates to mal-
formation rate and fetal weight.
Given the above likelihood, the marginal distribution of death and conditional distri-
bution of fetal weight and malformation can be expressed as:
0
@
~ dk
wkj~ dk
~ mkjwk;~ dk
1
A  N
0
@
0
@
d
wjd
mjw;d
1
A;
0
@
d 0nklk 0nklk
0lknk wjd 0lk
0lknk 0lk mjw;d
1
A
1
A
Note that, after conditioning on the means, the conditional and marginal outcomes are
assumed to be uncorrelated. For example, how ~ d informs wj~ d is taken into account via
the conditional mean wjd and conditional variance wjd.
Now, wjd and mjw;d can be expressed as
wjd = (0 + 1dose)
+ (wdw)(1 + d(nk   1))
 1
 

nk
j=1 ~ dij   nk(~ 0 + ~ 1)
d
!
mjw;d = (~ 0 + ~ 1dose)
+
m[md(1 + w(lk   1))   mwwdlk]
(1   w(lk   1))(1 + d(nk   1))   2
wdlknk
 

nk
j=1 ~ djk   nk(~ 0   ~ 1dose)
d
!
+
m[mw(1 + d(nk   1))   mwwdnk]
(1 + w(nk   1))(1 + w(lk   1))   2
wdnklk
 

lk
j=1wjk   lk(0   1dose)
w
!
Note that wjd can be expressed as the sum of marginal model for weight plus an adjust-
ment covariate. More speciﬁcally, this additional adjustment covariate is a function of
the mean standardized residuals for fetal death. Similarly, mjw;d can be expressed as the
sum of the marginal model for malformations plus two additional adjustment covariates,
one a function of the mean standardized deaths and the other a function of the mean
standardized weights. Unfortunately, these adjustment terms are quite complicated and
include parameters from the latent theory that are not estimable. However, these theoret-
ical models can be used to motivate simpler adjustment terms.
29First, the latent death model must be rewritten to reﬂect that death is observed as
a binary outcome. Thus, d = E[djk] = P(djk = 1) = P(~ djk > 0) = (
~ djk
d > 0) =
(
0
d +
1
ddose) = (0 +1dose) where the ~ 0 and ~ 1 are reparameterized to 0 and 1 to
ensure estimability.
From here, the conditional weight model can be expressed as:
wjd = 0 + 1dose + 2(1 + d(nk   1))
 1
 

nk
j=1djk=njk   nk(0 + 1)
p
(~ 0   ~ 1dose)[1   (0 + 1dose)]=nk
!
where wdw is taken to be a single parameter, 2 and d is estimated using the method of
moments from the residuals of the ﬁtted dose-response model.
For the conditional malformation model the theoretical adjustment covariates are
quite complicated and include parameters from the latent model that are not estimable.
However, this theoretical mean model can be used to motivate simpler adjustment terms
and helps justify models that previously used ad-hoc approaches. Speciﬁcally, Carey
derives adjusted covariates based on a ﬁrst order bivariate Taylor expansion around the
meannumberofimplantsandmeanlittersize. Inaddition, likethemarginaldeathmodel,
a reparameteriztion of the parameters is necessary for estimability. This approximation
to the conditional mean is expressed as:
mjw;d = (0 + 1dose) + 2
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
+ 3(Dk    D)
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
+ 4(nk    n)
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
+ 5

 wk   ^ w
^ w=
p
lk

+ 6(nk    n)

 wk   ^ w
^ w=
p
lk

+ 7(Dk    D)

 wk   ^ w
^ w=
p
lk

The covariates for the parameters 2 and 5 characterize the main effect of death ex-
30perience of the litter and fetal weight, respectively. The other four covariates can be inter-
preted as interaction effects in which the main effects are multiplied by either the litter’s
deviation from the average number of implants or the litter’s deviation from the average
number of deaths.
Given these marginal and conditional models, and using the following dose-response
framework:
E[djk]=
q
V ar(djk) = (0 + 1dosek)
E[mjk]=
q
V ar(mjk) = (0 + 1dosek)
E[wjk] = 0 + 1dosek
we can ﬁt the following GEE:
I X
k=1
0
B
@
@E(dk)
@ 0 0
@E(wkjdk)
@
@E(wkjdk)
@ 0
@E(wkjwk;dk)
@
@E(wkjwk;dk)
@ 0
1
C
A
T 0
@
Vdk 0 0
0 Vwk 0
0 0 Vmk
1
A
 1

0
@
dk   (0 + 1dosek)1nk
wk   E(wkjdk)
mk   E(mkjwk;dk)
1
A = 0
where
Vdk = 
1=2
dk [(1   d)Ink + dJnk]
1=2
dk =d
Vwk = 
1=2
wk [(1   w)Ilk + wJlk]
1=2
lk
Vmk = 
1=2
mk[(1   m)Ilk + mJlk]
1=2
mk=m
and
dk = diag[(0 + 1dose)(1   (0 + 1dose))]
wk = diag[
2
wjd]
mk = diag[(0 + 1dose)(1   (0 + 1dose))]
31Depending on the speciﬁc data set, not all adjustment covariates for the conditional
malformation model may be signiﬁcant, especially given the high potential for collinear-
ity among them. The interaction terms, in general, do not tend to be signiﬁcant, but both
main effect adjustment terms tend to be informative. What covariates one decides to in-
clude in the mean model should ultimately depend on the data. While using adjustment
covariates based on litter size and death rate have been in use as an ad-hoc method to
improve model ﬁt, Carey establishes a theoretical basis that justiﬁes the use of such ad-
justment covariates and speciﬁes what adjustment covariates are appropriate given the
assumed likelihood.
1.7 Research Plan
Analysis of developmental toxicology data presents several layers of statistical chal-
lenges, brought on by the litter effect and the correlation between multiple outcomes
of interest. Early methods have focused on speciﬁc pieces of the problem, such as the
litter effect, while later methods have built on these early models and added features to
account for multiple outcomes and their inherent correlation. More recent methods, for
example, allow an analysis which incorporates the hierarchical nature of live and non-
live outcomes while not resorting to the assumption of conditional independence and
still accounting for clustering.
The ultimate goal for developmental toxicity data analysis is to use the data to con-
duct an informed risk assessment of the toxin under study while characterizing the dose-
response relationships of individual outcomes. Typically, this is done by calculating a
joint BMD and associated BMDL. When multiple outcomes are concerned, a joint likeli-
hood that fully speciﬁes how the multiple outcomes are correlated is required to calculate
a joint BMD. While GEEs may be used to ensure estimates for model parameters are
robust to mis-speciﬁcation of between-litter correlations, as is the case with the Regan-
Catalano model, ultimately, the joint likelihood of the multiple outcomes must be spec-
iﬁed in order to characterize total risk and calculate a joint BMD. Thus, in any method
32with applications to developmental toxicology, there is a trade-off between specifying
enough likelihood to allow calculation of a BMD and forgoing making such assumptions
in favor of methods that calculate robust estimates that are not dependent on likelihood
assumptions.
Two methods, Christensen’s model and Carey’s model, discussed previously incor-
porate death as an outcome while not resorting to assuming conditional independence.
Both methods assume underlying latent variables following a normal distribution to
characterize the distribution of outcomes. This general approach, which assumes mal-
formations and deaths are observed when thresholds for latent variables are exceeded,
appeals to intuition and toxicological theory. It also presents a natural way to describe
inter-outcome correlation. However, these approaches have some limitations. First, the
accuracy of inference and risk estimation based on these models depends on the initial
likelihood assumptions. Second, the latent formulation of the likelihood makes some the-
oretical parameters non-estimable. In the case of Carey’s model, the latter issue forces the
use of approximations to the actual adjustment covariates derived from the theory for the
conditional malformation model.
An alternative approach that may work to circumvent some of these issues is to ex-
plore using a Plackett-Dale-type model instead of the multivariate normal to model the
three outcomes of interest. Recall that the Plackett-Dale approach for mixed outcomes
discussed in this paper. For live outcomes, the association between malformation and
weight is deﬁned by the global cross-ratio:
 k =
Fwk;mk(1   Fwk   Fmk + Fwk;mk)
(Fwk   Fwk;mk)(Fmk   Fwk;mk)
which is used to derive the joint cumulative distribution:
Fwk;mk =
(
1+(Fwk+Fmk)( k 1) S(Fwk;Fmk; k)
2( k 1)  k 6= 1
FwkFmk  k = 1
(1.2)
where
S(Fwk;Fmk; k) =
q
[1 + ( k   1)(Fwk + Fmk)]2 + 4 k(1    k)FwkFmk
33which can, in turn, be used to derive the joint density function fwk;mk. The orig-
inal approach discussed in the paper by Molenberghs et al. considers the associa-
tion due to clustering as a nuisance and therefore the psuedo-likelhiood score function
used, pl =
PK
k=1
Pnk
j=1 ln(fwjk;mjk(w;m)), does not incorporate any parameters deﬁning
the association between littermates. Geys et al. do propose an extension of the log-
pseudolikelihood function above that includes intra-litter association parameters. The
log-pseudolikelihood has the following form:
pl =
K X
k=1
nk X
j=1
ln(f1(wjk;mjk)) +
K X
k=1
nk X
j6=j0
ln(f2(wjk;mj0k))
+
K X
k=1
X
j0<j
ln(f3(wjk;wj0k)) +
K X
k=1
X
j0<j
ln(f4(mjk;mj0k))
where f1, f2, f3, f4 are all bivariate Plackett densities, but characterized by different odds
ratios. That is, f1 is the joint probability of weight and malformation from the same fetus,
f2 is the joint probability of weight and malformation of two different fetuses in the same
litter, f3 is the joint probability of weights between two different animals in the same litter
and f4 is the joint probability of malformations between two different animals in the same
litter. Thus, instead of using the global cross-ratio to deﬁne only the association between
malformation and weight of a fetus, Geys proposes using the same Plackett framework to
deﬁne all associations present within a litter. By assuming exchangeability within litters,
the number of cross-ratios to be estimated is reduced to four.
Borrowing this framework of using cross-ratios to determine within-litter association
may be of use in establishing a Plackett-Dale approach to developmental toxicology that
includes death as an outcome. While still deﬁning a distribution for the outcomes so that
univariate and joint BMDs can be calculated, the approach allows greater ﬂexibility in
deciding marginal distributions for the outcomes. In particular, binary variables such as
malformations can be modeled directly by a Bernoulli distribution rather than through
a more complex latent normal distribution. This feature may allow circumventing the
issue of non-estimable parameters that affects methods based on the multivariate normal
distribution.
34Given that malformation and death are hierarchical outcomes, it may be useful to
think of death, malformation, and absence of an adverse outcome as three possible out-
comes on an ordinal scale. Methods that model multiple ordinal responses based on the
Plackett distribution have been developed but not adapted to clustered multiple outcome
litter data, (Molenberghs and Lesaffre, 1994) and may be used as a template for a model
directly applicable to developmental toxicology. In particular, certain assumptions can
be exploited to reduce the number of association parameters that need to be estimated.
For example, by assuming exchangeability, we can claim the association between any
two littermates is identical. Thus, we should be then able to incorporate the intra-litter
correlation through a bivariate density of two ordinal variables, the outcome of fetus j
and the outcome of fetus j0, to characterize the litter association and avoid conditional
independence.
In the ordinal scale, the global cross ratios can be interpreted as cumulative odds
ratios. In the case of two trinomial outcomes, this amounts to four ratios to estimate.
Letting Hj, Mj, and Dj denote no adverse event, malformation, and death for fetus j,
respectively, the four cross-ratios are deﬁned to be:
 1 =
P(Hj [ MjjHj0 [ Mj0)=P(DjjHj0 [ Mj0)
P(Hj [ MjjDj0)=P(DjjDj0)
 2 =
P(DjjHj0 [ Mj0)=P(Hj [ MjjHj0 [ Mj0)
P(DjjDj0)=P(Hj [ MjjDj0)
 3 =
P(Hj [ MjjDj0)=P(DjjDj0)
P(Hj [ MjjHj0 [ Mj0)=P(DjjHj0 [ Mj0)
 4 =
P(DjjDj0)=P(Hj [ MjjDj0)
P(DjjHj0 [ Mj0)=P(Hj [ MjjHj0 [ Mj0)
Note that, because the two ordinal outcomes measure associations between are the same
variable but on different fetuses,  1 and  4, as well as  2 and  3, are the same cumulative
odds-ratios. Thus, number of association parameters to estimate can be reduced to two
in this setting.
Given this framework, we can construct the joint distribution of death and malfor-
mation which accounts for clustering via the two cross-ratio parameters. Furthermore,
we will explore how the distribution can be factorized into the resulting marginal distri-
35bution for death and conditional distribution of malformation given death. It will be of
particular interest to discover how the death of littermates affects the conditional distri-
bution of malformation and, speciﬁcally, how it compares to Carey’s model based on the
multivariate normal distribution.
Once a method that accounts for the association between death and malformation
without resorting to assuming conditional independence is developed, it will be of in-
terest to explore ways to extend the model to include fetal weight via the Plackett-Dale
approach discussed above. In particular, the conditional malformation model may be
used to motivate deriving the distribution of weight and malformation conditional on
death similar to (2). Again, it will be of interest to derive the conditional distribution of
fetal weight and malformation in order to assess how the death of littermates may affect
the joint distribution malformation and weight and whether the adjustment covariates
motivated by this conditional distribution are comparable to those described by Carey
and Christensen.
In both cases, it will be necessary to explore the forms of dose-response models to
ﬁt for the mean and association parameters that will depend on dose, and how to for-
mulate the pseudolikelihood for robust correction of litter effects not captured by the
Plackett-Dale formulation. Estimating equations will be derived from score functions of
the log-psuedolikelihood similar to the one used in the Placket-Dale model. The use of
sandwich estimators similar to (1.1) may be necessary to ensure the robustness of vari-
ance estimators. Since we are developing a likelihood model, it will be possible to use a
2 goodness-of-ﬁt statistic to empirically evaluate the how well the model ﬁts the data.
Methods for assessing joint risk so that a BMD can be calculated is another issue that must
be addressed. In the case where death and malformation are the only outcomes of inter-
est, the risk of an adverse event can be characterizes by 1 P(H). However, the inclusion
of fetal weight as an outcome may complicate how to characterize joint risk depending
on the nature of the model developed.
A comparison to already developed models that do not assume conditional inde-
36pendence, namely Christensen’s method and Carey’s method, ideally using the same
datasets, would be needed to evaluate whether the new methods give good ﬁtting pa-
rameter estimates and BMDs. We have access to many datasets to empirically evaluate
the method, including 10 EPA datasets of a variety of chemicals of standard sample size
(100-150 dams per study) as well as 1 very large study of the chemical 2,4,5-T with over
10,000 dams. In addition, 150 or so other National Toxicology Program (NTP) studies in
multiple agents are available that can be used to empirically evaluate ”asymptotic”-like
behavior. These include many positive studies as well as some negative studies, so the
model can be tested on a variety of data patterns. Also, simulation studies to assess how
robust the method is to deviations from the assumptions and performance under various
study sample sizes will also be conducted.
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382.1 Introduction
Controlled animal studies are used to study the effects of various potentially toxic sub-
stances such as drugs or environment contaminants. In such studies, human subjects are
not appropriate and researchers must rely on animal studies to assess toxicity from ex-
perimental data. Developmental toxicology studies are designed to examine the effect of
chemical substances on developing organisms. These studies involve exposing pregnant
animals (usually mice, rats, or rabbits) to a test substance during pregnancy and exam-
ining the effects on the fetuses. Studies typically use three or four dose groups plus a
control group, with at least 20 dams per dose group. The dams are sacriﬁced before de-
livery and the contents of the uterus examined. Outcomes of interest typically include
number of resorptions (early deaths), number of fetal deaths, and out of the surviving
fetuses: the number and type of malformations, fetal weights and fetal lengths. Malfor-
mations are typically categorized into three general types: Skeletal, Visceral, or External.
Figure 4.1 illustrates the relationships between all the various outcomes of interest (Kim-
mel and Price, 1990). The outcomes given the most emphasis in determining safe doses
are number of embryolethalities (resorption and deaths), number of malformations, and
reductions in fetal weight.
As one can see from ﬁgure 4.1, the data involve many correlations that must modeled,
making proper analysis challenging. For one, the major units of observation are clustered
into litters so intra-litter correlation between outcomes from the same dam is expected.
Secondly, among the live fetuses, we are interested in multiple outcomes (malformation
status and fetal weight) from each fetus and an inter-outcome correlation is also expected.
This correlation is usually not trivial and must be properly modeled for valid inference.
Also, the fact that malformation status is a binary outcome while fetal weight is a con-
tinuous outcome adds another layer of complication. Third, the hierarchical relationship
between the live outcomes and death further complicates interpretation the data. That
is to say, the live outcomes (malformation status and fetal weight) may not only be cor-
related with other live fetuses, but also with dead fetuses within the saml litter, and this
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Figure 2.1: Outcomes in Developmental Toxicity
correlation should not be ignored in the data analysis.
The ultimate goal of the data analysis is to ﬁt a dose-response model to each out-
come, and to use these models to inform safe doses for regulation purposes. A key
step translating the dose-response model to a ’safe’ a dose is the calculation of the BMD
(benchmark dose) and BMDL (benchmark dose - lower bound) (Gaylor et al., 1998), a
process referred to as quantitative risk estimation, part of the larger goal of quantita-
tive risk assessment. The BMD is deﬁned as the dose that corresponds to a given x %
increase in risk above background, where x is usually 5 or 10. The BMDL is the statis-
tical lower-bound (usually 95%) of the BMD, and is the quantity most useful in assess-
ing and establishing safety standards. Often, a BMDL is calculated for each outcome
and the smallest is chosen, which can lead to underestimating the safe dose and ignores
any correlation. A more valid approach would be to calculate a joint BMD that accounts
for the combined risk of all outcomes. This approach requires that joint risk, the prob-
ability of any adverse outcome, be estimable, meaning that a joint distribution for the
outcomes must be speciﬁed and that relevant inter-outcome correlations must be esti-
mated. For methods where this is not possible (often because inter-outcome correlations
are not estimated), conditional independence is assumed. That is, it is assumed that the
40Table 2.1: Malformation rates by different death rates and dose for 2,4,5-T data (CD-1
strain)
Controls and No Intervention 0.020 or 0.030 g/kg
Death Rate Live Fetuses Malformation Live Fetuses Malformation
Count Rate Count Rate
 5 % 2231 0.0049 2338 0.0081
5 - 15 % 1568 0.0038 2068 0.0063
15 - 25 % 783 0.0026 1126 0.0142
25 - 35 % 85 0.0 213 0.0
35 - 45 % 41 0.0 48 0.0833
> 45 % 24 0.0417 25 0.1600
0.045 g/kg or 0.060 g/kg 0.075 or 0.090 g/kg
Death Rate Live Fetuses Malformation Live Fetuses Malformation
Count Rate Count Rate
 5 % 1117 0.0858 119 0.5714
5 - 15 % 1270 0.1402 118 0.4492
15 - 25 % 1025 0.1737 107 0.7196
25 - 35 % 139 0.3237 16 1.0
35 - 45 % 70 0.2143 13 0.7692
> 45 % 100 0.69 64 0.8594
live outcomes (malformation and fetal weight) are independent of the death outcomes.
In other words, the death rate of a litter does not inform the malformation rate (or fetal
weights) of the litter. Thus, for example, if we are only interested in death and malfor-
mation outcomes, the joint risk, P(AdverseEvent) = P(DeadorMalformed), simpliﬁes to
1 (1 P(Dead)(1 P(MalformedjNotDead))). The approach, while commonly used,
is not satisfying, as there is no theoretical basis for this assumption, and indeed, an ex-
amination of a large data set, from the 2,4,5-Trichlorophenoxyacetic Acid Developmental
Toxicity Study (Chen and Gaylor, 1992), suggests there is a noticeable positive association
between death rate and conditional malformation rate. Table 2.1 shows that for any given
dose, litters with higher death rates tend to have higher conditional malformation rates
as well.
412.1.1 Previous Methods
Early research focused on the problem of accounting for intra-litter correlation when only
considering a single binary outcome, like embryolethality. Many important early models
were developed in the late 1970’s and early 1980’s, including the Beta-binomial model
(Williams, 1975), an extension of the binomial model, and the Ochi-Prentice model (Ochi
and Prentice, 1984), which used an underlying latent multivariate normal distribution to
describe the intra-litter correlation. The development of generalized estimating equations
(GEE) (Liang and Zeger, 1986) allowed researchers to model this data and perform ac-
curate inference without having to correctly specify the distributions or correlations of
the outcomes, making it a popular method for analyzing not just developmental toxicity
data, but a wide variety of clustered discrete data.
The research on mixed outcomes has largely focused on methods based on the latent
multivariate normal distribution, which gives us an intuitive and relatively simple way to
characterize the correlation between malformation and fetal weight. Catalano and Ryan
(Catalano and Ryan, 1992), as well as Fitzmaurice and Laird (Fitzmaurice and Laird,
1995), take advantage of the fact that the joint likelihood can be expressed as the prod-
uct of the marginal distribution for weight and conditional distribution of malformation
given weight. The factorization allows weight and malformation to be modeled sepa-
rately while still accounting for their correlation. Neither method is, however, conducive
for formal risk estimation as joint BMDs cannot be calculated using either model. Regan
and Catalano (Regan and Catalano, 1999) extend and improve on Catalano and Ryan’s
methodology. Their model, while still using the factorization of the latent normal distri-
bution as a framework, allows for the estimation of the inter-outcome correlation by dose
which makes the joint risk, and therefore the BMD and BMDL, possible to calculate. The
correlation parameters tend to increase with dose so allowing for them to be modeled as
a function of dose is an important feature of the methodology.
422.1.2 Plackett-Dale Models
Molenbergs, Geys, and Buyse (Molenberghs et al., 2001) have taken an alternative ap-
proach, using the Plackett-Dale distribution to model the two outcomes of interest. The
Packett-Dale (Plackett, 1965) (Dale, 1986) approach has an advantage over more tradi-
tional probit models in that there is ﬂexibility in choosing the marginal distributions of
the outcomes. So, for example, it is possible to assume the marginal distribution for mal-
formation is binomial rather than what is implied, for example, by the latent normal. Let
Fwk(x) be the cumulative distribution function for wk, the fetal weight of a fetus from litter
k and let Fmk(y) be the cumulative distribution function for mk, the malformation status
of a fetus from litter k. Then, if (mk;wk) follows a Plackett-Dale distribution, their joint
cumulative distribution function is
Fwk;mk =
(
1+(Fwk+Fmk)( k 1) S(Fwk;Fmk; k)
2( k 1)  k 6= 1
FwkFmk  k = 1
where
S(Fwk;Fmk; k) =
q
[1 + ( k   1)(Fwk + Fmk)]2 + 4 k(1    k)FwkFmk
 k, known as the global cross-ratio, deﬁnes the dependence structure of wk and mk,
 k =
Fwk;mk(1   Fwk   Fmk + Fwk;mk)
(Fwk   Fwk;mk)(Fmk   Fwk;mk)
and is used to derive the above joint cumulative density function. A psuedo-likelihood
based estimating equation, pl =
PK
k=1
Pnk
j=1 ln(fwjk;mjk(w;m)), is used to estimate dose-
response parameters.
Geys et al. (Geys et al., 2001) suggest, but do not implement, an extension of this
method that also estimates the within-litter associations for the malformation and weight
outcomes in which all associations are estimated. As we can see from ﬁgure 2.2, the
within-fetus malformation-weight association is not the only source of correlation. There
are also the litter-level associations, namely the association between malformation out-
comes within a litter, the association between fetal weights within a litter, and the asso-
ciation between malformation outcomes and fetal weights between fetuses of the same
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Figure 2.2: Associations present in live outcomes developmental toxicity data
litter, but these are essentially ignored in this method. One approach is to deﬁne each of
these associations through a global cross-ratio and then deﬁne Plackett-Dale distributions
around the cross-ratios. The estimating equation are based on a log-pseudolikelihood
with the following form:
pl =
K X
k=1
nk X
j=1
ln(f1(wjk;mjk)) +
K X
k=1
nk X
j6=j0
ln(f2(wjk;mj0k))
+
K X
k=1
X
j0<j
ln(f3(wjk;wj0k)) +
K X
k=1
X
j0<j
ln(f4(mjk;mj0k))
where f1, f2, f3, f4 are all Plackett densities characterizing different odds ratios: f1 is the
joint probability of weight and malformation from the same fetus, f2 is the joint probabil-
ity of weight and malformation of two different fetuses in the same litter, f3 is the joint
probability of weights between two different animals in the same litter and f4 is the joint
probability of malformations between two different animals in the same litter. Note that,
by assuming exchangeability within litters, the number of intra-litter association param-
eters to be estimated is reduced to three. Also note that, for the f2, f3, and f4 parts of
the log-pseudolikelihoods, we are summing over all possible pair-combinations within a
litter.
2.1.3 Hierarchical Relationship Between Outcomes
Less research has been done on accounting for the correlation induced by the hierarchi-
cal relationships between death and the live outcomes (malformation and fetal weight).
44For the sake of simplicity, we will ignore fetal weight and focus on the case where only
death and malformation are outcomes of interest. Dose response modeling is interested
in estimating the probability of death for a fetus as well as probability of malformation
given the fetus survived and it is straight forward to estimate them separately within a
dam. However, estimating joint risk of both outcomes is not as intuitive, unless we as-
sume conditional independence. Because this assumption is not necessarily expected to
be true in litter data, to compensate models typically include a covariate (usually litter
size or proportion dead) for the malformation dose-response model to serve as an ad-hoc
adjustment for the effect of death on malformation. This approach acknowledges the hi-
erarchical nature of the data by separating the effect of dose and the effect of death-rate
on malformation in the modeling. However, in joint risk assessment, this hierarchical
correlation is still often ignored and conditional independence is still assumed when cal-
culating joint risk.
Most methods proposed for this problem have been inspired from previous work re-
lying on the latent multivariate normal distribution. Christensen (Christensen, 2004) pro-
poses an extension to the Ochi-Prentice model, where death, malformation, and healthy
outcomes are considered ordinal. Speciﬁcally, two threshold parameters, m and d, are
used to deﬁne how the latent variable relates to the observed outcomes. Letting ~ yjk be the
latent variable for fetus j from dam k, if ~ yjk < m, then no adverse event is observed for
that fetus, if m < ~ yjk < d, then a malformation is observed for the fetus and if ~ yjk > d,
a fetal death is observed. ~ yk, the vector denoting the latent variables for the fetuses from
dam k, is assumed to follow a multivariate normal distribution with mean 1n and vari-
ance 2((1   )In + Jn). Letting Hk denote the number of healthy fetuses from litter k,
Mk denote the number of malformed fetuses from litter k, and Dk denote the number of
dead fetuses from litter k, the joint distribution of the three outcomes from litter k can be
expressed as:
P(Hk;Mk;Dk) /
Z
B
n(~ zkj0;1;)d~ zk
45where
~ zk = ~ yk   1nk
B = (~ zkj(~ zk <  m;k  Hk) [ (m  ~ zjk <  d;Hk < k < Hk + Mk)
[ (~ zjk   d;j > Hk + Mk)))
m = m   
d = d   
m and d are standardized cutpoints.
Using the above likelihood, the model speciﬁcation is as follows:
m = 

m(Xmm) + (X1)
D = 

d(Xdd) + (X1)
 = g(X2)
where g() can either be the identity function or Fisher’s Z-transformation. X1 is a ma-
trix of litter-speciﬁc covariates common to both both thresholds, while Xm and Xd are
litter speciﬁc litter-covariates speciﬁc to each threshhold. X2 is the matrix of litter-speciﬁc
covariates to . , m, d, and  are their respective model pararemter vectors.
Thus, since the status of a fetus is assumed to be determined by a latent normal dis-
tribution, one correlation parameter, , characterizes all three correlations of interest. Es-
timation under certain data scenarios can be difﬁcult. However, calculating joint risk, the
risk that a fetus experiences death or a malformation, is very easy and intuitive under this
model (joint risk is simply (m)).
Carey (Carey, 2006) develops a simpler model that still allows for conditional depen-
dence. Essentially, the model formalizes the ad-hoc approach of adding an adjustment
covariate to the malformation dose-response model to adjust for the death-malformation
correlation. The adjustment covariate is derived from a latent multivariate normal distri-
bution. However, because the correlation parameters are reparameterized into the adjust-
46ment covariate, joint risk estimation is not intuitive. Also, because the adjustment vari-
able is based on the continuous normal distribution while the observed data are binary,
the actual adjustmentcovariate used is anapproximation of the theoreticaladjustment co-
variate. It is unclear whether these approximations are accurate or whether it potentially
introduces bias.
Because we compare our proposed method with Carey’s method, we present Carey’s
method more formally, as applied to our situation, when only death and malformation
are outcomes of interest. Unlike Christensen’s model, Carey’s likelihood uses two latent
variables, one for death and one for malformation, denoted ~ d and ~ m respectively. The two
latent variables are assumed to follow a multivariate normal distribution. More speciﬁ-
cally, for the k-th litter:
 ~ dk
~ mk

 N

d
m

;

d dm
dm m

where
d = (~ 0 + ~ 1dosek)1nk
m = (~ 0 + ~ 1dosek)1lk
d = 
2
d((1   d)Ink + dJnk)
m = 
2
m((1   m)Ilk + mJlk)
dm = 
T
md = mdmdJnklk
and lk denotes the number of live fetuses while nk denotes the number of implants in
litter k.
Given the above likelihood, the marginal distribution of death and conditional distri-
bution of fetal weight and malformation can be expressed as:
 ~ dk
~ mkj~ dk

 N

d
mjd

;

d 0nklk 0nklk
0lknk 0lk mjd

47where mjd can be expressed as
mjd = (~ 0 + ~ 1dose) + (mdm)(1 + d(nk   1))
 1
 

nk
j=1 ~ dij   nk(~ 0 + ~ 1)dose
d
!
:
Note that mjd can be expressed as the sum of marginal model for latent malformation
plus an adjustment covariate that is a function of the mean standardized residual for fetal
death. While the adjustment term is a bit complicated and includes parameters from the
latent theory that are not estimable, this theoretical model is used to motivate a simpler
adjustment term:
mjd = (0 + 1dose) + 2
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
Mean models are then ﬁt using GEEs with the following dose-response framework:
E[djk]=
q
V ar(djk) = (0 + 1dosek)
E[mjk]=
q
V ar(mjk) = (0 + 1dosek)
To enable easy comparison between the models, we use a logit version of Carey’s method
rather than the proposed probit model. Given the two link functions tend to estimate
similar trends in practice, we believe the derived adjustment covariate derived by Carey
will still apply when the logit link function is used. Thus, in our comparisons, the Carey
model was ﬁt using the following dose-response functions:
logit(E[djk]) = 0 + 1dosek
logit(E[mjkj  D]) = 0 + 1dosek + 2
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
(2.1)
2.2 Proposed Method
We propose a method using the Plackett-Dale framework to model dose-response for hi-
erarchical data. It essentially takes an approach similar to Geys et al. in their proposed
extension but applies it to hierarchical data. As discussed earlier, the Plackett-Dale ap-
proach has certain advantages. It is not restricted to assuming the marginal distributions
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Figure 2.3: Associations present in heirarchical devlopmentoal toxicity data
are latent normal. Instead the marginal distributions are ﬂexible. This also gives added
ﬂexibility in choosing the link function for the dose-response models and also allows sep-
arate marginal models for each outcome, rather than have to model one outcome condi-
tional on the other. These advantages allow the resulting models to be easier to interpret.
It also allows for the direct estimation and modeling of the association parameters, pro-
viding a potential path to calculating joint risk.
The various outcomes and associations of interest present within a litter can be visu-
alized in ﬁgure 4.2. There is also the association between death outcomes within a cluster.
For the fetuses that did not die, there is the association between malformation outcomes
within a cluster. Finally, there is the association between death outcomes and malfor-
mation outcomes, which determines how the death rate of a particular dam will affect
the corresponding conditional malformation rate for the same litter. The idea here is not
to create a complicated likelihood model that will incorporate all possible outcomes and
possible associations, but rather to apply the Plackett-Dale framework to each association
parameter so that we can estimate all relevant association parameters as well as the death
rates and conditional malformation rates.
Formalizing the notation, let djk be a binary random variable that is 1 if fetus j from
dam k is dead and 0 if alive, and let  d be the odds ratio of a fetus j death outcome when
fetus j0, a fetus in the same dam group, is also dead vs when fetus j0 is not dead. Likewise,
49let mjkj  Djk be a binary random variable that is 1 if fetus j from dam k is malformed and
0 if not, given that fetus jk is known to not be dead, and let  m be the odds ratio of fetus
j having a malformation outcome when fetus j0 is also malformed vs when fetus j0 is not
malformed, assuming both fetus j and j0 are not dead. Finally, let  3 be the odds ratio of
fetus j (which is known to be alive) having a malformation outcome when fetus j0 is dead
vs when fetus j0 is not dead. Mathematically, their expressions are as follows:
 d =
P(DjjDj0)=P(  DjjDj0)
P(Djj  Dj0)=P(  Djj  Dj0)
 m =
P
 
Mjj  Dj
 Mj0j  Dj0

=P
   Mjj  Dj
 Mj0jDj0

P
 
Mjj  Dj
   Mj0j  Dj0

=P
   Mjj  Dj
   Mj0j  Dj0

 dm =
P
 
Mjj  Dj
 Dj0

=P
   Mjj  Dj
 Dj0

P
 
Mjj  Dj
   Dj0

=P
   Mjj  Dj
   Dj0

where Dj is a death outcome for fetus j and Mj is a malformation outcome for fetus
j. As with Regan-Catalano’s method, a dose-response model can be estimated for the
association parameter,  , and thus BMDs can be calculated.
Parameters  d,  m,  dm can be thought of as global cross-ratios that deﬁne the various
associations present in the data:  d is the within-cluster association between death out-
comes,  m is the within-cluster association between malformation outcomes, and  3 is the
association between death outcome and malformation outcome that is induced by con-
ditional dependence. From these cross-ratios, the joint probabilities for two deaths, two
malformations (given they are not dead), and one death and one malformation (given the
malformed fetus was known not to be dead), can be derived as:
F1 = P(Dj;Dj0) =
(
1+(2pd)( 1 1) S(pd;pd; d)
2( d 1)  d 6= 1
p2
d  d = 1
F2 = P(Mjj  Dj;Mj0j  Dj0) =
(
1+(2pmj  D)( m 1) S(pmj  D;pmj  D; m)
2( m 1)  m 6= 1
p2
mj  D  m = 1
F3 = P(Mjj  Dj0;Dj0) =
(
1+(pmj  D+pd)( dm 1) S(pmj  D;pd; dm)
2( dm 1)  dm 6= 1
pmj  Dpd  dm = 1
where S(p1;p2; ) =
p
[1 + (    1)(p1 + p2)]2 + 4 (1    )p1p2.
50From these joint probabilities we can derive the the probability mass functions for the
paired outcomes to be:
G1(dj;dj0) =
8
<
:
F1(pd; d) dj = 1;dj0 = 1
2(pd   F1(pd; d)) dj 6= dj0
1   2pd + F1(pd; d) dj = 0;dj0 = 0
G2(mj  Dj;mj  Dj0) =
8
<
:
F2(pmj  D; m) mj  Dj = 1;mj  Dj0 = 1
2(pmj  D   F2(pmj  D; )) mj  Dj 6= mj  Dj0
1   2pmj  D + F2(pmj  D; m) mj  Dj = 0;mj  Dj0 = 0
G3(mj  Dj;dj0) =
8
> > <
> > :
F3(pmj  D;pd; dm) mj  Dj = 1;dj0 = 1
pmj  D   F3(pmj  D; dm) mjDj = 1;dj0 = 0
pD   F3(pD; dm) mjDj = 0;dj0 = 1
1   pmj  D   pd + F3(pmj  D; dm) mj  Dj = 0;dj0 = 0
We take a similar approach to the one proposed in Geys et al. to derive the estimating
equations. Geys et al. propose summing all likelihoods to create a psuedolikelihood
to form the estimating equations. However, they were only considering live outcomes
(malformation and fetal weight). If we take the same approach and use the following
pseudolikelihood:
pl =
K X
k=1
X
j0<j
ln(G1(djk;dj0k))
+
K X
k=1
X
j0<j
ln(G2(mjkj  Djk;mj0kj  Dj0k))
+
K X
k=1
X
j6=j0
ln(G3(djk;mj0kj  Dj0k))
then we ignore the hierarchical relationship inherent in the data and we get biased es-
timates. Simulation studies show that pd was consistently underestimated and pmj  D was
consistently overestimated. We believe that simultaneously estimating the parameters for
the death and malformation models in this way possibly leads to a positive feedback loop
due to the presence of the G3 portion of the likelihood. The presence of G3 portion in the
pseudolikelihood means that in the estimation procedure, the estimate for pmj  D informs
the estimate of pd and vice versa in a very direct way and which may potentially lead to
extreme bias.
Thus, we propose a 2-step procedure for the estimation. First, estimate dose response
51parameters for pd and  d from estimating equations based on
pl1 =
K X
k=1
X
j0<j
ln(G1(djk;dj0k))
Then, estimates for pm,  m, and  3 can then be estimated from estimating equations based
on
pl2 =
K X
k=1
X
j0<j
ln(G2(mjkj  Djk;mj0kj  Dj0k))
+
K X
k=1
X
j6=j0
ln(G3(djk;mj0kj  Dj0k))
by substituting parameters for pd and  d with their estimates obtained from step one.
Thus, we estimate two dose-response models:
k1 =

logit(pdk)
log( dk)

= Xk11
k2 =
0
@
logit(pmj dk)
log( mk)
log( dmk)
1
A = Xk22
We use the logit-link for the probability models and the log-link for the   models, but
other options, such as the probit-link for the probability models are also possible.
The estimating equations used to estimate 1 and 2 are
U(1) =
N X
k=1

@k1
@1
T 
@k1
@1
 T 
@pl1
@k1

and
U(2) =
N X
k=1

@k2
@2
T 
@k2
@2
 T 
@pl2
@k2

respectively, where 1 = (pd; d) and 2 = (pmj  D; m; dm).
The covariance estimates for 1 and 2 are
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@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1
52and
^ cov( ^ 2)=
 
N X
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@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Uk(2)Uk(2)
T
! 
N X
k=1
@Uk(2)
@2
! T   
 
2= ^ 2
respectively.
Because this method treats each possible pairing within a dam as the outcome, it
weighs each dam differently than other methods that use the implant or fetus as an out-
come. For example, when modeling pd, a logistic regression would weight each dam by
the number of implants for that dam, nk. However, the Plackett-Dale model, because it
treats each possible pairing from a dam as a data point, weights each dam by something
closer to n2
k. This can lead to potentially biased estimates and inference inconsistent with
established methods. Indeed, examining the three log-likelihoods shows us that they do
not simplify to what one would expect under independence. The three log-likelihoods of
dam k under independence are as follows:
X
j0<j
ln(G1(djk;dj0k)) = (nk   1)[nk;d=1ln(pdk) + nk;d=0ln(1   pdk)]
X
j0<j
ln(G2(mjkj  Djk;mj0kj  Dj0k))=(lk   1)[lk;m=1ln(pmj d) + lk;m=0ln(1   pmj d)]
X
j6=j0
ln(G3(djk;mj0kj  Dj0k)) = (lk)nk;d=1ln(pdk) + (lk   1)nk;d=0ln(1   pdk)
+ (nk   1)[lk;d=1ln(pmj d) + lk;d=0ln(1   pmj d)]
The likelihoods for each dam are weighted by a function of number of implants or litter
size (or both) when no litter-level associations exist ( d = 1; m = 1; dm = 1). Ideally, in
the case that no litter-level associations exist, we expect the log-likelihood to be similar
to the log-likelihoods used in a ordinary logistic regression, where each fetus is weighted
equally. However, dams with larger implant sizes and litter sizes are weighted more
heavily in our method, giving weight to fetuses of lower doses, which could potentially
inﬂuence parameter estimates and inference. In order to prevent this extraneous weight-
ing where dams with larger implant counts or litter sizes are weighted disproportionately
higher, we divide the derivative of the log-likelihood by the weighting factor so that our
53method conforms to the same weighting as a standard logistic regression under complete
independence. Thus, instead of using

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in our estimating equations.
Because the units are the paired outcomes, if no pairs exist for a particular dam, that
datacan’tbeincludedintheanalysis. Thisincludeslitterswithonlyoneimplantandwith
onlyonesurvivingfetus. Theformercaseissorarethatitdoesn’tmeritanyconsideration.
The second case though is not impossible if the data set considered is large enough and
the number of implants are relatively small. In such cases, the death outcome pairs and
the malformation-death pairs can contribute to the estimation for the models for pd,  d,
 dm, but we cannot use the outcome of the surviving fetus to inform the models for pmj  D
and  m. Typically, however, this phenomenon is rarely observed in practice. The only
realistic scenario in which we would observe a signiﬁcant number of litters with only one
surviving fetus is the case where the highest dose group has an extremely high death rate
such that many of the dams in that dose group have no or just one surviving fetuses. In
such situations, it is common to drop that dose-group entirely from the analysis because
it will potentially affect the dose-response model greatly even though it does not really
54inform the low-dose effect of the study agent due to a differing mechanism of action
toxicologically at the highest dose. So for the purposes of developmental toxicity studies,
this limitation is not a signiﬁcant problem.
The above estimation procedure was programmed in R (version 2.15). For both steps
of the estimation procedure, the Newton-Raphson algorithm for non-linear sets of equa-
tions is used to estimate the model parameters. Both backtracking and the perturbation
of the jacobian when not positive deﬁnite are implemented in the algorithm (Press et al.,
2007). Functions to calculate ﬁrst and second derivatives for G1, G2, and G3 with respect
to each parameter were created. Starting values for the pd and pm d models are calculated
by running the equivalent logistic regression models with GEEs. For the starting values
for the  d,  m, and  dm models, a starting value of 0.0001 is used. For the EG mice dataset
(presented below), a study with a typical sample size and data-pattern, the ﬁrst estima-
tion procedure took 4 iterations and the second estimation procedure took 3 iterations
for convergence. The ﬁrst procedure took 13.36 seconds while the second procedure took
28.48 seconds on a Dell Precision 390 desktop computer with an Intel(R) Pentium(R) 4
CPU 3.00 GHz 2.99 GHz processer running Windows 7 Professional.
2.3 Example
2.3.1 NTP Study of EG in Mice
To illustrate our method, we ﬁt the model to a developmental toxicity study conducted by
theNationalToxicologyProgramtostudytheeffectofEthyleneGlycol(EG)inmice. Rele-
vant summary statistics for the data set are presented in table 2.3.1. While developmental
toxicity studies typically examine multiple types of malformations, for our purposes we
will deﬁne a malformation outcome as any type of malformation observed. The data set
exempliﬁes typical traits of such investigations. Both the death rate and the conditional
malformation rate increase with dose, but the conditional malformation rate appears to
be more sensitive to dose. In the addition, the outcomes have very different background
55Table 2.2: Summary Statistics for EG Mice Data
dose (g/g/day) Dams Implants Deaths % Malformations %
0 25 384 37 11.1 1 0.337
0.75 24 310 34 11.0 26 9.42
1.5 23 266 37 13.9 89 38.9
3.0 23 283 57 20.4 129 57.1
Table 2.3: Model Selection for EG data for pd and  d models. An asterisk under 1, d or d2
indicate a constant, linear, or quadratic dose trend respectively
logit(pd) log( d)
Model 1 d d2 1 d
1 * * * * *
2 * * * *
3 * * *
4 * *
Comparison Wald-test statistic p-value
1-2 0.213 0.644
2-3 0.0386 0.844
3-4 6.80 0.009
rates of response; the baseline malformation rate is near 0 but the control death rate is
non-trivial at greater than 10%.
We ﬁt the following models:
logit(pd) = d0 + d1dose
ln( d) = d0
logit(pmj d) = m0 + m1dose + m2dose
2 (2.2)
ln( m) = m0
ln( dm) = dm0
We decided this model ﬁt the data best after model selection was performed. There was
notstrong evidenceofthe associationparameterschanging withdose. Hence, forthesake
of parsimony, they are assumed to be constant across dose groups. The quadratic model
for the conditional malformation outcomes ﬁt the data better than the linear model and
thus was chosen for this analysis. Table 2.3.1 shows Wald test comparisons for the pd and
 d models and Table 2.3.1 show Wald test comparisons for the pm,  m, and  dm models.
The resulting parameter estimates and associated standard errors are shown in Table
56Table 2.4: Model Selection for EG data for pm,  m and psidm models. An asterisk under 1,
d or d2 indicate a constant, linear, or quadratic dose trend respectively. All models are ﬁt
with the same death model speciﬁcations (linear in logit(pd) and constant in ln( d))
logit(pm) log( m) log( dm)
Model 1 d d2 1 d 1 d
1 * * * * * * *
2 * * * * * *
3 * * * * *
Comparison Wald-test statistic p-value
1-2 17.4 0.00003
1-3 3.55 0.169
Table 2.5: Parameter Estimates, Standard Errors, and 95% Conﬁdence Intervals for EG
mice data (model 4.4)
param estimate standard error 95% conﬁdence interval
d0 -2.20 0.180 (-2.55, -1.85)
d1 0.264 0.101 (0.07, 0.46)
d0 0.521 0.139 (0.25, 0.79)
m0 -5.26 0.563 (-6.36, -4.16)
m1 4.60 0.804 (3.02, 6.18)
m2 -0.917 0.219 (-1.35, -0.49)
m0 1.23 0.219 (0.80, 1.66)
dm0 0.218 0.158 (-0.09, 0.528)
A.1. Typically, the second-order parameters (here, the s) tend to have larger standard
errors and much wider conﬁdence intervals and it is harder to achieve statistical signif-
icance for those parameters. For this data set, we see that none of the dose-response
parameters for the   models were statistically signiﬁcant at the .05 level, and in fact, the
death-malformation association is not detectable at the 0.05 level for this data set (p-value
= 0.17). However, the positive estimate for the parameter hints that the model is capturing
the expected positive correlation between death and malformation.
The estimated probabilities for each dose group are shown in Table 2.3.1 with the
estimated  s shown in table 2.3.1.
For the death dose-reponse model, we calculated a BMD0:05 of 1.60 g/kg/day and
BMDL0:05 of 1.10 g/kg/day. For the malformation dose-response model, we calculated a
BMD0:05 of 0.596 g/kg/day and BMDL0:05 of 0.522 g/kg/day. As expected, the BMD0:05
57Table 2.6: Estimates for Probabilities by Dose
dose (g/kg) LCL ^ pd UCL LCL log(^ pm) UCL
0.0 0.0726 0.100 0.136 0.00172 0.00516 0.0154
0.75 0.0951 0.120 0.149 0.0631 0.0889 0.124
1.5 0.117 0.142 0.171 0.286 0.395 0.515
3.0 0.143 0.197 0.267 0.432 0.570 0.698
Table 2.7: Estimates for  s for EG data
  estimate 95% conﬁdence interval
 d 1.68 (1.28, 2.21)
 m 3.43 (2.23, 5.25)
 dm 1.24 (0.911, 1.70)
and BMDL0:05 estimates are much lower for malformation outcomes than death out-
comes, since malformation rate was shown to be more sensitive to dose in this study.
We do not present the results of the models ﬁtted, but we note that the probability
modelswereveryrobusttohowthe  parameterswereestimated. The  modelestimates,
on the other hand, were more sensitive to how the probability models were speciﬁed.
2.3.2 2,4,5-T Study in Mice
We also evaluated our method on a larger data set from a study examining the effects
of 2,4,5-Trichlorophenoxyacetic Acid (2,4,5-T) (Chen and Gaylor, 1992). Several strains
of mice were used in this large experiment and we examine here a subset of the data in
the CD-1 strain. Relevant summary statistics for the data set are presented in table 2.3.2.
As we can see by the number of dams per dose group, the study did employ a balanced
study design because doses were added dynamically as the experiment was conducted
over time.
In this large data set, we would expect the phenomenon of conditional dependence to
be more easily observed. Christiansen made a convincing case that a correlation between
conditional malformation rate and death rate for this data by looking at the conditional
58Table 2.8: Malformation rates by different death rates and dose for 2,4,5-T data (CD-1
strain)
dose (g/kg/day) Dams Implants Deaths % Malf %
0.000 698 8061 820 10.2 33 0.456
0.020 307 3637 410 11.3 24 0.744
0.030 722 8300 1079 13.0 79 1.09
0.045 98 1120 229 20.4 110 12.3
0.060 592 6865 1408 20.5 858 15.7
0.075 44 482 214 44.4 159 59.3
0.090 83 917 494 53.9 268 63.4
malformation rates by dose and by death rate. He observes that even for dams at the
same dose level, dams with higher death rates tend to also have higher malformation
rates. Table 2.1 shows the malformation rates by death rates for dose group. The data
from this table only includes litters with 10 to 13 implants to control for the possible effect
of litter size. It also only includes litters with at least one live outcome.
Thus, for these data, we would expect to be able to detect statistically signiﬁcance for
the  dm parameters. Using the same model-ﬁtting strategy we employed for the EG data,
we found the following best ﬁtting model:
logit(pd) = d0 + d1dose + d2dose
2
ln( d) = d0 + d1dose
logit(pmj d) = m0 + m1dose (2.3)
ln( m) = m0 + m1dose
ln( dm) = dm0
Tables 2.3.2 and 2.3.2 show the relevant Wald-test comparisons.
We note that the baseline  dm is indeed statistically signiﬁcant. The model parame-
ter estimates, standard errors, and 95% conﬁdence intervals are shown in Table A.1. For
this data set, we observe that dm0 is statistically signiﬁcant at the two-sided 0.05 level,
conﬁrming that the death-malformation association is indeed detectable. There is no ev-
59Table 2.9: Model Selection for 2,4,5-T data for pd and  d models. An asterisk under 1, d or
d2 indicate a constant, linear, or quadratic dose trend respectively
logit(pd) log( d)
Model 1 d d2 1 d d2
1 * * * * * *
2 * * * * *
3 * * * *
4 * * * *
Comparison Wald-test statistic p-value
1-2 2.10 0.147
2-3 36.01 < 0:0001
2-4 30.71 < 0:0001
Table 2.10: Model Selection for 2,4,5-T data for pm,  m and  dm models. An asterisk under
1, d or d2 indicate a constant, linear, or quadratic dose trend respectively. All models are
ﬁt with the same death model speciﬁcations (quadratic in logit(pd) and linear in ln( d))
logit(pm) log( m) log( dm)
Model 1 d d2 1 d d2 1 d d2
0 * * * * * * * *
1 * * * * * * * *
2 * * * * * * *
3 * * * * * *
4 * * * * *
5 * * * *
6 * * * *
Comparison Wald-test statistic p-value
1-2 2.72 0.100
0-2 1.73 0.188
2-3 1.12 0.290
3-4 0.087 0.768
4-5 671.7 < 0:0001
4-6 9.74 0.00180
60Table 2.11: Parameter Estimates, Standard Errors, and 95% Conﬁdence Intervals for 245T
data (CD-1 strain)
param estimate standard error 95% conﬁdence interval
d0 -2.15 0.0551 (-2.26, -2.04)
d1 -3.58 3.75 (-10.9, 3.77)
d2 304.23 50.69 (204.9, 403.6)
d0 0.887 0.149 (0.596, 1.19)
d1 16.7 3.01 (10.8, 22.6)
m0 -6.33 0.174 (-6.68,-5.99)
m1 79.3 3.06 (73.3, 85.3)
m0 3.51 0.367 ( 2.79, 4.23)
m1 -18.6 5.94 (-30.2, -6.90)
dm0 0.613 0.0739 (0.468, 0.758)
idence that this association increases with dose. The signiﬁcantly positive dm0 conﬁrms
that conditional dependence is detectable with a sufﬁciently large data set. We also note
that the method estimates m1 to be negative and the baseline association to be extremely
high. It is possible this is an artifact of the low malformation rates in the control group.
When an extreme number of the same outcome (in this case, non-malformed fetuses) are
observed, the level of association may be inﬂated, resulting in a high baseline estimate for
 m and an estimated negative trend.
Theestimatedprobabilitiesand  valuesforeachdosegroupareshowninTable2.3.2.
The estimate for log( dm) is 0.613 with a conﬁdence interval of (0.468, 0.758).
For the death dose-repose model, we calculated a BMD of 0.0430 g/kg/day and
BMDL0:05 of 0.0379 g/kg/day. For the malformation dose-response model, we calcu-
lated a BMD of 0.0432 g/kg/day and BMDL0:05 of 0.0419 g/kg/day. We note that, un-
like the EG data where the malformation BMD is much lower than the death BMD, the
two BMDs estimates for the 2,4,5-T data are very similar. Here, the common practice of
choosing the smaller of the two BMDLs as a guide to a safe dose may actually signiﬁ-
cantly underestimate the overall risk of a negative outcome. In this case, that approach
would completely ignore the risk of malformation even though the malformation risk is
similar to the death risk at low dose levels. This data set underlies the importance of
61Table 2.12: Estimates for Probabilities and  s by Dose
dose (g/kg) LCL ^ pd UCL LCL log( ^  d) UCL
0.0 0.0946 0.104 0.115 0.596 0.887 1.18
0.020 0.102 0.109 0.117 1.02 1.22 1.42
0.030 0.112 0.121 0.131 1.21 1.39 1.56
0.045 0.144 0.155 0.167 1.48 1.64 1.80
0.060 0.203 0.219 0.236 1.69 1.89 2.08
0.075 0.297 0.330 0.366 1.88 2.14 2.39
0.090 0.428 0.498 0.569 2.06 2.39 2.72
dose (g/kg) LCL ^ pmj d UCL LCL log( ^  mj d) UCL
0.0 0.00126 0.00177 0.00249 2.79 3.51 4.23
0.020 0.00683 0.00860 0.0108 2.64 3.14 3.65
0.030 0.0157 0.0188 0.0225 2.56 2.96 3.36
0.045 0.0525 0.0593 0.0669 2.41 2.68 2.95
0.060 0.155 0.171 0.190 2.18 2.40 2.62
0.075 0.364 0.405 0.448 1.84 2.12 2.40
0.090 0.636 0.691 0.742 1.42 1.84 2.27
exploring satisfactory ways of calculating joint risk so that a joint BMD can be calculated
for risk assessment. The proposed method does not have a straight forward formula to
calculate joint risk because it is not based on a full likelihood model; a possible avenue of
research is to construct a method for joint BMD calculation that takes advantage of direct
calculations of the association parameter between death and malformation outcomes.
2.4 Comparison to other models
In this section, we compare the P-D model proposed here to previously proposed meth-
ods that account for correlation between death and malformation. We examine estimates
for pd and pmjd by dose group for four methods: the P-D method, Carey’s method, a
”naive” method, and an ”empirical” method. The ”naive” method is merely ﬁtting a
logistic regression for the death data and the malformation data with GEEs and assum-
ing conditional independence. For Carey’s model, we ﬁt the same dose response models
but add the adjustment covariate described in (2.1) for the malformation model. In both
cases, we assume exchangeability for the working correlation matrix. The ”empirical”
62Table 2.13: Estimated Probabilities by Dose and Estimation Method for EG Mice Data
dose (g/kg) ^ pd-Emp ^ pd-Naive ^ pd-P-D ^ pd-Carey
0.0 0.108 0.102 0.100 0.102
0.75 0.110 0.122 0.120 0.122
1.5 0.139 0.145 0.142 0.145
2.0 0.201 0.202 0.197 0.202
dose (g/kg) ^ pmj d-Emp ^ pmj d-Naive ^ pmj d-P-D ^ pmj d-Carey
0.0 0.00337 0.00537 0.00537 0.00527
0.75 0.0942 0.0906 0.0889 0.0918
1.5 0.389 0.396 0.395 0.404
2.0 0.571 0.567 0.570 0.572
method simply calculates the empirical probabilities without any modeling. The empiri-
cal method gives estimates closest to the true probabilities and can be used to gauge bias
that might be introduced in model-ﬁtting for each of the methods presented.
We also compare BMD and BMDLs calculated using our method, Carey’s method
and the ”naive” method. There are several choices for how to calculate a malformation
BMD from Carey’s model. We take the simplest approach by calculating risk at the mean
of the residual terms. Theoretically, the mean adjustment covariates, which are based on
residuals of the death model, should have mean zero. Thus, it is reasonable to interpret
the dose-response parameter as the marginal dose effect on malformation (conditional on
the fetus being alive). The BMDs and corresponding BMDLs are for a 5% increase in risk.
Note that for the death model, Carey’s method and the ”naive” method are identical so
a separate BMD for the naive method is not included. BMDLs are calculating using the
method proposed by Kimmel and Gaylor (Kimmel and Gaylor, 1988).
2.4.1 Comparisons using EG Study Data
Table 2.4.1 shows the probability estimates by dose and estimation method. We note that
both pd and pmj  D estimates are fairly similar by dose across estimation methods, and are
consistent with the empirical estimates.
63Table 2.14: Comparison of BMD and BMDL from various models
Death model Malformation model
P-D Carey P-D Carey Naive
BMD 1.60 1.55 0.596 0.587 0.590
BMDL 1.10 1.08 0.522 0.509 0.513
Relative Difference 0.312 0.303 0.124 0.132 0.131
Table 2.14 show the BMD and BMDL estimates for each method. We see that for
both the death and malformation models, our model predicts slightly higher BMD and
BMDL. The differences for the death model are, however, very small. Figure 2.4 show
the dose response models for death and malformation, as well as the empirical death and
malformation rates by dose (shown in green). We see that both methods provide very
similar ﬁts. We also note that, while the quadratic malformation model gives us a better
ﬁt than the linear model, with probability estimates more consistent with the empirical
estimates, it also assumes the malformation rate peaks at around 2.5 g/kg and then starts
to decline. In other words, it is a non-monotonic trend. This may be controversial but we
believe that for the purposes of benchmark dose analysis, accuracy in low dose estimates,
which the quadratic model provides, is more important.
Table 2.14 also gives the relative difference between BMD and BMDLs (BMD BMDL
BMD ).
We see no large difference between methods, suggesting that the BMD variability is es-
sentialy the same for all methods.
2.4.2 Comparisons using 2,4,5-T Study Data
Table 2.4.2 shows the probability estimates by dose and estimation method. We note
that the pd estimates are fairly similar by dose across estimation methods, and appear
consistent with the empirical estimates. However, we note that the pmj  D estimates for
Carey’s method and our method diverge in the higher dose groups. The pmj  D estimates
from Carey’s method is much higher than the pmj  D estimate from our method or the
naive method for dose group (0.60 g/kg) and higher. Figure 2.5 shows the dose re-
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65Table 2.15: Estimated Probabilities by Dose and Estimation Method
dose (g/kg) ^ pd-Emp ^ pd-Naive ^ pd ^ pd-Carey
0.000 0.101 0.109 0.104 0.109
0.020 0.110 0.112 0.109 0.112
0.030 0.130 0.123 0.120 0.123
0.045 0.195 0.157 0.155 0.157
0.060 0.196 0.222 0.219 0.222
0.075 0.412 0.335 0.330 0.335
0.090 0.530 0.506 0.498 0.506
dose (g/kg) ^ pmj d-Emp ^ pmj d-Naive ^ pmj d ^ pmj d-Carey
0.000 0.00456 0.00190 0.00177 0.00108
0.020 0.00745 0.00910 0.00860 0.00698
0.030 0.00109 0.0198 0.0188 0.0176
0.045 0.123 0.0616 0.0593 0.0678
0.060 0.157 0.176 0.172 0.228
0.075 0.592 0.410 0.405 0.545
0.090 0.633 0.694 0.691 0.830
sponse models for death and malformation and illustrate the same phenomenon. We
note that the ^ pmj  D(0:090g=kg) for Carey’s model (0.830) is much greater than the empir-
ical ^ pmj  D(0:090g=kg) (0.633) but the ^ pmj  D(0:075g=kg) for our model (0.405) and the naive
model (0.410) is much lower than the empirical ^ pmj  D(0:075g=kg) (0.592), making it difﬁ-
cult to make a judgment on which method provides the better ﬁt. All methods give very
similar estimates for the lower doses, suggesting that the estimates for the BMDs will not
vary greatly between methods.
Table 2.16 shows the BMD and BMDL estimates from each method and we indeed
see that for both death models, our model has slightly higher BMDs and BMDLs. On the
other hand, for the malformation model, our BMD and BMDL are higher than Carey’s
model. Both differences are, however, very small. Our model’s BMDL is 2% smaller than
Carey’s BMDL for the deaths and 3% greater for the malformations. Figure 2.5 show the
dose response models for death and malformation. Overall, we see that both methods
give us similar results in terms of quantitative risk assessment. The relative differences
also shown in Table 2.16 also indicate that the variability of the BMD is similar across
methods.
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67Table 2.16: Comparison of BMD and BMDL from various models
Death model Malformation model
P-D Carey P-D Carey Naive
BMD 0.0430 0.0438 0.0432 0.0417 0.0427
BMDL 0.0379 0.0387 0.0418 0.0406 0.0413
Relative Difference 0.118 0.116 0.0324 0.0264 0.0328
2.5 Discussion
In this paper, we use the Plackett-Dale distribution as a framework to develop a method
for modeling hierarchical clustered developmental toxicity data. The method allows us
to marginally evaluate death and conditional malformation as a function of dose while
accounting for the various litter-level associations that are present in the data, including
the association between death and malformation within a litter. It also allows us to model
the litter-level associations as a function of dose.
One advantage of this approach is that it is more ﬂexible in its distributional assump-
tions. Previously proposed methods that account for the hierarchical nature of the data,
such as Christiansen’s model and Carey’s model, are developed from the latent normal
distribution. In Christiansen’s model in particular, this assumption necessitates model-
ing outcome-speciﬁc thresholds rather than direct probabilities, making the interpreta-
tion of dose-response parameter estimates for the probability models less intuitive than
more commonly used methods for binary data, such as logistic regression. However the
Plackett-Dale approach to analyzing the data allows us to choose the marginal distribu-
tions for outcomes of interest. Thus, we can choose to assume binary outcomes, death
and malformation, come from a binomial distribution, and use the corresponding logistic
link. Also, our method is more ﬂexible in terms of describing the various associations
among outcomes. While Christiansen’s model assumes all litter-level associations can be
described with one parameter, our method more ﬂexibily estimates the litter-level associ-
ations into three different components.
68The method also has the advantage of modeling the conditional malformation di-
rectly, unlike Carey’s method or previous ad-hoc procedures that include an adjustment
covariate to adjust for the death-malformation association. Thus, we can interpret the
dose-response parameter for the conditional malformation as the overall effect of dose
on malformation rate, whereas Carey’s method must interpret the dose-response param-
eter as the effect of dose on malformation rate conditional on the adjustment covariate.
It is not clear what this interpretation tells us. One possible interpretation is that it is the
effect of dose on the malformation rate if there was no death-malformation correlation.
Or, since the adjustment covariate is based on the residuals of the death model and thus
should have mean zero, another possible interpretation is that it is the overall dose effect
(since on average, the adjustment covariate should not have an effect). Even when assum-
ing these interpretations are valid, there is still a danger in using Carey’s model. Carey’s
adjustment covariate is derived from a latent normal framework. However, because we
cannot collect data on the latent values, the adjustment covariates are transformed to the
binary setting by necessity. The resulting loss of information may result in bias that may
affect dose-response estimates. In contrast, our method’s interpretations are much more
straight forward.
We ﬁt the model on two data sets and found probability estimates, as well as BMD
and BMDLs, to be consistent with similar models at low dose levels. We also note that
when we applied our method to a large data set that had strong empirical evidence sug-
gesting that the conditional independence assumption does not hold (the 2,4,5-T study),
we were able to detect a statistically signiﬁcant baseline association between death out-
comes and malformation outcomes. It is also worth noting the malformation model for
this method does deviate somewhat from Carey’s model at higher doses.
There are several avenues for further research. One is to take advantage of our es-
timate for  dm to develop a method for joint risk estimation. Currently, we can estimate
BMDs for each outcome, but ideally, we would like to be able to estimate joint risk so
we could calculate a joint BMD. Our method estimates the relevant association,  dm, that
69ties the two outcomes together, but the nature of the Plackett-Dale distribution, in which
pairs of fetuses are the unit of analysis, makes translating the information to calculate
joint risk for one fetus not straightforward. Another research area would be to extend the
method to include continuous outcomes such as fetal weight. Because the Plackett-Dale
distribution allows ﬂexibility in the marginal distribution, incorporating this continuous
outcome should be possible, though the number of associations parameters to estimate
would increase substantially.
It would also be of interest to explore the behavior of our model in different settings
(for example, data with higher correlations) and compare results with Carey’s model. We
would be interested in whether model estimates and standard errors, as well as BMDs
and BMDLs, differ substantially between the two methods. Also of interest is the small
sample behavior of our method. Does our calculation method of the model parameters
lead to a systematic bias of the parameter estimates? And do the theoretical standard
errors for the parameters match up with what we observe in simulations? These kinds of
inquiries can be made through simulations studies where we have more control over the
trends in the data.
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Characteristics of the Plackett-Dale Method for Modeling
Hierarchical Outcomes in Developmental Toxicity Data via
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713.1 Introduction
Controlled animal studies are used to study the effects of various potentially toxic sub-
stances such as drugs or environment contaminants. In such studies, human subjects are
not appropriate and researchers must rely on animals to assess toxicity from experimen-
tal data. Developmental toxicology studies are designed to examine the effect of chemical
substances on developing organisms. These studies involve exposing pregnant animals
(usually mice, rats, or rabbits) to a test substance during pregnancy and examining the
effects on the developing implants and fetuses. Studies typically use three or four dose
groups plus a control group, with at least 20 dams per dose group. The dams are sac-
riﬁced before delivery and the contents of the uterus examined. Outcomes of interest
typically include number of resorptions (early deaths), number of fetal deaths, and out
of the surviving fetuses: the number and type of malformations, fetal weight and fetal
length. Malformations are typically categorized into three general types: Skeletal, Vis-
ceral, or External. Figure 3.1 illustrates the relationships between the various outcomes
of interest (Kimmel and Price, 1990). The outcomes given the most emphasis in deter-
mining safe doses are number of embryolethalities (resorption and deaths), number of
malformations, and reductions in fetal weight.
As one can see from ﬁgure 3.1, the data involve many correlations that must modeled,
making statistical proper analysis challenging. For one, the major units of observation are
clustered into litters so intra-litter correlation between outcomes from the same dam is ex-
pected. Secondly, among the live fetuses, there is interest in analyzing multiple outcomes
(malformation status and fetal weight) from each fetus and an inter-outcome correlation
is also expected. This correlation is usually not trivial and must be properly modeled for
valid inference. Also, the fact that malformation status is a binary outcome while fetal
weight is a continuous outcome adds another layer of complication. Third, the hierarchi-
cal relationship between the live outcomes and death further complicates interpretation
the data. That is to say, the live outcomes (malformation status and fetal weight) may
not only be correlated with other live fetuses, but also with dead fetuses within the same
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Figure 3.1: Outcomes in Developmental Toxicity
litter, and this correlation should not be ignored in the data analysis. Indeed, an examina-
tion of a large data set, from the 2,4,5-Trichlorophenoxyacetic acid developmental toxicity
study (Chen and Gaylor, 1992), suggests there is a measurable and non-trivial positive
association between death and conditional malformation.
3.1.1 Previous Methods
Early research focused on the problem of accounting for intra-litter correlation when only
considering a single binary outcome, like death. Many important early models were de-
veloped in the late 1970’s and early 1980’s, including the beta-binomial model (Williams,
1975), an extension of the binomial model, and the Ochi-Prentice model (Ochi and Pren-
tice, 1984), which used an underlying latent multivariate normal distribution to describe
the intra-litter correlation. The development of generalized estimating equations (GEE)
(Liang and Zeger, 1986) allowed researchers to model these data and perform accurate
inference without having to correctly specify the distributions or correlations of the out-
comes, making it a popular method for analyzing not just developmental toxicity data,
but a wide variety of clustered discrete data.
73The research on mixed outcomes has largely focused on methods based on the la-
tent multivariate normal distribution, which gives us an intuitive and relatively simple
way to characterize the correlation between malformation and fetal weight. Catalano
and Ryan (Catalano and Ryan, 1992), as well as Fitzmaurice and Laird (Fitzmaurice
and Laird, 1995), take advantage of the fact that the joint likelihood can be expressed as
the product of the marginal distribution for weight and conditional distribution of mal-
formation. The factorization allows weight and malformation to be modeled separately
while still accounting for their correlation. Neither method is, however, conducive for
formal risk estimation as joint BMDs cannot be calculated using either model. Regan
and Catalano (Regan and Catalano, 1999) extend and improve on Catalano and Ryan’s
methodology. Their model, while still using the factorization of the latent normal distri-
bution as a framework, allows for the estimation of the inter-outcome correlation by dose
which makes joint risk, and therefore joint BMD and BMDL, possible to calculate. The
correlation parameters tend to increase with dose so allowing for them to be modeled as
a function of dose is an important feature of the methodology.
3.1.2 Hierarchical Relationship Between Outcomes
Less research has been done on accounting for the correlation induced by the hierarchical
relationships between death and live outcomes (malformation and fetal weight). For the
sake of simplicity, here we will ignore fetal weight and focus on the case where only
death and malformation are outcomes of interest. Dose response modeling is interested
in estimating the probability of death for a fetus as well as probability of malformation
given the fetus survived and it is easy enough to estimate them separately within a dam.
However, estimating joint risk of both outcomes is not as intuitive, unless we assume
conditional independence. Because this assumption is not necessarily expected to be true
in litter data, to compensate some models include a term (usually litter size) as a covariate
for the malformation dose-response model to serve as an ad-hoc adjustment for the effect
of death-rate on malformation. This approach acknowledges the hierarchical nature of
the data by separating out the effect of dose and the effect of death-rate on malformation
74in the modeling. However, in joint risk assessment, this hierarchical correlation is still
often ignored and conditional independence is still assumed when calculating joint risk.
Most methods proposed for this issue have been inspired from previous work relying
on the latent multivariate normal distribution. Christiansen (Christensen, 2004) proposes
an extension to the Ochi-Prentice model, where death, malformation, and healthy out-
comes are considered ordinal. Speciﬁcally, two threshold parameters, m and d, are used
to deﬁne how the latent variable relates to the observed outcomes. Letting ~ yjk be the la-
tent variable for fetus j from dam k, if ~ yjk < m, then no adverse event is observed for that
fetus, if m < ~ yjk < d, then a malformation is observed for the fetus and if ~ yjk > d, a fetal
death is observed. The vector, ~ yk, denoting the latent variables for the fetuses from dam
k, is assumed to follow a multivariate normal distribution with mean 1n and variance
2((1   )In + Jn). Under these assumptions, it is possible to ﬁt linear models for m, d,
and . Parameters  and  are inestimable and are assumed to be 0 and 1 respectively.
In this model, since the status of a fetus is assumed to be determined by a latent
normal distribution, one correlation parameter, , characterizes all three correlations of
interest. Estimation under certain data conditions can be difﬁcult. However, calculating
joint risk, the risk that a fetus experiences death or malformation, is straight forward and
intuitive under this model (joint risk is simply (m)).
Carey (Carey, 2006) develops a simpler model that still allows for conditional de-
pendence. Essentially, she formalizes the ad-hoc approach of adding a covariate to the
malformation dose-response model to adjust for the death-malformation correlation. The
adjustment covariate is derived from a latent multivariate normal distribution. However,
because the correlation parameters are reparameterized into the adjustment covariate,
joint risk estimation is not intuitive. Also, because the adjustment variable is based on the
continuous normal distribution while the observed data are binary, the actual adjustment
covariate used is an approximation of the theoretical adjustment covariate. It is unclear
whether these approximations are accurate or whether it potentially introduces bias.
753.1.3 Plackett-Dale
Molenbergs, Geys, and Buyse (Molenberghs et al., 2001) have taken an alternative ap-
proach, using the Plackett-Dale distribution to model malformation and fetal weight. The
Packett-Dale (Plackett, 1965) (Dale, 1986) approach has an advantage over more tradi-
tional probit models in that there is ﬂexibility in choosing the marginal distributions of
the outcomes. So, for example, it is possible to assume the marginal distribution for mal-
formation is binomial rather than what is implied, for example, by the latent normal. Let
Fwk(x) be the cumulative distribution function for wk, the fetal weight of a fetus from litter
k and let Fmk(y) be the cumulative distribution function for mk, the malformation status
of a fetus from litter k. Then, if (mk;wk) follows a Plackett-Dale distribution, their joint
cumulative distribution function is
Fwk;mk =
(
1+(Fwk+Fmk)( k 1) S(Fwk;Fmk; k)
2( k 1)  k 6= 1
FwkFmk  k = 1
where
S(Fwk;Fmk; k) =
q
[1 + ( k   1)(Fwk + Fmk)]2 + 4 k(1    k)FwkFmk
 k, known as the global cross-ratio, deﬁnes the dependence structure of wk and mk,
 k =
Fwk;mk(1   Fwk   Fmk + Fwk;mk)
(Fwk   Fwk;mk)(Fmk   Fwk;mk)
and is used to derive the above joint cumulative density function. A psuedolikelihood
based estimating equation, pl =
PK
k=1
Pnk
j=1 ln(fwjk;mjk(w;m)), is used to estimate dose-
response parameters.
Geys et al. (Geys et al., 2001) suggest, but do not implement, an extension of this
method that also estimates the within-litter associations for the malformation and weight
outcomes in which all associations are estimated. As we can see from ﬁgure 3.2, the
within-fetus malformation-weight association is not the only source of correlation. There
are also three other correlations to potentially model, but are essentially ignored in this
method. For their extension, they propose deﬁning each of these associations through a
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global cross-ratio and then deﬁne Plackett-Dale distributions around the cross-ratios. The
estimating equation are based on a log-pseudolikelihood with the following form:
pl =
K X
k=1
nk X
j=1
ln(f1(wjk;mjk)) +
K X
k=1
nk X
j6=j0
ln(f2(wjk;mj0k))
+
K X
k=1
X
j0<j
ln(f3(wjk;wj0k)) +
K X
k=1
X
j0<j
ln(f4(mjk;mj0k))
where f1, f2, f3, f4 are all Plackett densities characterizing different associations present
in the data:  1,  2,  3 and  4.
3.1.4 Extension to Hierarchical Outcomes
Cudhea proposed a method using the Plackett-Dale framework to model dose-response
for hierarchical data (Cudhea, 2013). It essentially takes the same approach of Geys et al.
in their proposed extension but applies it to hierarchical data.
The various outcomes and associations of interest present within a litter can be visu-
alized in ﬁgure 3.3. First, there is the association between two death outcomes within a
cluster. For the fetuses that did not die, there is the association between two malformation
outcomes within a cluster. Finally, there is the association between death outcomes and
malformation outcomes, which determines how the death experience of a particular dam
will affect the corresponding conditional malformation rate for the same dam.
Let us formalize the notation. Let djk be a binary random variable that is 1 if fetus j
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Figure 3.3: Associations present in hierarchical developmental toxicity data
from dam k is dead and 0 if alive, and let mjkj  Djk be a binary random variable that is 1 if
fetus j from dam k is malformed and 0 if not, given that fetus jk is known to not be dead.
All three   parameters have odds ratio interpretations. Speciﬁcally:
 d =
P(DjjDj0)=P(  DjjDj0)
P(Djj  Dj0)=P(  Djj  Dj0)
 m =
P
 
Mjj  Dj

Mj0j  Dj0

=P
   Mjj  Dj

Mj0jDj0

P
 
Mjj  Dj
   Mj0j  Dj0

=P
   Mjj  Dj
   Mj0j  Dj0

 dm =
P
 
Mjj  Dj
 Dj0

=P
   Mjj  Dj
 Dj0

P
 
Mjj  Dj
   Dj0

=P
   Mjj  Dj
   Dj0

where Dj is a death outcome for fetus j and Mj is a malformation outcome for fetus
j. As with Regan-Catalano’s method, a dose-response model can be estimated for the
association parameters:  d,  m and  dm.
Parameters  d,  m,  dm can be thought of as global cross-ratios that deﬁne the various
associations present in the data:  d is the within-cluster association between death out-
comes,  m is the within-cluster association between malformation outcomes, and  3 is the
association between death outcome and malformation outcome that is induced by con-
ditional dependence. From these cross-ratios, the joint probabilities for two deaths, two
malformations (given they are not dead), and one death and one malformation (given the
78malformed fetus was known not to be dead), can be derived as:
F1 = P(Dj;Dj0) =
(
1+(2pd)( 1 1) S(pd;pd; d)
2( d 1)  d 6= 1
p2
d  d = 1
F2 = P(Mjj  Dj;Mj0j  Dj0) =
(
1+(2pmj  D)( m 1) S(pmj  D;pmj  D; m)
2( m 1)  m 6= 1
p2
mj  D  m = 1
F3 = P(Mjj  Dj0;Dj0) =
(
1+(pmj  D+pd)( dm 1) S(pmj  D;pd; dm)
2( dm 1)  dm 6= 1
pmj  Dpd  dm = 1
where S(p1;p2; ) =
p
[1 + (    1)(p1 + p2)]2 + 4 (1    )p1p2.
From these joint probabilities one can derive the the probability mass functions for
the paired outcomes to be:
G1(dj;dj0) =
8
<
:
F1(pd; d) dj = 1;dj0 = 1
2(pd   F1(pd; d)) dj 6= dj0
1   2pd + F1(pd; d) dj = 0;dj0 = 0
G2(mj  Dj;mj  Dj0) =
8
<
:
F2(pmj  D; m) mj  Dj = 1;mj  Dj0 = 1
2(pmj  D   F2(pmj  D; )) mj  Dj 6= mj  Dj0
1   2pmj  D + F2(pmj  D; m) mj  Dj = 0;mj  Dj0 = 0
G3(mj  Dj;dj0) =
8
> > <
> > :
F3(pmj  D;pd; dm) mj  Dj = 1;dj0 = 1
pmj  D   F3(pmj  D; dm) mjDj = 1;dj0 = 0
pD   F3(pD; dm) mjDj = 0;dj0 = 1
1   pmj  D   pd + F3(pmj  D; dm) mj  Dj = 0;dj0 = 0
The method uses a 2-step estimation procedure. The model ﬁrst estimates dose response
parameters for pd and  d from estimating equations based on
pl1 =
K X
k=1
X
j0<j
ln(G1(djk;dj0k)):
Then, estimates for pm,  m, and  3 can then be estimated from estimating equations based
on
pl2 =
K X
k=1
X
j0<j
ln(G2(mjkj  Djk;mj0kj  Dj0k))
+
K X
k=1
X
j6=j0
ln(G3(djk;mj0kj  Dj0k))
by substituting parameters for pd and  d with their estimates obtained from step one.
79Thus, we estimate two sets of dose-response models:
k1 =

logit(pdk)
log( dk)

= Xk11
k2 =
0
@
logit(pmj dk)
log( mk)
log( dmk)
1
A = Xk22:
We use the logit-link for the probability models and the log-link for the   models, but
other options, such as the probit-link for the probability models are also easily accommo-
dated.
The estimating equations used to estimate 1 and 2 are
U(1) =
N X
k=1

@k1
@1
T 
@k1
@1
 T 
@pl1
@k1

and
U(2) =
N X
k=1

@k2
@2
T 
@k2
@2
 T 
@pl2
@k2

respectively, where 1 = (pd; d) and 2 = (pmj  D; m; dm).
The derivatives of the psuedolikelihoods (pl1 and pl2) are deﬁned as follows:

@pl1
@k1

=
0
B
@
1
nk 1
P
j0<j
@
@pdk
ln(G1(djk;dj0k))
P
j0<j
@
@ dk
ln(G1(djk;dj0k))
1
C
A
and

@pl2
@k2

=
0
B B B B
B B B B
@
1
lk 1
P
j0<j
@
@pmj  Dk
ln(G2(mj  Djk;mj  Dj0k))
+ 1
nk 1
P
j6=j0
@
@pmj  dk
ln(G3(djk;mj dj0k))
P
j0<j
@
@ mj  dk
ln(G2(mj  Djk;mj  Dj0k))
P
j6=j0
@
@ kln(G3(djk;mj  Dj0k))
1
C C C C C
C C C
A
:
The covariance estimates for 1 and 2 are
^ cov( ^ 1)=
 
N X
k=1
@Uk(1)
@1
! 1 
N X
k=1
Uk(1)Uk(1)
T
! 
N X
k=1
@Uk(1)
@1
! T  
  
1= ^ 1
80and
^ cov( ^ 2)=
 
N X
k=1
@Uk(2)
@2
! 1 
N X
k=1
Uk(2)Uk(2)
T
! 
N X
k=1
@Uk(2)
@2
! T   
 
2= ^ 2
respectively.
The Plackett-Dale approach to analyzing developmental toxicity data has been used
empirically to analyze several toxicity data sets but the method has not been systemati-
cally evaluated. Therefore, it is of great interest to study the behavior of this model in a
more controlled setting. Thus, this paper sets out to investigate the properties and operat-
ing characteristics of the method via simulations. Speciﬁcally, we investigate whether our
method’s estimates under reasonable sample sizes are, on average, consistent with their
expectations. We study this by comparing the values of parameter estimates at each dose,
obtained from simulations, to their expected values at each dose, obtained by running
the model on a simulated data with an extremely large sample size in order to establish
”population” values.
While methods have been developed to model the issue of conditional dependence,
there has yet to be a systematic comparison of these methods. In addition, there has been
little research investigating how different the results from these more sophisticated mod-
els are from a naive method that assumes conditional independence. For these reasons,
we also compare the behavior of the proposed method to Carey’s method as well as to the
naive method (which assumes conditional independence). Christiansen’s method is not
included in the analysis because his method does not model conditional malformation
(it is also known to be computationally intensive). Because we compare our proposed
method with Carey’s method in this paper, we present Carey’s method, as applied to our
situation, when only death and malformation are outcomes of interest, more formally
here. Unlike Christensen’s model, Carey’s likelihood uses two latent variables, one for
death and one for malformation, denoted as ~ d and ~ m respectively. The two latent vari-
ables are assumed to follow a multivariate normal distribution. More speciﬁcally, for the
81k-th litter:
 ~ dk
~ mk

 N

d
m

;

d dm
dm m

where
d = (~ 0 + ~ 1dosek)1nk
m = (~ 0 + ~ 1dosek)1lk
d = 
2
d((1   d)Ink + dJnk)
m = 
2
m((1   m)Ilk + mJlk)
dm = 
T
md = mdmdJnklk
and lk denotes the number of live fetuses while nk denotes the number of implants in
litter k.
Given the above likelihood, the marginal distribution of death and conditional distri-
bution of fetal weight and malformation can be expressed as:
 ~ dk
~ mkj~ dk

 N

d
mjd

;

d 0nklk 0nklk
0lknk 0lk mjd

where mjd can be expressed as
mjd = (~ 0 + ~ 1dose) + (mdm)(1 + d(nk   1))
 1
 

nk
j=1 ~ dij   nk(~ 0 + ~ 1)dose
d
!
:
Note that mjd can be expressed as the sum of marginal model for latent malformation
plus an adjustment covariate that is a function of the mean standardized residuals from
the fetal death model. While the adjustment term is a bit complicated and includes pa-
rameters from the latent theory that are not estimable, this theoretical model is used to
motivate a simpler, more practical adjustment term:
mjd = (0 + 1dose) + 2
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
:
82Mean models are then ﬁt using GEEs with the following dose-response framework:
E[djk]=
q
V ar(djk) = (0 + 1dosek)
E[mjk]=
q
V ar(mjk) = (0 + 1dosek)
To enable easy comparison between our model and Carey’s model, we use a logit model
version of her method rather than the proposed probit model. Given the two link func-
tions tend to estimate similar dose-response trends in practice, we believe the derived
the adjustment covariate derived by Carey will still apply when the logit link function
is used. Thus, in our comparisons, the Carey models was ﬁt using the following dose-
response models:
logit(E[djk]) = 0 + 1dosek
logit(E[mjk]) = 0 + 1dosek (3.1)
+ 2
 
 dk   logit 1(^ 0 + ^ 1dose)
p
logit 1(^ 0 + ^ 1dose)[1   logit 1( ^ 0 + ^ 1dose)]=nk
!
Finally, the paper investigates the sensitivity of dose-response parameters to the
model choice for the association parameters. Since the association parameters are mod-
eled simultaneously along with the probability parameters, how we choose to model the
association parameters will affect the resulting probability models. Thus, how sensitive
the probability parameters are to mis-modeling the   models is of great interest, and the
simulations give us an opportunity to study, on average, this sensitivity.
3.2 Simulations
3.2.1 Simulation Methodology
We conducted a simulation study to investigate the behavior of our model. Because the
model is not based on a single full-likelihood, it is impossible to simulate data from a
true distribution consistent with our model. Furthermore, simulating from a Plackett-
Dale distribution can be fairly complex. Instead, here we simulate from a multivariate
83latent normal distribution, and account for conditional dependence in a manner similar to
Carey’s model. This allows for a simpler simulation model and facilitates more intuitive
comparisons between previously proposed models, speciﬁcally Carey’s model. Using a
multivariate normal framework for simulating the data means that we cannot calculate
theoretical   values, however, we can determine arbitrarily accurate estimates for the
”true”   values, as will be shown. Basing the simulation method on Carey’s method
also allows for ﬂexibility in how each of the three association parameters vary with dose.
Thus, it is possible to simulate data where we know ﬁtting a linear dose-response model
for the   parameters is accurate.
We present the latent normal framework used in simulating the data more formally
below: For litter k,
 ~ dk
~ mk

 N

d
m

;

d dm
dm m

where
d = (~ 0 + ~ 1dosek)1nk
m = (~ 0 + ~ 1dosek)1lk
d = 
2
d((1   d)Ink + dJnk)
m = 
2
m((1   m)Ilk + mJlk)
dm = 
T
md = mdmdJnklk:
Here, ~ dk and ~ mk denote the latent variable vectors for death and malformation, respec-
tively while nk and lk denote the number of implants and litter size for litter k. We use a
factorization argument to to re-express the joint density as
 ~ dk
~ mkj~ dk

 N

d
mjd

;

d 0nklk
0lknk mjd

where
mjd = (0 + 1dose) + (mdm)(1 + d(nk   1))
 1
 

nk
j=1 ~ dij   nk(~ 0 + ~ 1)
d
!
mjd = 
2
m((1   m)Ilk + mJlk)   
2
md
2
wnk(1 + d(nk   1))
 1Jlk
84Table 3.1: Simulation Parameters by Dose
dose (g/kg/day) cdk cmk d m dm
0 -1.175 -1.200 0.000 0.000 0.000
0.75 -1.075 -0.900 0.066 0.054 0.060
1.5 -0.960 -0.590 0.142 0.123 0.141
2.0 -0.725 0.110 0.300 0.300 0.300
dose (g/kg/day) pd pmj  D  d  m  dm
0 0.120 0.115 0.994 1.000 1.002
0.75 0.142 0.180 1.241 1.177 1.208
1.5 0.169 0.264 1.555 1.377 1.495
3.0 0.235 0.501 2.382 1.960 2.163
and use this latent distribution to simulate our data. In practice, for each dam, we simu-
late the death latent outcomes from a N(0nk;d) distribution and then use a dose-speciﬁc
cutoff, cdk, to determine whether a particular fetus is dead or alive (a cutoff of 0 would
mean there is a 50% chance the fetus is dead). In simulating the corresponding malfor-
mation data for the same dam, we simulate from a N(0lk;mjd) distribution and then use
cmk  (mdm)(1+d(nk 1)) 1


nk
j=1 ~ dij
d

as the cutoff for that dam, where cmk is the cutoff
(independent of the death outcomes for the litter) for malformation.
We simulated 5,000 datasets. Each data set had 100 dams equally distributed among
four dose groups to conform to typical toxicity study sample sizes. The dose groups we
used were 0 g/kg/day (control), 0.75 g/kg/day, 1.5 g/kg/day, and 3 g/kg/day. Each
dam had 15 implants, again consistent with studies in rodents and rabbits. The cutoffs
and correlation parameter values we used for each dose, as well as the corresponding
probabilities and  s for these parameter values are shown in Table 3.1.
The probabilities and   values were estimated by running an intercept model via our
method on four data sets, one per dose group, each with 125,000 dams. The parameter
estimates from each intercept model are considered the ”true” values for our simulation
study. Our goal was to eliminate as much lack-of-ﬁt as possible so we could evaluate any
potential bias of the method independent of bias due to model lack-of-ﬁt. The parameter
values were chosen so that the relationship between logit(p) and dose, as well the rela-
85tionship between log( ) and dose, would be linear. This linearity was established for all
ﬁve dose-response parameters via trial and error. Because the method is not based on a
full-likelihood method, and because of the complexity of the Plackett-Dale distribution,
it is not practical to simulate the data in such a way that the true values for each param-
eter in each dose-response model is a known quantity. However, in order to study the
method’s consistency with respect to its expectations, we need to understand the true
values.
The parameter values are chosen to be consistent with the trends typically seen in
toxicity studies. Speciﬁcally, with increasing dose, we would expect to see an increase
in death rate, a relatively much higher increase in conditional malformation rate corre-
sponding to a dose increase, and an increase in all three correlation parameters with dose.
In particular, we emulated the trends observed in the EG mice data set.
It is somewhat more difﬁcult to ascertain what would be an appropriate range of
values for the  parameters. While our simulation scheme is essentially the same frame-
work assumed for Carey’s model, her model considers these parameters ancillary and are
not directly estimated. To obtain an idea of appropriate values for , we ﬁt a GEE inter-
cept model (assuming exchangeability) for each dose on the EG mice data and examined
the estimates of the correlation parameters, shown in Table 3.2. We note that, while the
change in association parameters was not statistically signiﬁcant in this analysis, the ta-
ble suggests that there is a trend for association to increase with dose. In particular, m
appears to range from near 0 to around 0.37. For the sake of simplicity, we chose to range
our  values from 0 to 0.3 for all 3  parameters. This allows for a fairly strong overall
trend for association with dose that allows us to observe the behavior of our model in
a somewhat complex situation in terms of correlation structure. Given that a potential
concern for our model is that the probability models may be susceptible to bias when the
association parameters are large, we thought it prudent to look at the model’s behavior
with somewhat high values for the  parameters.
Table 3.3 gives the true values for logit(pd), logit(pmj  D), lm( d), lm( m), lm( dm) by
86Table 3.2: Correlation estimates by dose for EG mice data
dose (g/kg/day) d m
0 0.0415 -0.00557
0.75 0.0786 0.0170
1.5 0.0557 0.274
3 0.0929 0.366
Table 3.3: True values for logit(pd), logit(pmj  D), lm( d), lm( m), and lm( dm) by dose
dose (g/kg/day) logit(pd) logit(pmj  D) lm( d) lm( m) lm( dm)
0 -1.99 -2.04 -0.00582 -0.000173 0.00196
0.75 -1.80 -1.52 0.216 0.163 0.189
1.5 -1.59 -1.03 0.441 0.320 0.402
3.0 -1.18 0.00415 0.868 0.671 0.771
each dose group, as calculated from running the intercept model on 125,000 simulated
data sets with the parameter speciﬁcations used for our study (shown in Table 3.1). Fig-
ure 3.4 shows these points and straight line ﬁts for each of the ﬁve parameters. From these
ﬁgures we can visually verify that the goodness of ﬁt of the linear model with the chosen
link functions is very high.
While we treat these values as the true outcomes in our study, ultimately they are
all estimates obtained from a very large simulated data set, and thus have corresponding
conﬁdence intervals. These conﬁdence intervals and their lengths are shown in Table 3.2.1
for the logit(pd) and logit(pmj  D) parameters and in Table 3.2.1 for log( d), log( m), and
log( dm). Table 3.6 shows the lengths of conﬁdence intervals relative to the range for each
parameter, by dose (range being deﬁned as the difference between the parameter value at
the highest dose and the lowest dose, which in this case is 3 where  is the slope of the
parameter’s dose response model). We feel that the lengths of the conﬁdence intervals
are short enough that the sample size of 125,000 dams is sufﬁciently large to approximate
the true expected value for our proposed model.
The estimation of the model parameters were programmed and executed in R (ver-
sion 2.13). For both steps of the estimation procedure, the Newton-Raphson algorithm
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Figure 3.4: True values of logit(pd), logit(pmj  D), lm( d), lm( m), and lm( dm) by dose with
linear model ﬁt
Table 3.4: Conﬁdence intervals and their ranges for the estimated true probability param-
eter estimates by dose
logit(pd) logit(pmj  D)
dose CI length CI length
0 (-1.994, -1.984) 0.00876 (-2.042, -2.033) 0.00955
0.75 (-1.807, -1.798) 0.00967 (-1.521, -1.512) 0.00910
1.5 (-1.597, -1.587) 0.0107 (-1.030, -1.021) 0.00917
3.0 (-1.186, -1.174) 0.0124 (-0.00112, 0.00940) 0.0105
88Table 3.5: Conﬁdence intervals and their ranges for the estimated true probability param-
eter estimates by dose
lm( d) lm( m) lm( dm)
dose CI length CI length CI length
0 (-0.0108, -0.0008) 0.0100 (0.0062, 0.0059) 0.0121 (-0.0020, 0.0059) 0.0079
0.75 (0.210, 0.221) 0.0114 (0.158, 0.169) 0.0105 (0.185, 0.193) 0.0080
1.5 (0.435, 0.448) 0.0129 (0.315, 0.325) 0.0105 (0.398, 0.406) 0.0089
3.0 (0.860, 0.876) 0.0158 (0.665, 0.678) 0.0134 (0.765, 0.777) 0.012
Table3.6: CIlengthrelativetorangeforlogit(pd), logit(pmj  D), lm( d), lm( m), andlm( dm)
by dose
dose logit(pd) logit(pmj  D) lm( d) lm( m) lm( dm)
(g/kg/day)
0 0.0108 0.00467 0.0115 0.0180 0.0102
0.75 0.0119 0.00446 0.0130 0.0157 0.0104
1.5 0.0132 0.00449 0.0148 0.0157 0.0116
3.0 0.0154 0.00515 0.0180 0.0200 0.0157
for non-linear sets of equations is used. Both backtracking and the perturbation of the
jacobian when not positive deﬁnite are implemented in the algorithm (Press et al., 2007).
Functions to calculate ﬁrst and second derivatives for G1, G2, and G3 with respect to each
parameter were created. Starting values for the pd and pm d models were calculated by
running the equivalent logistic regression models with GEEs, ignoring hierarchical corre-
lation. For the starting values for the  d,  m, and  dm models, a starting value of 0.0001
is used. The simulations were done on a Rocks cluster with Sun Grid Engine (SGE), with
each node having a processor speed of 2.66 GHz. The total running time for the simula-
tions, which included simulating data sets and formatting them to allow analysis via the
P-D method, the actual calculations of the model parameters for both the P-D method,
Carey’s method and the naive method, and the compilation of summary statistics, took
26.06 hours. The seed was set at 984.
89Table 3.7: Simulation Results: Means
dose (g/kg/day) pd pmj d  d  m  dm
0 0.119 0.115 1.02 0.998 1.02
0.75 0.142 0.178 1.24 1.16 1.22
1.5 0.168 0.265 1.52 1.37 1.47
3 0.233 0.500 2.37 1.96 2.18
Table 3.8: Simulation Results: Bias
dose pd pmj d  d  m  dm
(g/kg/day)
0  9:48  10 4  2:08  10 4 2:43  10 2  2:30  10 3 1:41  10 2
0.75 2:88  10 4  2:21  10 3 1:73  10 4  1:10  10 2 1:23  10 2
1.5  8:62  10 4 1:08  10 3  2:88  10 2  2:39  10 3  2:07  10 2
3 1:26  10 3  1:97  10 4  1:05  10 2  1:18  10 3 2:14  10 2
3.2.2 Simulation results
For each of the 5,000 data sets we ﬁt the following model:
logit(pd) = d0 + d1dose
ln( d) = d0 + m1dose
logit(pmj d) = m0 + m1dose (3.2)
ln( m) = m0 + m1dose
ln( dm) = dm0 + dm1dose:
Out of the 5,000 datasets, the method successfully converged 4,997 times. Table 3.7 shows
the means for the estimates of interest, pd, pm,  d,  m,  dm, by dose. Tables 3.8 and 3.9
show the bias and percentage bias, respectively, for each parameter by dose (under the
heading ”P-D method” for Table 3.9). We see that the bias is relatively small and there
does not seem to be any consistent direction or pattern for any particular dose group or
parameter.
Table 3.10 shows the mean parameter estimates for the model as well as the mean and
empirical standard deviations for each parameter (under the heading ”P-D method”). We
90Table 3.9: Simulation Results: Percentage Bias by dose for the P-D method, Carey’s
method, and the naive method
P-D method Carey’s method Naive method
dose pd pmj d  d  m  dm pd pmj d pd pmj d
(g/kg/day) (%) (%) (%) (%) (%) (%) (%) (%) (%)
0 -0.79 -0.18 2.45 -0.23 1.40 -0.79 -1.98 0.79 -0.12
0.75 0.20 -1.22 0.01 -0.93 1.01 0.21 0.45 0.21 -1.32
1.5 -0.51 0.41 -1.85 -0.17 -1.38 -0.51 4.11 -0.51 0.0058
3 -0.53 -0.04 -0.44 -0.06 0.99 -0.51 5.55 -0.51 -0.76
notethatthemeanandempiricalstandarddeviationsarefairlyclosethoughtheempirical
standard deviations are slightly larger, with the exception of d0.
We also examined the coverage of the parameter values for each dose. Typically,
these are not calculated in a standard simulation analysis. Instead, the coverage and
bias for the model parameters would be calculated. However, in our case, because our
method is not based on a full likelihood model, we feel it is more appropriate to examine
estimates for each dose, where we we have a very precise estimate for the true values.
Table 3.11 shows the coverage for each probability and   for each dose. The coverage
is consistently lower than 95% regardless of parameter for dose. This may have to do
with the fact that our calculation method seems to slightly underestimate the standard
deviation of the parameters. We also note that the coverage seems to decrease as dose
increases. However, the coverage is fairly close to 0.95 at the lower doses.
91Table 3.10: Mean, Empirical Standard Deviation, and Mean Theoretical Standard Devia-
tion for Parameter Estimates for the P-D method, Carey’s method, and the naive method
P-D method
parameter mean emp sd mean theoretical sd
^ d0 -2.00 0.138 0.135
^ d1 0.269 0.0947 0.0910
^ d0 0.00138 0.183 0.171
^ d1 0.276 0.126 0.115
^ m0 -2.05 0.140 0.135
^ m1 0.684 0.0884 0.0833
^ m0 -0.0197 0.186 0.176
^ m1 0.221 0.118 0.110
^ dm0 -.00649 0.137 0.132
^ dm1 0.252 0.0959 0.0930
Naive method
parameter mean emp sd mean theoretical sd
^ d0 -2.01 0.139 0.136
^ d1 0.269 0.0957 0.0932
^ m0 -2.05 0.142 0.138
^ m1 0.697 0.0898 0.0885
Carey’s method
parameter mean emp sd mean theoretical sd
^ d0 -2.01 0.139 0.136
^ d1 0.269 0.0957 0.0932
^ m0 -2.09 0.145 0.139
^ m1 0.749 0.0960 0.0788
^ m2 0.333 0.0660 0.0656
Table 3.11: Coverage by dose for each parameter
dose (g/kg/day) pd pm  d  m  dm
0.0 0.945 0.941 0.938 0.935 0.943
0.75 0.941 0.940 0.920 0.923 0.940
1.5 0.934 0.935 0.902 0.926 0.923
3.0 0.928 0.923 0.879 0.888 0.927
923.2.3 Comparison to Carey’s method and Naive method
We also ﬁt Carey’s model (3.1) on the same 5,000 simulated data sets to compare to the
P-D method. Speciﬁcally, we ﬁt the following model:
logit(pd) = d0 + d1dose
logit(pmj  D) = m0 + m1dose
+ 2
0
@
 dk   logit 1(^ d0 + ^ d1dose)
q
logit 1(^ d0   ^ d1dose)[1   logit 1( ^ d0 + ^ d1dose)]=nk
1
A
where dk is the observed death rate for dam k and nk is the number of implants for dam
k.
The naive model is simply ﬁtting the logistic regression model for pd and pmj  D using
GEE, without any consideration for correlation in the hierarchical outcomes. Speciﬁcally
the models ﬁt are:
logit(pd) = d0 + d1dose
logit(pmj  D) = m0 + m1dose:
Table 3.10 shows the mean parameter estimates for Carey’s model as well as the mean
and empirical standard deviations for each parameter. As expected, we see that condi-
tional malformation dose response is quite different between the two methods. We also
observe that the empirical standard deviations seem to be slightly higher for the equiva-
lent parameters from the P-D model. This is possibly due to lack of ﬁt in Carey’s mode
and the naive model. However, given that this is true even for the death models, and
both models give near identical means for their parameter estimates, it may indicate that
the P-D model gives slightly more stable results, despite the added complexity. We also
observe that the mean theoretical standard deviation also tends to be slightly lower than
the empirical standard deviation for all three methods.
We also evaluated the bias of the three methods. Table 3.9 shows the percentage bias
for pd and pmj  D for each dose group. Not surprisingly, the differences in bias are small
93between all methods for the death model. For the malformation model, we ﬁnd that
the P-D method is less biased than Carey’s method, especially for the higher dose groups.
This is expected, since the parameters of the simulations were chosen to ﬁt the P-D model.
The bias of the naive model is actually comparable to the P-D model. Only the percentage
bias for the last two dose group is substantially different for the two methods, and even
there, the percent bias does not exceed 1%.
3.2.4 Sensitivity to   model speciﬁcation
We also examine the sensitivity of the pd and pmj d parameters to what models are ﬁt to
the   parameters. In the simulation studies above we ﬁt linear models to the each of
the three   parameters that we know to be true. In practice though, it may be difﬁcult to
detect a trend in these second order parameters because the standard deviations are much
higher. Indeed, even in the 2,4,5-T study, with a sample size of over 2,500 dams, a linear
trend in dose for the  dm was not statistically signiﬁcant (Cudhea, 2013). Thus, incorrectly
ﬁtting a constant model for these association parameters is entirely plausible, making it
importanttoassesshowthepd andpm modelparametersareaffectedwhenoversimpliﬁed
association model parameters are used. To examine this sensitivity, we ﬁt two alternative
models to the same 5,000 simulated data sets. One in which the  dm parameter is assumed
to be constant across doses and another in which all three   parameters are assumed to
be constant across doses. Speciﬁcally, the two alternative models are as follows:
logit(pd) = d0 + d1dose
ln( d) = d0 + m1dose
logit(pmj d) = m0 + m1dose (3.3)
ln( m) = m0 + m1dose
ln( dm) = dm0
94Table 3.12: Mean Parameter Estimates for models (3.2), (3.3), and (3.4)
parameter mean (model 3.2) mean (model 3.3) mean (model 3.4)
^ d0 -2.00 -2.00 -2.01
^ d1 0.269 0.269 0.269
^ d0 0.00138 0.00143 0.484
^ d1 0.276 0.276 NA
^ m0 -2.05 -2.05 -2.05
^ m1 0.684 0.681 0.681
^ m0 -0.0197 -0.0191 0.477
^ m1 0.221 0.221 NA
^ dm0 -.00649 0.424 0.424
^ dm1 0.252 NA NA
and
logit(pd) = d0 + d1dose
ln( d) = d0
logit(pmj d) = m0 + m1dose (3.4)
ln( m) = m0
ln( dm) = dm0:
The mean parameter estimates for all three models are shown in Table 3.12. The per-
centage biases by dose for pd and pm  D for each of the three models are shown in Table 3.13.
Both tables show that the bias on pd and pmj d introduced by misﬁtting the   parameters
is minimal. Oversimplifying the   models does seem to slightly bias the estimates for the
probabilities in higher doses, but even in those cases the percent bias does not exceed 1%.
Likewise, oversimplifying the  dm appears to have little effect on the model parameters
for  d and  m. Table 3.13 also compares the percent bias for these parameters between
models 3.3 and 3.4 and the results do not seem to indicate that the  d and  m parameters
are more sensitive to misspeciﬁcation of the  dm model than the pd and pmj  D parameters
are.
95Table 3.13: Simulation Results: Percentage Bias of parameters for models 3.2, 3.3, and 3.4
model 3.2 model 3.3 model 3.4
dose (g/kg/day) pd(%) pmj  D(%) pd(%) pmj  D(%) pd(%) pmj  D(%)
0 -0.79 -0.18 -0.78 0.021 -0.78 0.032
0.75 0.21 -1.22 0.21 -1.22 0.20 -1.21
1.5 -0.51 0.41 -0.51 0.27 -.51 0.26
3 -0.51 -0.04 -0.54 -0.34 -.52 0.35
dose (g/kg/day)  d(%)  m(%)  d(%)  m(%)
0 2.45 -0.23 2.44 -0.18
0.75 0.01 -0.93 0.01 -0.93
1.5 -1.85 -0.17 -1.85 -0.23
3 -0.44 -0.06 -0.44 -0.23
3.3 Discussion
In this paper, we conduct a simulation study to explore the small sample behavior of the
P-D method for model developmental toxicity data without assuming conditional inde-
pendence. The method, based on the Plackett-Dale distribution, allows for the evaluation
death and conditional malformation outcomes as a function of dose while accounting for
the various litter-level associations that are present in the data, including the association
betweendeathoutcomesandmalformationswithinalitter. Italsoallowsformodelingthe
litter-level association with an odds-ratio interpretations, including as function of dose.
Theoretically, the model has some advantages over previously proposed models that also
relax the conditional independence assumption. One advantage of this approach is that
it is more ﬂexible in its distributional assumptions. Since the method does not rely on
the latent normal distribution, it allows for a theoretical justiﬁcation to use the intuitive
and widely prevalent logistic link function over the probit link function. It also not only
allows for the possibility that litter-level associations can change with dose, but that dif-
ferent types of litter level associations can increase at different rates. It also models the
conditional malformation probability directly, unlike previous methods.
The simulation study showed the method’s variance estimators are close to the em-
pirical variances and that the estimation procedure did appear be able to estimate the
96parameters with minimal bias. Thus, the small sample behavior of the model seems to
be consistent with its large sample expectations. We also compared the simulations re-
sults from the P-D model to Carey’s model and the naive model and found that for the
comparable parameters (the parameters for the death model and the intercept parameter
for the malformation model), the estimates are fairly similar for the naive and the P-D
models. We also found that using the equivalent parameter for Carey’s model to estimate
conditional tended to overestimate the conditional malformation probabilities. This is not
surprising since Carey’s model estimates the conditional malformation probability slope
given the adjustment covariate which depends on the death rate of the litter. It is worth
noting the simulation study indicates that if one only uses m1 to describe the increase in
conditional malformation probabiilty by dose, then one will overestimate the trend. We
also observed that, despite the complexity of the P-D model, the variance estimates for
the parameters were fairly close on average as well (for the comparable parameters).
We also assessed the how sensitive the probability model parameters were to mis-
ﬁtting the   model parameter and found that oversimplifying the   models had only a
small impact on the estimates for pd and pm  D. This is not surprising given how similar the
probability estimates are between the P-D model and the naive model.
There are several avenues for further research to explore. One is to extend the method
to include continuous fetal weight as an outcome of interest. Because the Plackett-Dale
distribution allows ﬂexibility in the marginal distribution, incorporating this continues
outcome should be possible (though the number of associations parameters to estimate
would increase substantially). It would also be of interest to explore the behavior of our
model in different settings (for example, data with higher correlations) and compare re-
sults with Carey’s model. In particular, It would be of interest to see whether model
estimates and standard deviations, differ substantially between the two methods.
The ultimate goal of the data analysis, however, is to ﬁt a dose-response model to
each outcome, and to use these models to inform safe doses for regulation purposes. A
key step translating the dose-response model to a ’safe’ a dose is the calculation of the
97BMD (benchmark dose) and BMDL (the associated lower bound) (Gaylor et al., 1998), a
process referred to as quantitative risk estimation, part of the larger and more general
goal of quantitative risk assessment. The BMD is deﬁned as the dose that corresponds
to a given percent increase in risk above background (usually 5 or 10%). The BMDL is
the statistical lower-bound (usually 95%) of the BMD, and is the quantity most useful in
assessing and establishing safety standards. Often, a BMDL is calculated for each out-
come and the smallest is chosen, which can lead to underestimating the safe dose and
ignores any correlation. A more valid approach would be to calculate a joint BMD that
accounts for the combined risk of all outcomes. This approach requires that joint risk, the
probability of any adverse outcome, be estimable, meaning that a joint distribution for
the outcomes must be speciﬁed and that relevant inter-outcome correlations must be esti-
mated. For methods where this is not possible (often because inter-outcome correlations
are not estimated), conditional independence is assumed. That is, it is assumed that the
live outcomes (malformation and fetal weight) are independent of the death outcomes.
In other words, the death rate of a litter does not inform the malformation rate (or fetal
weights) of the litter. Thus, for example, if we are only interested in death and malfor-
mation outcomes, the joint risk, P(Adverse Event) = P(Dead or Malformed), simpliﬁes
to 1   (1   P(Dead)  (1   P(Malformed j Not Dead))). The approach, while commonly
used, is not satisfying, as there is no theoretical basis for this assumption.
Therefore, it is of great interest to take advantage of our estimate for  dm to develop
a method for joint risk estimation. Currently, we can estimate BMDs separately for each
outcome, but ideally, we would like to be able to estimate joint risk so we could calculate a
jointBMD.Ourmethodestimatestherelevantassociation,  dm, thattiesthetwooutcomes
together, but the nature of the Plackett-Dale distribution, in which pairs of fetuses are the
unit of analysis, makes translating the information to calculate joint risk for one fetus not
straightforward. Thus, pursuing a method to calculate joint BMDs from the P-D model, as
well as Carey’s method, would be worthwhile. By applying these methods to real data, as
well as various simulated scenarios, we can compare the various methods to one another.
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994.1 Introduction
Controlled animal studies are used to study the effects of various potentially toxic sub-
stances such as pharmaceuticals or environmental contaminants. In such studies, human
subjects are often not appropriate and researchers must rely on animal studies to assess
toxicity from experimental data. Developmental toxicology studies are designed to ex-
amine the effect of chemical substances on developing organisms. These studies involve
exposing pregnant animals (usually mice, rats, or rabbits) to a test substance during preg-
nancy and examining the effects on the fetuses. Studies typically use three or four dose
groups plus a control group, with at least 20 dams per dose group. The dams are sac-
riﬁced before delivery and the contents of the uterus examined. Outcomes of interest
typically include number of resorptions (early deaths), number of fetal deaths, and out
of the surviving fetuses, the number and type of malformations, fetal weights and fe-
tal lengths. Malformations are typically categorized into three general types: Skeletal,
Visceral, or External. Figure 4.1 illustrates the relationships between all the various out-
comes of interest (Kimmel and Price, 1990). The outcomes given the most emphasis in
determining safe doses are number of embryolethalities (resorption and deaths), number
of malformations, and reductions in fetal weight.
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Figure 4.1: Outcomes in Developmental Toxicity
100As one can see from Figure 4.1, the data involve many possible correlations that must
be modeled, making proper analysis challenging. The major units of observation are
clustered into litters so intra-litter correlation between outcomes from the same dam is
expected. Secondly, among the live fetuses, there are multiple outcomes (malformation
status and fetal weight) from each fetus and an inter-outcome correlation is also expected.
This correlation is usually not trivial and must be properly modeled for valid statistical
inference. The fact that malformation status is a binary outcome while fetal weight is a
continuous outcome adds another layer of complication. Third, the hierarchical relation-
ship between the live outcomes and death further complicates interpretation the data.
That is to say, the live outcomes (malformation status and fetal weight) may not only be
correlated with other live fetuses, but also with dead fetuses within the same litter, and
this correlation cannot be ignored in the data analysis.
The ultimate goal of the data analysis is to measure dose-response relationships in
each outcome, and to use these models to inform safe doses for regulation purposes. This
process, referred to as quantitative risk estimation, is part of the larger goal of quantitative
risk assessment. In the past, a key step in translating the dose-response model to a ’safe’
a dose was the calculation of the NOAEL (no-observed-adverse-effect level), the highest
observed dose in which the chemical has a statistically signiﬁcant effect. However, this
metric has major ﬂaws, in that they are restricted to actual doses from the experiment,
they encourage poor (small sample size) study designs, and does not provide a corre-
sponding estimate of associated risk (Crump, 1984). Thus this statistic has been replaced
in favor of the more precise and dose-response model driven BMD (benchmark dose) and
BMDL (benchmark dose - lower bound) (Gaylor et al., 1998).
The BMD is deﬁned as the dose that corresponds to a given percent increase in risk
above background (usually 5 or 10 %). The increase is known as the benchmark response,
or BMR. The BMD is obtained from solving
p(dose) p(0)
1 p(0) = BMR.
The BMDL is the statistical lower-bound (usually 95%) of the BMD, and is the quan-
tity most useful in assessing and establishing safety standards. There are several meth-
101ods to calculate the BMDL including the standard Wald approach, where BMDL:95 =
BMD   1:645  sqrt(var(BMD)), and the maximum likelihood approach, where the
BMDL:95 is the dose that satisﬁes 2(lmax l1) = 1:6452 and minimizes the BMD (lmax is the
unrestrictedmaximizedlog-likelihoodandl1 isthelog-likelihoodundersomeconstraint).
The Wald approach is known to yield unstable results and the maximum likelihood ap-
proach requires a model that assumes a full likelihood distribution. For this paper, we use
a method for calculating a BMDL proposed by Kimmel and Gaylor (Kimmel and Gaylor,
1988). In this method, we calculate the dose that corresponds to the speciﬁed excess risk
for the 95% upper conﬁdence bound of the dose-response curve. In practice, this means
the BMDL:95 is the dose that solves ^ r(dose) + 1:645se(^ r(dose)) = BMR where se(^ r(dose)
is calculated via the delta method.
Characterizing risk using the methods described above works well when only con-
sidering a single adverse outcome. However, in many cases, more than one outcome is of
interest (for example death and malformation). The simplistic approach to determining a
safe dose in this scenario is to calculate a BMD for each outcome and then choose the low-
est one. This approach does not take into account the joint toxic effects of the outcomes,
however, and can lead to an underestimation of the safe dose, especially when the out-
comes have low correlation (Ryan, 1992). A better approach is to calculate a BMD based
on joint risk that combines all outcomes of interest. In the context of developmental tox-
icology, where death and malformation are outcomes of interest, this means calculating
one BMD based on P(M[Djdose) rather than choosing the smaller of two BMDs based on
P(Djdose) and P(Mj  D;dose). This approach requires that joint risk, the probability of any
adverse outcome, be estimable, meaning that a joint distribution for the outcomes must
be speciﬁed and that relevant inter-outcome correlations must be estimated. For methods
where this is not possible (often because inter-outcome correlations are not estimated),
conditional independence is assumed. That is, it is assumed that the live outcomes (mal-
formation and fetal weight) are independent of the death outcomes. In other words, the
death rate of a litter does not inform the malformation rate of the litter. Thus, the joint
102risk, P(Adverse Event) = P(Dead or Malformed), simpliﬁes to
P(Adverse Event) = 1   (1   P(Dead)  (1   P(Malformed j Not Dead))): (4.1)
The approach, while commonly used, is not satisfying, as there is no theoretical basis for
this assumption and it ignores potentially substantial correlation in the litter.
In this paper, we present three methods to analyze such data, and then propose three
approaches to calculate the joint risk BMD that take advantage of the unique properties
of the method. We then evaluate and compare the resulting joint BMDs in real data as
well as in simulated scenarios.
4.2 Methods
4.2.1 Naive Method
Thenaivemethodsimplyassumesconditionalindependence, andthusignoresthehierar-
chical correlation present in the data. In other words, death outcomes and malformation
outcomes (conditional on the fetuses being alive) are modeled separately. The intra-litter
correlations, between death outcomes and between malformation outcomes, need not be
ignored and are accounted for via using GEEs (Liang and Zeger, 1986) to estimate the
model parameters and their standard errors.
4.2.2 Carey’s Method
Carey (Carey, 2006) develops a straightforward model that allows for conditional depen-
dence. The method, taking a similar approach to Regan’s model for fetal malformation
and fetal weight (Regan and Catalano, 1999), essentially formalizes the ad-hoc approach
of adding an adjustment covariate to the malformation dose-response model to adjust for
the death-malformation correlation.
103Carey’s likelihood uses two latent variables, one for death and one for malforma-
tion, denoted as ~ d and ~ m respectively. The two latent variables are assumed to follow a
multivariate normal distribution. More speciﬁcally, for the k-th litter:
 ~ dk
~ mk

 N

d
m

;

d dm
dm m

(4.2)
where
d = (~ 0 + ~ 1dosek)1nk
m = (~ 0 + ~ 1dosek)1lk
d = 
2
d((1   d)Ink + dJnk) (4.3)
m = 
2
m((1   m)Ilk + mJlk)
dm = 
T
md = mdmdJnklk
and lk denotes the number of live fetuses while nk denotes the number of implants in
litter k.
Given the above likelihood, the marginal distribution of death and conditional distri-
bution of fetal malformation can be expressed as:
 ~ dk
~ mkj~ dk

 N

d
mjd

;

d 0nklk 0nklk
0lknk 0lk mjd

where mjd is given by
mjd = (~ 0 + ~ 1dose) + (mdm)(1 + d(nk   1))
 1
 

nk
j=1 ~ dij   nk(~ 0 + ~ 1)dose
d
!
or the sum of the marginal model for latent malformation plus an adjustment covariate
that is a function of the mean standardized residual for fetal death. While the adjustment
term is a bit complicated and includes parameters from the latent theory that are not
estimable, this theoretical model is used to motivate a simpler adjustment term:
mjd = (0 + 1dose) + 2
 
 dk   (^ 0 + ^ 1dose)
p
(^ 0   ^ 1dose)[1   ( ^ 0 + ^ 1dose)]=nk
!
104Mean models are then ﬁt using GEEs within the following dose-response framework:
E[djk]=
q
V ar(djk) = (0 + 1dosek)
E[mjk]=
q
V ar(mjk) = (0 + 1dosek)
To enable easy comparison between our model and Carey’s model, we use a logit model
version of her method rather than the proposed probit model. Given the two link func-
tions tend to estimate similar trends in practice, we believe the adjustment covariate de-
rived by Carey will still apply in principle even under the logit link:
logit(E[djk]) = 0 + 1dosek
logit(E[mjk]) = 0 + 1dosek + 2
 
 dk   logit 1(^ 0 + ^ 1dose)
p
logit 1(^ 0   ^ 1dose)[1   logit 1( ^ 0 + ^ 1dose)]=nk
!
Both dose-response models are ﬁt using GEEs.
4.2.3 Plackett-Dale framework
Cudhea proposed a method using the Plackett-Dale framework to model dose-response
for hierarchical data (Cudhea, 2013). It takes a similar approach to Geys (Geys et al., 2001)
but applies it to hierarchical data.
The various outcomes and associations of interest present within a litter can be vi-
sualized in Figure 4.2. First, there is the association between two death outcomes within
a litter. For fetuses that did not die, there is the association between two malformation
outcomes within a cluster. Finally, there is the association between death outcomes and
malformation outcomes, which determines how the death experience of a particular dam
will affect the corresponding conditional malformation within the same dam.
Let us formalize the notation. Let djk be a binary random variable that is 1 if fetus j
from dam k is dead and 0 if alive, and let mjkj  Djk be a binary random variable that is 1 if
fetus j from dam k is malformed and 0 if not, given that fetus jk is known to not be dead.
Parameters  d,  m,  dm from Figure 4.2 can be thought of as global cross-ratios that
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Figure 4.2: Associations present in hierarchical developmental toxicity data
deﬁne the various associations present in the data:  d is the within-cluster association
between death outcomes,  m is the within-cluster association between malformation out-
comes, and  3 is the association between the death outcome and malformation outcome
that is induced by conditional dependence. From these cross-ratios, the joint probabili-
ties for two deaths, two malformations (given they are not dead), and one death and one
malformation (given the malformed fetus was known not to be dead), can be derived as:
F1 = P(Dj;Dj0) =
(
1+(2pd)( 1 1) S(pd;pd; d)
2( d 1)  d 6= 1
p2
d  d = 1
F2 = P(Mjj  Dj;Mj0j  Dj0) =
(
1+(2pmj  D)( m 1) S(pmj  D;pmj  D; m)
2( m 1)  m 6= 1
p2
mj  D  m = 1
F3 = P(Mjj  Dj0;Dj0) =
(
1+(pmj  D+pd)( dm 1) S(pmj  D;pd; dm)
2( dm 1)  dm 6= 1
pmj  Dpd  dm = 1
where Dj is a death outcome and Mj is a malformation outcome for fetus j, and
S(p1;p2; ) =
p
[1 + (    1)(p1 + p2)]2 + 4 (1    )p1p2.
From these joint probabilities one can derive the probability mass functions for the
106paired outcomes:
G1(dj;dj0) =
8
<
:
F1(pd; d) dj = 1;dj0 = 1
2(pd   F1(pd; d)) dj 6= dj0
1   2pd + F1(pd; d) dj = 0;dj0 = 0
G2(mj  Dj;mj  Dj0) =
8
<
:
F2(pmj  D; m) mj  Dj = 1;mj  Dj0 = 1
2(pmj  D   F2(pmj  D; )) mj  Dj 6= mj  Dj0
1   2pmj  D + F2(pmj  D; m) mj  Dj = 0;mj  Dj0 = 0
G3(mj  Dj;dj0) =
8
> > <
> > :
F3(pmj  D;pd; dm) mj  Dj = 1;dj0 = 1
pmj  D   F3(pmj  D; dm) mjDj = 1;dj0 = 0
pD   F3(pD; dm) mjDj = 0;dj0 = 1
1   pmj  D   pd + F3(pmj  D; dm) mj  Dj = 0;dj0 = 0
The method uses a 2-step estimation procedure, The model ﬁrst estimates dose response
parameters for pd and  d, and then uses the parameter estimate for pd to estimate pm,
 m and  dm. The exact estimation equations used for both steps are described by Cud-
hea (Cudhea, 2013), as are the formulas for the covariance estimates.
4.3 Estimation of Joint Risk
The methods presented that don’t assume conditional independence divide the corre-
lation parameter into three separate association parameters (between death outcomes,
between malformation outcomes, and between death and malformation outcomes) and
are based on distributions that explicitly connect hierarchical association (between death
and malformation outcomes) and joint risk. However, no intuitive formula for P(M [D)
exists for these two models. This is so because, for Carey’s model, the association param-
eters are not directly estimated, and for the P-D model, a full likelihood distribution is not
assumed or used in the estimation of the parameters. These two methods do, however,
estimate parameters that measure the level of correlation between the death and malfor-
mation outcomes. The challenge then, is to incorporate this information into joint risk for
death and malformation so that a joint BMD can be calculated.
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The naive method for calculating joint risk is to use formula (4.1). The formula is derived
from the assumption that conditional dependence is true. In other words, it assumes that
the death rate of a litter will not inform the conditional malformation rate that same litter,
the very assumption that we seek to relax in our models. Thus, it is a somewhat unsat-
isfying to use this formula for BMD and BMDL estimation. Nevertheless, it is a simple
and popular way to calculate joint risk, so the option is explored in this paper. Theoreti-
cally, ignoring the hierarchical correlation in joint risk, as this method does, should lead
to overestimating joint risk and thus underestimating the joint BMD as long as the hierar-
chical association is positive at all doses. Thus, in all practical scenarios, we expect using
this naive joint risk formula to be a conservative method for calculating a joint BMD.
4.3.2 Mean adjustment method
In principle, the mean adjustment method is not very different from the naive method.
It uses the same joint risk formula, but it uses an alternative way to calculate P(Mj  D).
Recall that, in Carey’s method, conditional malformation is modeled as a function of
dose and also an adjustment covariate that is a function of litter size and death rate.
If we choose to model logit(pmj  D) linearly with dose then we would ﬁt the model
logit(pmj  D) = 0 + 1dosek + 2

 dk logit(^ 0+^ 1dose) p
logit(^ 0 ^ 1dose)[1 logit( ^ 0+^ 1dose)]=nk

. Theoretically, on
average, the adjustment covariate should be zero, since both  dk and logit(^ 0 + ^ 1dose)
are unbiased estimators of the death rate at the speciﬁed dose. Therefore, in the naive
method, 2 is ignored in calculating P(Mj  D). An alternative way of calculating joint
risk is to include the adjustment covariate in the calculation of the conditional malforma-
tion probability. Since the adjustment covariate is dam speciﬁc rather than dose speciﬁc,
(because nk and  dk varies by dam), we propose using the observed mean adjustment co-
variate for the purpose of calculating joint risk. By including 2 into the formula for joint
risk, we can incorporate information about the association between death and malforma-
tion outcomes into the calculation of the BMD and BMDL. Theoretically, the mean of the
108adjustment covariate is expected to be zero, and thus, the estimate of the BMD should
not differ much from using the naive method. In practice however, the mean adjustment
covariate is often non-zero (examples can be found in appendix A.2). Thus, it is possible
thatignoringtheadjustmentcovariatewillleadtoabiasedestimateofPmj  D andtherefore,
of the BMD as well. Furthermore, the inclusion of the 2 parameter in the calculation of
the BMDL will actually take into account the uncertainty associated with that parameter.
Using the naive method with Carey’s model ignores this uncertainty and thus possibly
underestimates the BMDL.
4.3.3 Placket-Dale method
Recall that in the Plackett-Dale model, the parameter that measures the association be-
tween death and malformation is  dm. Thus, to incorporate the association between hi-
erarchical outcomes in a joint risk formula for the P-D model must entail including this
parameter. We propose using the formula
P(Adverse Event) = 1   G3(0;0):
Recall that G3(mj  Dj;dj0) is the full probability mass function derived from F3(mj  Dj;dj0),
the joint probability that fetus j is malformed and fetus j0 is dead, given that fetus j is
not dead. Parameter  dm characterizes the association between fetus j and fetus j0. Thus,
G3(0;0) is the probability, for a given pair of fetuses from the same dam, that neither are
malformed or dead, given that one is known to be not dead. It is not the probability
that a single fetus experiences no adverse outcomes. Although somewhat ad-hoc, we
believe that G3 does have properties that make it a plausible candidate to use as a proba-
bility mass function for the outcome of one fetus. First, in the absence of any correlation
between death and live outcomes in a dam, G3(0;0) simpliﬁes to Pd(0)Pm(0j  D), the prob-
ability of a fetus being healthy when conditional independence is assumed. Second, the
manner in which the estimate for  dm affects joint risk is, for the most part, intuitive. Let
us assume the death rate and conditional malformation rate are the same between two
dams, but one has a higher  dm. Then, we would expect the litter with the higher  dm
109to have a higher joint risk, since an increase in  dm results in an increase in G3(0;0) and
thus, a decrease in joint risk. This is consistent with our intuitive understanding of how
hierarchical outcomes correlations should affect joint risk. The higher this correlation, the
higher one would expect the death outcome and the malformation outcomes to be con-
sistent, and thus the outcome of no adverse event (no death or malformation) should be
more likely.
4.4 Example
To illustrate the methods described above, we apply them to two different datasets, an
NTP study examining the effects of Ethanol Glycol (EG) in mice (Price et al., 1985) and
a large sample study examining the effects of 2,4,5-Trichlorophenoxyacetic Acid (2,4,5-T)
in mice (Chen and Gaylor, 1992). The EG data set is an example of a fairly typical study,
with 98 dams and four dose groups. The 2,4,5-T data set is much larger, with 2455 dams
and 7 dose groups. The following ﬁve methods are used to calculate the BMD and BMDL
for both datasets:
1. Using the naive model with the naive joint risk formula
2. Using the P-D model with the naive joint risk formula
3. Using Carey’s model with the naive joint risk formula
4. Using the P-D model with the P-D formula for joint risk
5. Using Carey’s model with the mean-adjustment joint risk.
The naive formula is applicable for all models and thus examined for all three models
discussed here. The model ﬁts used are the same as those used by Cudhea (Cudhea,
2013), and are shown in appendix A.1.
110Table 4.1: BMD, BMDL, and Relative Difference (RD) for EG Mice data
Method 1 2 3 4 5
BMD 0.504 0.512 0.503 0.517 0.503
BMDL 0.420 0.434 0.407 0.389 0.424
RD 0.168 0.153 0.191 0.248 0.158
4.4.1 NTP Study of EG in Mice
Table4.1showstheBMDandBMDLestimatesforﬁvedifferentmethodsfortheEGstudy.
The BMD estimates range from 0.503 g/kg to 0.517 g/kg. We see that using the P-D
model, regardless of what method we use to calculate the BMD, gives us a higher BMD
than the other methods. The BMDL estimates range from 0.389 to 0.434. We do not note
anyobviouspattern withregardstohow theBMDLsdifferbymethod. Therelativediffer-
ences between BMD and BMDL (deﬁned to be (BMD BMDL)=BMD) range from 0.153
to 0.248. The P-D joint risk formula includes the parameter  dm, a second order parameter
that tends to have estimates with a high variance, and that added uncertainty in the joint
risk estimates is expected to be reﬂected in a higher variance BMD estimate. Thus, it is
not surprising that the relative difference between BMD and BMDL when using method
4 (P-D model with P-D risk formula) is much greater than the relative difference using
method 2 (P-D model with the naive joint risk formula). It is, however, somewhat sur-
prising that we observe the relative difference of method 5 (Carey’s model with the joint
risk formula that includes the adjustment term) is actually smaller than that of method 3
(Carey’s model with the naive joint risk formula) since method 5 includes an additional
parameter in its joint risk formula. This is especially interesting since we do not observe
a strong positive correlation between the adjustment term and the other parameter esti-
mates in the conditional malformation model. The P-D model assumes  dm is constant
across dose and estimates  dm for this data set to be a relatively low 1.24 (95% CI of (0.912,
1.70)) which explains the homogeneous BMD estimates from the ﬁve different estimation
methods.
111Table 4.2: BMD, BMDL, and Relative Difference (RD) for 2,4,5-T Mice data
Method 1 2 3 4 5
BMD 3.45 3.41 3.46 3.46 3.47
BMDL 3.09 3.06 3.12 2.92 3.13
RD 0.104 0.103 0.097 0.158 0.098
4.4.2 Study of 2,4,5-T in Mice (CD-1 strain)
Table 4.2 shows the risk estimates for the same ﬁve methods for a study of 2,4,5-T on
mice (CD-1 strain). All ﬁve methods give similar estimates for the BMDs, ranging from
3.41 dg/g to 3.47 dg/g. The Plackett-Dale joint risk formula gives the lowest BMDL
while Carey’s model (regardless of what which joint risk formula is used) give the largest
BMDLs. The P-D-model assumes  dm is constant across dose and estimates  dm to be 1.85
(95% CI of (1.60, 2.13 )), much higher than what was estimated for the EG study, making
the homogeneity BMD estimates from the ﬁve different estimation methods observed for
this data set somewhat surprising.
4.5 Simulations
4.5.1 Methodologic development
A simulation study was conducted to examine the behavior of the ﬁve BMD and BMDL
methods, under 8 different scenarios, each deﬁned by three parameters, the increase in
themagnitudeofthedeathdoseresponse, themagnitudeoftheconditionalmalformation
dose response, and the increase in magnitude of the within-cluster correlations (including
the correlation between death and malformation correlation) by dose. We evaluate the
simulation design parameters in a binary fashion (”high” and ”low”). Thus the eight
different scenarios can be described as:
1. high pd slope, high pmj  D slope, high   slopes
1122. high pd slope, high pmj  D slope, low  s slopes
3. high pd slope, low pmj  D slope, high  s slopes
4. high pd slope, low pmj  D slope, low  s slopes
5. low pd slope, high pmj  D slope, high  s slopes
6. low pd slope, high pmj  D slope, low  s slopes
7. low pd slope, low pmj  D slope, high  s slopes
8. low pd slope, low pmj  D slope, low  s slopes
The method of simulation is based on Carey’s model. The latent normal framework used
is shown in equations (4.2) and (4.3).
We use a factorization argument to re-express the joint density as
 ~ dk
~ mkj~ dk

 N

d
mjd

;

d 0nklk
0lknk mjd

where
mjd = (0 + 1dose) + (mdm)(1 + d(nk   1))
 1
 

nk
j=1 ~ dij   nk(~ 0 + ~ 1)
d
!
mjd = 
2
m((1   m)Ilk + mJlk)   
2
md
2
wnk(1 + d(nk   1))
 1Jlk
and use this latent distribution to simulate the data. In practice, for each dam, we simu-
late the death latent outcomes from a N(0nk;d) distribution and then use a dose-speciﬁc
cutoff, cdk, to determine whether a particular fetus is dead or alive (a cutoff of 0 would
mean there is a 50% chance the fetus is dead). In simulating the corresponding malfor-
mation data for the same dam, we simulate from a N(0lk;mjd) distribution and then use
cmk  (mdm)(1+d(nk 1)) 1


nk
j=1 ~ dij
d

as the cutoff for that dam, where cmk is the cutoff
(independent of the death outcomes for the litter) for malformation.
For each scenario, 5,000 data sets were simulated, each with 4 dose groups (0, 0.75,
1.5, and 3.0), 25 dams per dose group, and 15 fetuses per dam. The cutoff values and
113correlation values by dose for each simulation scenario can be found in appendix A.3. In
some simulations scenarios, not all data sets were successfully simulated. However, these
cases compromised less than 1% of attempts.
For each scenario we modeled the data in three different ways: via the naive condi-
tional independence method, the P-D method, and the mean-adjustment method. Specif-
ically, for the naive method, we ﬁt the model:
pd = logit
 1(d0 + d1dose)
pmj  D = logit
 1(m0 + m1dose)
For the P-D method, we ﬁt the model:
pd = logit
 1(d0 + d1dose)
pmj  D = logit
 1(m0 + m1dose)
 d = exp(d0 + d1dose) (4.4)
 m = exp(m0 + m1dose)
 dm = exp(dm0 + dm1dose)
For Carey’s method, we ﬁt the model:
pd = logit
 1(d0 + d1dose)
pmj  D = logit
 1(m0 + m1dose + m2adjustment)
In other words, for each parameter, we ﬁt a simple linear model with with no polynomial
terms.
For some data sets, an attempt to calculate a BMD failed. In some cases, it is possible
that a BMD does not exist for the ﬁtted model due to a shallow death rate or the con-
ditional malformation rate (or both) (or due to the event rates actually decreasing rather
than increasing with dose). In these cases, which are much more common in scenarios
where the death rate or conditional malformation rate are low, a joint BMD will not exist.
Table 4.5.1 shows the number of times we were not able to calculate a joint BMD for each
114Table 4.3: Number of failed BMD calculation attempts by scenario and BMD calculation
method
method 1 method 2 method 3 method 4 method 5
Scenario 1 0 0 0 0 0
Scenario 2 0 0 0 0 0
Scenario 3 0 0 0 0 0
Scenario 4 0 0 0 0 0
Scenario 5 0 0 0 0 0
Scenario 6 0 0 0 0 0
Scenario 7 31 34 31 105 32
Scenario 8 16 14 16 48 16
joint BMD calculation method and simulation scenario. As is evident in the table, this
only occurred in scenarios 7 and 8, where both the increase in death rate by dose, and the
increase in malformation rate by dose are relatively low by design. The fact that we ob-
serve more failures in scenario 7, where the correlations increase more quickly with dose,
is possibly an artifact of the conditional malformation rates tending to decrease as the cor-
relation parameters increase. It is worth noting that we do observe that method 4, which
uses the P-D BMD calculation method, is more susceptible to failure than the others. This
is not surprising since, in extreme circumstances, it is possible for the P-D joint risk for-
mula to decrease with dose even as the death rate and conditional rate are estimated to
increase with dose (See appendix A.5 for detail). However, given how rarely these fail-
ures occur (2.1% of the time for Scenario 7) and are only observed in extreme scenarios
designed speciﬁcally for understanding performance of the methods under sub-optimal
conditions, it does not appear that this is a signiﬁcant practical weakness of the method.
4.5.2 Results
Figure 4.3 shows the BMD distributions for the ﬁve methods via modiﬁed boxplots for
simulation scenarios 1-4. Likewise, Figure 4.4 shows the same for scenarios 5-8. These
boxplots show the median BMDL (red) and empirical BMDL (green) for each method
and their corresponding conﬁdence intervals. The median BMDL is the median of the
115BMDL distribution while the empirical BMDL is the 5th percentile BMDs calculated from
the relevant empirical distribution. The mean BMD is also included, indicated with a
blue dot. The rest of the plot is the same as a typical boxplot where the box spans the 25th
percentile to the 75th percentile and the central bar signiﬁes the median.
For all eight scenarios, we observe consistent patterns between the ﬁve methods.
First, Carey’s model using the naive joint risk formula always gives the lowest median
BMD. On the opposite end of the spectrum, the BMDs using the P-D model with the P-D
joint risk formula are consistently the least conservative. We also note that BMDs from
method1(naivemethodwithnaivejointrisk)haveaverysimilardistributiontomethod2
(P-D method with P-D joint risk), but with method 2 consistently having a slightly higher
median BMD. Method 5 (mean-adjustment model with mean-adjustment joint risk) does
not hold to a consistent pattern in relation to the other four methods. In the simulation
scenarios where the dose-response for pd is high (1-4), method 5 gives the second lowest
median BMD, below method 1 (naive model with naive joint risk) but above method 2
(P-D model w/ P-D joint risk). In the other four scenarios, where the dose response for pd
is low, method 5 actually provides median BMDs that are higher than the median BMDs
for method 1. In the case of scenarios 5 and 6 (both scenarios in which pd dose response
is low and pm dose response is high), method 5’s median BMDs are actually higher than
those of method 2.
The distribution of empirical BMDLs appears to follow those for the BMDs. For sce-
narios 7 and 8, the empirical BMDLs have very wide conﬁdence intervals, such that all
ﬁve overlap, and thus it is difﬁcult to discern speciﬁc patterns. The median calculated
BMDLs, on the other hand, do not follow the same patterns as the median BMDs. In
fact, in most situations, the conﬁdence intervals for the calculated median BMDLs do not
overlap with the conﬁdence intervals for the empirical BMDLs. For the methods that use
the naive joint risk formula, the calculated median BMDs are consistently higher than the
empirical BMD. For method 4 (PD model w/ P-D joint risk), the opposite is true; the me-
dian calculated BMDL is lower than the empirical BMD. For method 5 (mean-adjustment
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Figure 4.3: Boxplots of joint BMDs for simulation scenarios 1, 2, 3, and 4
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Figure 4.4: Boxplots of joint BMDs for simulation scenarios 5, 6, 7, and 8
118method w/ mean-adjustment joint risk), there is no clear pattern. In scenarios 1 and 2,
the median BMDL is lower than the lower bound of the empirical BMDL, in scenarios 3
and 4, the median BMDL is higher than the upper bound of the empirical BMD, while in
scenarios 5 and 6, the median BMDL is contained within the conﬁdence interval of the
95% conﬁdence interval. Because the calculated BMDLs have a different pattern than the
BMDs, determining which method is most conservative or least conservative according
to BMDL is dependent on the dose-response patterns. For scenarios 1, 2, 3, 5, and 7, we
observe that method 3 is still the most conservative. However, in scenarios 4, 6, and 8, it
appears method 4 is most conservative. However, we do note that for scenarios 4, 6, and
8, the the difference in median BMDL for methods 3 and 4 are fairly slight whereas they
are much more pronounced in methods 1, 2, 3, and 5.
Numerical mean and median summaries for the joint BMDs and BMDLs, as well as
associated standard deviations, are shown in Table 4.5.2 for all 8 scenarios.
Itisalsoworthnotingthatforeachmethodandscenario, thedistributionoftheBMDs
appear to be right-skewed. This is not surprising given the nature of the data (theoretical
minimum of 0 with no theoretical maximum). In addition, the skew seems to increase as
the respective median increases.
4.5.3 Relationship between BMD estimates and association parameters
We note that, as expected, the differences between the ﬁve methods seem to be more ex-
treme in the scenarios where the dose-response for the association parameters is higher.
When we compare BMD distributions from scenarios where the dose-response between
high vs. low   values, it is clear that the difference between methods 4 and 5 (methods
that account for death-malformation association in the calculation of the BMD) and meth-
ods 2 and 3 (methods that use the same modeling technique but use the naive joint risk
to calculate joint BMDs) is much greater under the high   scenario. However, it is impor-
tant to note that these scenarios don’t necessarily share the same dose-response for pd and
119Figure 4.5: Mean, median and standard deviations for the joint BMD and BMDLs, as well
as the empirical BMDL values, from all eight simulation scenarios for all ﬁve methods
BMD BMDL
Scenario Method mean median stdev empirical mean median stdev
1 1 0.331 0.326 0.0411 0.275 0.287 0.284 0.0301
2 0.336 0.331 0.0406 0.280 0.294 0.291 0.0306
3 0.299 0.296 0.0346 0.251 0.267 0.265 0.0280
4 0.357 0.351 0.0476 0.292 0.289 0.287 0.0289
5 0.324 0.320 0.0366 0.273 0.272 0.268 0.0303
2 1 0.301 0.299 0.0229 0.266 0.271 0.270 0.0195
2 0.303 0.302 0.0232 0.269 0.274 0.273 0.0197
3 0.288 0.286 0.0217 0.255 0.262 0.261 0.0191
4 0.311 0.309 0.0248 0.275 0.269 0.268 0.0188
5 0.299 0.297 0.0223 0.265 0.263 0.262 0.0196
3 1 0.466 0.450 0.0871 0.358 0.380 0.373 0.0524
2 0.469 0.454 0.0851 0.363 0.386 0.379 0.0526
3 0.419 0.405 0.0762 0.326 0.355 0.349 0.0491
4 0.508 0.488 0.105 0.383 0.371 0.365 0.0465
5 0.434 0.421 0.0724 0.343 0.360 0.353 0.0515
4 1 0.468 0.456 0.0699 0.377 0.392 0.390 0.0457
2 0.470 0.458 0.0699 0.379 0.396 0.390 0.0457
3 0.442 0.431 0.0443 0.358 0.378 0.372 0.0443
4 0.447 0.437 0.0638 0.365 0.382 0.376 0.0449
5 0.491 0.478 0.0788 0.391 0.374 0.369 0.0391
5 1 0.448 0.430 0.0911 0.345 0.365 0.430 0.0509
2 0.463 0.446 0.0937 0.357 0.381 0.373 0.0537
3 0.421 0.406 0.0837 0.326 0.353 0.345 0.0523
4 0.513 0.486 0.132 0.380 0.368 0.361 0.0479
5 0.463 0.446 0.132 0.361 0.368 0.359 0.0586
6 1 0.422 0.415 0.0538 0.351 0.365 0.361 0.0376
2 0.429 0.421 0.0549 0.356 0.372 0.368 0.0384
3 0.411 0.404 0.0530 0.341 0.360 0.356 0.0385
4 0.447 0.438 0.0612 0.367 0.357 0.354 0.0337
5 0.429 0.422 0.0549 0.356 0.366 0.362 0.0405
7 1 0.886 0.722 0.653 0.499 0.556 0.525 0.135
2 0.924 0.756 0.664 0.518 0.587 0.553 0.143
3 0.834 0.677 0.518 0.466 0.553 0.518 0.148
4 1.26 0.884 1.24 0.565 0.544 0.521 0.107
5 0.892 0.726 0.652 0.504 0.577 0.541 0.156
8 1 0.962 0.832 0.550 0.578 0.643 0.613 0.143
2 0.992 0.853 0.581 0.593 0.663 0.633 0.149
3 0.940 0.810 0.542 0.560 0.646 0.615 0.150
4 1.13 0.933 0.782 0.624 0.598 0.579 0.107
5 0.962 0.831 0.546 0.579 0.659 0.629 0.153
120pmj  D. Indeed, we note that the BMDs from the high   scenarios from methods 1, 2, and
3 (all using the naive joint risk formula) are also higher than their counterparts from the
low   scenarios. Thus, there is a possibility that the discrepency between the difference
between BMDs from calculation methods that account for conditional dependence and
calculation methods that ignore conditional dependence for high   vs low   scenarios is
actually not related to the magnitutde of the death-malformation association and more to
do with the magnitude of the risk of death and malformation outcomes.
To investigate this discrepancy while accounting for BMD magnitude, we examined
a standardized version of the difference between methods 2 and 4, and the difference
between methods 3 and 5. Speciﬁcally, for each simulation scenario, we report (median
BMD for method 4 - median BMD for method 2) / median BMD for method 2 and (me-
dian BMD for method 5 - median BMD for method 3) / median BMD for method 3. Ta-
ble 4.5.3 shows these values for each scenario. While we do observe that high   scenarios
have a higher relative difference than their low   counterparts across both methods, we
also note that these relative differences vary by pd and pmj  D speciﬁcation and still seem
to depend on individual outcome risk. Therefore, individual outcome risk is still poten-
tially a confounder (summary statistics for individual outcome risk BMDs estimates can
be found in appendix A.6).
A more helpful plot might be Figure 4.6 which shows all eight relative differences for
both methods against their respective naive BMDs. These plots illustrate that, for the P-D
method, even when controlling for individual outcome risk, the relative differences for
the BMDs tend to be higher for high   scenarios. While we cannot make any deﬁnitive
conclusions based on these results due to small sample size, the observed trend does seem
to suggest that BMD calculation methods that account for the hierarchical correlation are
indeed sensitive to the hierarchical correlation. It is also worth noting that it appears that
the relative difference in the P-D method seems to increase as the naive BMD increases,
but no such strong trend is observed for the mean-adjustment method.
To more thoroughly understand how the differences between methods change as the
121Table 4.4: Relative difference between median BMDs of method 2 and 4, and of method 3
and 5
P-D method mean adjustment method
(method 2 vs. 4) (method 3 vs. 5)
high  s low  s high  s low  s
high pd, high pmj  D 0.0579 0.0259 0.0813 0.0389
high pd, low pmj  D 0.0756 0.0433 0.0410 0.0141
low pd, high pmj  D 0.0900 0.0406 0.0999 0.0438
low pd, low pmj  D 0.1698 0.0936 0.0733 0.0260
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Figure 4.6: Relative Difference vs. median naive BMD for the P-D method and Carey’s
method
122magnitude of the correlation increases, we conduct another simulation study, looking at
10 simulation scenarios in total, but only where the s change in the simulation parame-
ters. The correlation parameters used for each scenario can be found in Table A.3 in ap-
pendix A.3. To distinguish these simulation scenarios from the eight used in section 4.5.2,
they are labeled with an asterisk (*). For cdk and cmk, the same values are used as in sce-
narios 1 and 2, the ones corresponding to the high pd, high pmj  D scenarios. The reason
for using these cutoffs is to minimize the number of BMD calculations that fail due to
the simulated study having a negative dose-response trend for one of the outcomes. The
likelihood of this happening increases when combining low dose-response trends for the
outcomes and high dose-response trends for the correlation parameters. Since we look at
fairly high correlation patterns for this examination, using a high dose-response for the
outcome probabilities seemed especially prudent in order to minimize bias resulting from
failed BMD calculations.
Because these various scenarios won’t necessarily have the same death and malfor-
mation probabilities for each dose, we examine the median relative differences between
methods to control for individual level risk. Again, we deﬁne the relative difference
between the BMD from method A from method B to be (BMDA   BMDB)=BMDB.
Figure 4.7 plots these relative differences against the median estimated dm1, the dose-
response parameter for the  dm model, for a given simulation scenario, to evaluate how
the median relative differences change as the level of hierarchical association changes.
The ﬁgure shows the trend for most of the 10 relative differences examined is fairly linear
or exponential. Thus, the degree to which these methods differ from each other, for the
most part, appears to increase as the associations increase, and does so at a predictable
rate. There are, however, two notable exceptions. The median relative difference between
method 2 (naive/P-D) vs method 1 (naive/naive), as well as between method 4 (P-D / P-
D) vs. method 1 (naive/naive), increase as hierarchical correlation initially increases, but
then begin to decrease for scenarios where hierarchical association slopes are fairly high.
For the median relative difference between methods 2 and 1, this shift occurs somewhere
between scenarios 7* and 8* while for the median relative difference between methods
1234 and 1, the shift occurs somewhere between scenarios 9* and 10*. The median relative
difference between methods 2 and 1 actually changes from positive to negative, meaning
the joint BMD estimates for method 2 are smaller for method 1 in these extreme scenarios.
Since these two methods use the same naive joint risk formula, and since the death model
parameter estimates have been observed to be fairly consistent for any given estimation
method, it is resonable to suspect that what is driving this shift in relative difference
are the parameter estimates for the malformation model. Speciﬁcally, in scenarios with
extremely high correlation dose-response trends, the P-D model predicts a lower dose-
response for malformation than the naive model does. It should be stressed though that
scenarios 7* through 10* are not likely to be observed in practice. Thus, we do not believe
this somewhat odd behavior of the P-D model based methods is a weakness in practice.
4.5.4 BMDs for individual outcomes
Figures 4.8 and 4.9 show the distribution of the individual death and malformation BMDs
in comparison to the distribution of the joint BMDs via boxplots (without whiskers, as in
Figures 4.3 and 4.4). As expected, the joint BMDs are consistently lower than either of the
individual BMDs, once again highlighting the danger of underestimating risk when only
using single-outcome BMDs for risk assessment, especially in scenarios when the risk of
one outcome is not dominant relative to the other. Also as expected, the death BMDs for
each method have very similar distributions, since it has been observed in previous sim-
ulations that the death model from the P-D method gives estimates very similar to simply
using GEEs (Cudhea, 2013). The malformation BMDs, however, differ quite signiﬁcantly
based on method. The ﬁgures illustrate that the individual malformation BMDs, not the
death BMDs, are a primary driver in the differences in joint BMDs between methods.
In some cases, such as scenarios 3 and 4, where the death rate is overwhelmingly low
compared to the malformation rate, we see that the joint BMD is not much lower than
the death BMD. However, in more realistic scenarios where the conditional malformation
rate is consistently higher than the death rate, the difference between joint and individual
BMDs seems to be non-trivial.
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Figure 4.8: Boxplots of joint and individual BMDs for simulation scenarios 1, 2, 3, and 4
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Figure 4.9: Boxplots of joint BMDs for simulation scenarios 5, 6, 7, and 8
1274.5.5 Sensitivity to mis-specifying   models
It is also of interest to investigate how sensitive the P-D method for joint BMD calculation
is to misspeciﬁcation of the   models, and in particular, the  3 model. It has been shown
that the pd and pmj  D models are robust to   model misspeciﬁcation (Cudhea, 2013). How-
ever, for joint BMD calculations, the estimates for the  3 model are also used and over
simplifying the model may affect the joint BMD estimates signiﬁcantly. Figure 4.10 shows
the distributions of the joint BMDs, and the corresponding median joint BMDLs (both cal-
culated and empirical) from a simulation study for three different   model speciﬁcations,
for both scenarios 5 and 6 (exact numerical values of summary statistics can be found in
appendix ). Speciﬁcally, the   model speciﬁcations are as follows:
ln( d) = d0 + m1dose
ln( m) = m0 + m1dose (4.5)
ln( dm) = dm0
and
ln( d) = d0
ln( m) = m0 (4.6)
ln( dm) = dm0:
and the original speciﬁcation (4.4) used in the previous simulations.
We observe that the mean and median of the BMD estimates are slightly higher for
models 4.5 and 4.6. This is as expected, since the simpliﬁed  dm models used should the-
oretically overestimate the  dm parameters at the lower doses, near to where the BMD
resides. We also observe that the difference between the BMD distribution for model 4.4
and models 4.5 and 4.6 is greater for scenario 5 than in scenario 6. This is also as expected
since the hierarchical correlation is greater for scenario 6. We also note that the gap be-
tween estimated BMD and estimated BMDL seems to be relatively stable among all three
models, implying that simplifying the second order parameter models does not greatly
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Figure 4.10: Boxplots of joint BMDs for models 4.4, 4.5, and 4.6 for simulation scenarios 5
(left) and 6 (right), and corresponding BMDL estimates.
Table 4.5: Relative differences between median BMD and median BMDL for mod-
els 4.4, 4.5, and 4.6 for scenarios 5 and 6
model 4.4 model 4.5 model 4.6
Scenario 5 0.257 0.247 0.250
Scenario 6 0.192 0.190 0.190
inﬂuence BMDL estimation. Table 4.5 shows the median relative difference between BMD
and BMDL (deﬁned to be (BMD-BMDL)/BMD) for each method and each scenario exam-
ined. Given the difﬁculty in detecting statistical signiﬁcance in the slope for second order
parameters, if being conservative is a priority, it is perhaps advisable to use the full model
to estimate  dm even when the dose-response trend for the parameter is not statistically
signiﬁcant.
1294.5.6 Bias
While the investigations above have compared how the various methods for BMD cal-
culations differ from one another, they do not provide any insight into bias. In order
to investigate bias, we must know the ”true” joint risk at each dose so that a true joint
BMD can be calculated from the data. How we characterize the true joint risk depends
on how we simulate the data. Using Carey’s model’s as a basis for simulation is a useful
approach. The joint distribution of a death and malformation outcome from the same
fetus can be expressed as
 ~ djk
~ mjkj~ djk

 N

d
mjd

;

d 0
0 mjd

where d = ~ 0+ ~ 1dose, mjd = ~ 0+ ~ 1dose+
(dmm)
(1+d(nk 1))


nk
j=1 ~ dij nk(~ 0+~ 1)dose
d

, d = 1 and
mjd = 1  
dmnk
1+d(nk 1). Because the correlation between ~ djk and ~ mjkj~ djk are assumed to be
zero in this factorized form, the joint risk formula is given by 1 (1 P(D))(1 P(Mj  D)).
This model is the basis for how the data are simulated in all the simulations presented
earlier in the paper, letting d and m equal zero and deﬁne cutoffs that deterimine how
the latent variable translates into an outcome in practice. Thus, P(D) is deﬁned to be
(~ 0 + ~ 1dosej = 0; = d) and P(Mj  D) is deﬁned to be ((~ 0 + ~ 1dose) + (dmm)(1 +
d(nj 1)) 1


nj
k=1
~ djk nj(~ 0+~ 1)dose
d

j = 0; = mjd). However, in the simulation scenarios
presented, the cutoffs were determined arbitrarily for each dose. Thus, the exact joint risk
is known only for the four doses, making it impossible to calculate a true joint BMD.
We conduct a new set of simulations here, where d, m, and dm follow simple linear
dose-response trend so that joint risk is known for every dose, and thus the true joint
BMD can be calculated for each simulation scenario. Note that the formula for P(Mj  D) is
dependent on the death outcomes for the entire litter. For a marginal value for P(Mj  D),
we replace the adjustment covariate with the expected mean of the adjustment covariate,
which is 0, so that P(Mj  D) = ((~ 0 + ~ 1dose)j = 0; = mjd). Hierarchical correlation is
not ignored in this formula since mjd is a function of dm.
We examine four simulation scenarios (A, B, C and D). In all four scenarios, the mod-
130Table 4.6: dm parameter values for simulation scenarios A, B, and C as well as their
corresponding joint risk values by dose
dose dm joint risk
A B C D A B C D
0 0 0 0 0.197 0.248 0.248 0.248 0.238
0.75 0 0.0749 0.171 0.268 0.366 0.360 0.353 0.345
1.5 0 0.149 0.332 0.336 0.504 0.489 0.470 0.469
3.0 0 0.291 0.598 0.462 0.771 0.739 0.710 0.722
els for death and malformation cutoff are the same. Speciﬁcally, we use the models death
cutoff =  1:25+0:2dose and malformation cutoff =  1+0:5dose. These parameters were
chosen to reﬂect a typical study in which the malformation outcome is more sensitive to
dose than the death outcome. The dm parameter changes with differs for each scenario.
Speciﬁcally, in scenario A, we use g(dm) = 0, in scenario B, we use g(dm) = 0:1dose, in
scenario C we use g(dm) = 0:23dose, and in scenario D, we use g(dm) = 0:2 + 0:1dose
where g is Fisher’s z-transformation. In Scenario A, there is no correlation so conditional
independence is a valid assumption. In scenario B, the correlation is relatively low even
in the higher dose groups. In scenario C, the correlation begins low but increases dramat-
ically with dose while in scenario D, the inter-outcome correlation is relatively high even
at lower doses. Table 4.5.6 shows the correlation parameters at each dose as well as the
corresponding joint risk based on this model. The true joint BMDs calculated from this
joint risk formula for scenarios A, B, C and D are, 0.258, 0.269, 0.312, and 0.318 respec-
tively.
Because the data are simulated under a probit model, and we are assessing bias for
these simulations, the joint BMD estimates are also calculated under the probit model. Ta-
ble 4.5.6 shows the median joint BMD, percent bias, and median joint BMDL for each of
the four scenarios using the probit link. We see that the bias is much smaller for scenario
A when the probit link is used. For scenarios C and D, in which the hierarchical correla-
tion parameter is the highest, method 4 has the least bias of the ﬁve methods examined.
For these two scenarios, all other methods substantially underestimate the true joint BMD
ranging from 19% to 9.1% bias. Both method 2 and method 4 are substantially less biased
131than method 1, which completely ignores hierarchical association. Method 3 is not only
the most biased of these methods, but also does not follow an intuitive pattern. Namely,
the median BMD does not appear to increase as hierarchical correlation increases. For sce-
nario B, however, method 4 is the worst performing method, overestimating the true joint
BMD by 5% while method 1, which assumes conditional independence in both model and
joint risk formula, is the most accurate. It is possible that when the hierarchical correla-
tion is low but not zero, the  3 estimates are not as stable, leading to inaccurate estimates.
Whatever the reason, the simulations suggest that the methods’ accuracy is highly de-
pendent on the strength of the correlation: For high correlation scenarios, method 4 is
recommended while for weak correlation scenarios methods 1 and 5 are more reliable.
It is also worth noting that the method 1 results for scenarios B and C appear to
conﬁrm that, in scenarios where the hierarchical association is fairly strong, using the
simplest method for analyzing the data, and thus completely ignoring conditional de-
pendence, does indeed lead to an underestimation of the joint BMD. Furthermore, at
least for scenarios C and D, the more complicated models that do not ignore hierarchical
association appear to be signiﬁcantly more accurate, underlying the importance of using
such methods in risk assessment. Methods 2 and 5, while still underestimating the BMD
in these scenarios, have median BMD estimates higher than the naive method so seem
to account for at least some of the correlation present in the data. It is also worth noting
that, differences in median joint BMDL estimates are much smaller compared to the BMD
estimates because the variance for the BMD in method 4 is much larger compared to other
methods. For example, in scenario C, methods 1, 4 and 5 have almost the same median
joint BMDL despite the stark contrast in median joint BMD.
As equally important factor in BMD estimation is the link function used for the death
and malformation models. Table 4.5.6 shows the same simulation results as Table 4.5.6
but with the model parameters estimated using a logit link function. For the four sce-
narios investigated, the BMD results from the logit link are consistently greater than the
equivalent results from the probit link. The relative differences between the median logit
132link BMDs and and probit link BMDs are shown in the table as well. Median BMD esti-
mates from logit models are 6% to 9% higher than medians from the probit models, exact
differences being dependent on scenario and method. The discrepancy between the pro-
bit and logit models appears to increase as correlation increases for all ﬁve methods, and
that discrepancy increases at different rates depending on the method. For example, for
method 1, the logit median BMD appears to overestimate the probit median BMD by 6.5%
in scenario A and by 6.9% in scenario D. In method 5, the logit median BMD is also 6.5%
greater than the probit median BMD in scenario A, but for scenario D it is 8.7% greater.
Thus, the simulation results show that using the wrong link function leads to signiﬁcantly
less accurate BMD estimates. In scenario A, where all ﬁve methods were fairly accurate
using the probit link, the logit link overestimates by about 7%. Similarly, while for sce-
narios C and D, method 4 was very accurate with the probit models, it overestimates the
BMD by about 7.5% using the logit models. This is expected since the data were simu-
lated under a latent multivariate normal framework, which implies the probit link is the
correct model.
One of the most important aspects of joint risk assessment is in the low-dose extrap-
olation that is made possible by ﬁtting dose-response models. Unfortunately, in practice,
there is no theoretical basis for assuming one link function is more appropriate than the
other. In addition, studies do not typically collect dose-response data for very low doses
where the BMD likely resides, making it difﬁcult to ascertain which link function is the
most appropriate for a given data set.
4.6 Discussion
In this paper we present ﬁve different methods for calculating joint BMDs for develop-
mental toxicity data, four of which are based on models that relax the common but theo-
retically unsatisfactory conditional independence assumption. These ﬁve methods were
formally evaluated and compared via simulations under various scenarios. Speciﬁcally,
the ﬁve methods evaluated are as follows:
133Table 4.7: Expected BMD, median joint BMDs, and % bias for all ﬁve BMD calculations
methods examined for simulation scenarios A, B, C, and D (probit link)
BMD Calculation Method
Truth 1 2 3 4 5
Scenario A
Joint BMD 0.258 0.260 0.260 0.260 0.260 0.260
% bias -0.508 4.83 4.90 -0.506 -0.542
Joint BMDL 0.245 0.246 0.246 0.234 0.245
Scenario B
Joint BMD 0.269 0.270 0.274 0.260 0.283 0.270
% bias -0.158 -1.90 3.55 -5.12 0.430
Joint BMDL 0.245 0.250 0.239 0.239 0.246
Scenario C
Joint BMD 0.312 0.277 0.288 0.253 0.311 0.280
% bias 11.2 7.52 18.8 0.311 10.0
Joint BMDL 0.243 0.255 0.229 0.245 0.244
Scenario D
Joint BMD 0.318 0.275 0.289 0.258 0.318 0.288
% bias 13.6 9.10 18.8 0.0286 9.37
Joint BMDL 0.245 0.258 0.235 0.258 0.252
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1351. Using the naive model and using the naive joint risk formula
2. Using the P-D model and using the naive joint risk formula
3. Using Carey’s model and using the naive joint risk formula
4. Using the P-D model and using the P-D formula for joint risk
5. Using Carey’s model with mean-adjustment formula for joint risk.
The simulations showed that method 3 consistently gave the most conservative BMD
estimates while method 4 was consistently the most anti-conservative. Individual mal-
formation BMDs for the different models showed a similar trend while individual death
BMDs tended to be similar. The calculated BMDLs tended to over or underestimate the
empirical BMDL (5th percentile of the simulated BMDs) depending on method and sce-
nario. Speciﬁcally, the methods that used the naive joint risk formula (1, 2 and 3) tended
to have median BMDLs higher than the equivalent empirical BMDs while method 4’s
median BMDLs were consistently lower than the equivalent empirical BMDs. Therefore,
when comparing these methods based on BMDL, method 4 is no longer consistently the
most anti-conservative. Also, comparisons between the methods that use the naive joint
risk formula and methods that do not suggest that the difference between these methods
are indeed dependent on the magnitude of the hierarchical correlation. An investigation
in how the speciﬁcation of the   models affects BMD and BMDL estimates conﬁrmed
that assuming that  3 does not change with dose increases the BMD and BMDL estimates
(assuming the hierarchical correlations increase with dose in reality), but only slightly.
We also conducted a separate simulation study focusing speciﬁcally on evaluating
differences between these methods as the hierarchical correlation increases. The study
showed that the relative differences between the methods, for the most part, increased in
a fairly linear and predictable pattern as hierarchical correlation (measured with median
 dm slope) increased.
136Anothersimulationstudywasconductedtoassessthebiasoftheﬁvemethods. While
it is difﬁcult to make any conclusions about methods using the P-D model due to possi-
ble lack-of-ﬁt driving the bias estimates, the results suggest that when the hierarchical
associations are fairly high, the P-D method gives the most accurate BMD estimates. Both
methods 2 and 5 give similar estimates that are higher than those from method 1, as
expected, since ignoring this hierarchical correlation should theoretically increase the es-
timated risk. Method 3 BMD estimates seem to differ very little among the four scenarios,
suggesting that the interpretation of 2 for Carey’s model is, indeed, the dose-response
for the conditional malformation outcome if no hierarchical correlation exists in a litter.
However, since this correlation often does exist, this interpretation has little practical use.
Even as we observe that the joint risk methods based on the P-D model are the most
accurate, it must be noted that in the P-D model, every kind of association, between death
outcomes and malformation outcomes or otherwise, is conceptualized as between two
different fetuses, only existing in a group of implants. Thus, applying this concept to
evaluate risk for a single implant is still an ad-hoc approach born out of convenience
and intuition. Perhaps because of this, the method can lead to unintuitive results in cer-
tain situations. In particular, in the case where we have the marginal P(D) and P(Mj  D)
increasing relatively slowly with dose, but  dm increasing quickly with dose, we may
observe that the joint-risk decreases as dose increases. This paradoxical situation is an
unfortunate aspect of our formula for joint risk. F3(0;0) increases as  dm increases, but
also decreases as pd and pm decreases. Thus, in certain scenarios, it is possible for F3(0;0)
to increase, and thus 1   G3(0;0) to decrease, as dose increases. It should be noted, how-
ever, that this scenario where  dm increases at a relatively high rate while pd and pmj  D do
not is an extreme hypothetical scenario that has not been observed in experimental data.
To illustrate, consider a scenario where pd = :1, pmj  D = :1, and  dm = 1:1 for a given dose.
Then, according to the P-D method, the joint BMD at this dose is 0.189. In order for the
joint BMD to decrease slightly, say to 0.186, then pd and pmj  D must increase only slightly,
from 0.1 to 0.105 while  dm must increase dramatically from 1.1 to 3.0. This illustrates the
behavior of the joint risk method but the numerical example is extreme and not expected
137Table 4.9: Median adjustment covariate for the EG mice data
dose 0 0.75 1.5 3.0
adjustment covariate
(median) -0.117 -0.492 -0.225 -0.306
Table 4.10: Median adjustment covariate for the 2,4,5-T mice data
dose 0 0.02 0.03 0.045 0.06 0.075 0.09
adjustment covariate
(median) -0.373 -0.402 -0.422 -0.255 -0.929 -0.0141 0.306
in practice.
It should also be noted that method 5, where we use the mean of the adjustment
covariate, is still a somewhat simplistic approach that ignores the possibility that this
covariate changes with dose. Indeed, assuming the adjustment covariate changes with
dose can be thought of as a possible parallel to how the P-D method can assume  dm
increases with dose since 2

 dk logit(^ 0+^ 1dose) p
logit(^ 0 ^ 1dose)[1 logit ^ 0+^ 1dose)]=nk

and  dm(dose) both char-
acterize the association between death and malformation outcomes at a particular dose.
Thus, ﬁtting a linear regression model to the adjustment covariates and using dose spe-
ciﬁc means is a potential alternative to using the overall mean. For statistical inference,
such an approach may be unsatisfactory since the uncertainty of the linear model will
not be accounted for in the resulting BMDL calculations. However, it may offer a more
accurate picture of the BMD (and thus the BMDL as well). In both EG and 2,4,5-T data
sets, there does not seem to be an obvious pattern between adjustment covariate and
dose (Table 4.9 and Table 4.10 shows the median adjustment covariate by dose for the EG
study and 2,4,5-T study, respectively), so in practice this alternative approach may not re-
sult in signiﬁcantly different BMD results. How the mean/median adjustment covariate
changes with respect to dose in various situations is something that should be studied to
assess the appropriateness of this approach (the adjustment covariate may not increase in
a linear fashion, for example, making a simple linear regression possibly inappropriate).
138The ability to estimate joint BMDs is an essential part of any method that models
developmental toxicity data since deﬁning a safe dose is the ultimate goal for these stud-
ies. The hierarchical nature of the outcomes of these studies has made if very difﬁcult
for a single method to both allow joint BMD estimation and also model death and condi-
tional malformation as unique outcomes with parameters that are easy to interpret. The
P-D model and Carey’s model are two models that account for hierarchical associations
inherent in the data but also model both death and conditional malformation outcomes
separately in a relatively straightforward manner, but had no obvious way to integrate
the parameters pertaining to the hierarchical association to joint BMD calculation. The
joint BMD calculation methods proposed in this paper (methods 4 and 5) are an attempt
to improve the utility of these models by making it possible to use them for joint risk esti-
mation, negating the need to ﬁt a completely separate model to the data (such as a model
that treats all adverse outcomes as one binary or ordinal variable) in order to answer
questions about joint risk.
There are several other avenues of further research to explore. One possibility is to ex-
plore the aforementioned extension to method 5, by modeling the adjustment covariate.
An investigation of bias conducted in this paper hints that such an approach may not be
signiﬁcantly more accurate in practice, but a more formal assessment may prove useful.
Another possibility is to formalize a method for weighting the outcomes (e.g: weigh-
ing death as more signiﬁcant than malformation) in such a way that a weighted joint
BMD statistic can be calculated. The models presented open the opportunity for such a
method by treating death and malformation as different outcomes. Another is to study
existing goodness-of-ﬁt statistics (such as Pearson’s Chi-square statistic), or develop new
goodness-of-ﬁt tests speciﬁc to Carey’s model and the P-D model, so that investigators
will have better diagnostic tools when considering model ﬁt or choosing which model is
most appropriate for the data. It is also of interest to study the distribution of the various
BMD calculation methods proposed in yet more detailed simulations, especially scenar-
ios in which the hierarchical correlation is high even in the low doses, and scenarios in
which the three correlations increase by dose at different rates.
1395.1 Conclusions
Usingthemethodologydeveloped, wecanmodelthedose-responsetrendsforbothdeath
and malformation, as well as three litter-level association parameters, including an asso-
ciation parameter for the hierarchical association between death and malformation. The
model allows us to not only relax the potentially erroneous assumption of conditional
independence between live and non-live outcomes, and also estimates the association
deﬁning this conditional dependence and can model how it changes with dose.
The model assumes that the litter-level correlation can be described by three distinct
association parameters, the association between death outcomes, the association between
live-outcomes, and the association between death and live outcomes, each with an odds
ratio interpretations. This means each association parameter describes the association
between two fetal outcomes within a litter, and thus exchangeability is assumed within
a litter. The model assumes that each kind of pairing within a litter follows a bivariate
Plackett-Dale distribution. The dose-response parameters for death, and then the param-
eters for malformation and the death-malformation association, are estimated sequen-
tially. The method allows for separate dose-response models for death and malformation
(conditional on the fetus not being dead), as well as the three association parameters.
While the model does estimate these association parameters, it does not use a full-
likelihood distribution to describe the data. Therefore, the calculation of joint risk is not
straightforward. A joint risk formula is developed based on the proposed model that
takes advantage of the estimation of the death-malformation association. BMDs calcu-
lated using this joint risk formula performed exceptionally well compared to other meth-
140ods in simulation scenarios where conditional dependence was strong.
5.2 Advantages
Previous methodology that relaxes the conditional independence assumption either sim-
plify the correlation structure of the data (Christensen’s method (Christensen, 2004) uses
only one parameter to describe all inherent litter-level correlations) or do not directly
estimate all relevant correlation parameters (In Carey’s method (Carey, 2006), the param-
eter for the adjustment term contains information on the magnitude of the hierarchical
correlation, but is not a direct estimate). The proposed model, on the other hand, as-
sumes a ﬂexible correlation structure that assumes three separate association parameters
to describe all litter-level correlation (like Carey’s model) and also allows for the direct
estimation (like Christensen’s method) for each one. In addition, the method allows for
modeling the dose-response for each of these parameters, allowing for a fairly complete
picture of the nature of how the data changes as dose changes.
The dose-response parameters also have more intuitive interpretations than the
equivalent models in other methods. Christensen’s method models cutoffs for a theo-
retical latent normal distribution. Thus, none of the parameters directly estimates con-
ditional malformation risk (instead, it models death risk and adverse event risk), which
is not ideal for toxicologists who are speciﬁcally interested in conditional malformation
risk. Carey’s method models death and conditional malformation in a straightforward
manner. However, the malformation model involves an adjustment covariate based on
the death-model residuals. Thus, the interpretation of the dose-response parameter is
conditional on the adjustment covariate being zero in a litter. This is not ideal since toxi-
cologists are ultimately interested in malformation risk at the population level, not at the
litter-speciﬁc level (Theoretically, the adjustment variable should be zero on average, but
this has not been observed in datasets). The proposed model has an advantage over both
latent normal methods in that it models death risk and malformation risk in a straight-
forward matter, but also does not rely on adjustment covariates to relax conditional in-
141dependence. Thus, the dose-response parameter for conditional malformation can be
safely interpreted as the population level effect of dose. In addition, the Plackett-Dale
framework allows for assuming a Bernoulli random variable for death and conditional
malformation rather than a latent normal. This allows for the theoretically justiﬁed use
of the more widely used logit link function for modeling death and malformation rather
than the probit link.
Furthermore, Simulations conducted in chapter 4 suggest the joint risk BMD calcu-
lation method proposed for this model is much more accurate than naive methods that
assume conditional independence or the ad-hoc non-naive method developed for Carey’s
method, at leastinhighcorrelation scenarios. Giventhat theultimategoal ofthesestudies
is risk assessment, this is a very promising ﬁnding.
5.3 Limitations
The same BMD bias assessment simulations also fond that the proposed method’s BMDs
overestimated the bias when correlation was low, suggesting that the method is not nec-
essarily appropriate for all data patterns. The second order parameter estimates also tend
to have high variances, making any dose-response trend in the association parameters
harder to detect in studies with small sample sizes. This is especially problematic for
BMD calculations since they rely on the estimate of the hierarchical association parameter.
Simulations conducted showed that the BMD calculations are fairly robust to misspeci-
ﬁcation of the correlation parameter for certain data patterns. However, it is possible
this may be of concern for scenarios where the dose-response trend for the association
parameter is more extreme.
The high variance of the second order parameters also affect the statistical inference
for the BMDs. The BMDL calculations account for uncertainty in the  dm parameter.
In many data patterns, we see that even as the BMD calculations are the most accurate
for the proposed model, they are the least precise and have lower BMDLs than other
142methods. Thus, even while we observed that other methods were overly conservative in
BMD estimation, in practice, the proposed method can have the lowest BMDL and thus,
be the most conservative approach, negating any practical advantage the method may
have in terms of accuracy.
A signiﬁcant limitation of the model, because it considers pairs of fetuses as the unit
of data, is its inability to include fetus-level effects. In the context of these toxicity studies,
studying the population level effect of dose on the outcomes is a priority so including
fetus-level effects are not necessary. However, not being able to include individual-level
covariates limits the use of this model outside of this somewhat narrow context.
Finally, extending the Plackett-Dale approach to include other outcomes, namely lit-
ter weight, is not as straightforward as methods that assume a latent normal distribution.
The Plackett-Dale distribution is well-suited for modeling mixed outcomes. However, the
frameworkwedeveloped wouldincludemanymoresecond orderparameterstoestimate
if the method were to be extended to include fetal weight. This, in turn may decrease the
precision of the model signiﬁcantly, and may even lead to a lack of stability. Estimation of
the parameters is also likely to be very computationally intensive if fetal weights were to
be included. In the proposed method, for each type of pairing, there are at most four pos-
sible outcomes, greatly simplifying the computations for parameter estimation. No such
shortcut is likely to exist if a continuous outcome is introduced into the model. In addi-
tion, as the method is based on bivariate Plackett-Dale distribution, there is no intuitive
method for calculating joint risk for three outcomes.
5.4 Future Research
The Plackett-Dale approach we developed to modeling hierarchical outcomes, as yet,
does not include fetal weight. An obvious next step would be expand the model to in-
clude this outcome. However, as outlined in section 5.3, computational difﬁculties can
be foreseen using this approach, and the resulting model may not be all that pragmatic
143to use. However, there is much to be studied concerning the method already developed.
More extensive simulations to study the model’s behavior, under a wider variety of sim-
ulation scenarios, would be useful in understanding in what circumstances, if at all, the
model will break down. It would also be of great interest to get a better understanding of
which data patterns the BMD estimates are the most accurate in, and which data patterns
the BMD estimates tend to be biased in. In particular, the thesis did not explore how the
model is affected by varying correlation dose-responses. It would be of interest to see
how the model behaves in scenarios, for example, where the hierarchical correlation is
low but death and malformation correlation is high, and how that differs from scenarios
where all three correlations are high.
Part of the reason this kind of detailed investigation of how changes in speciﬁc cor-
relation parameters affect model performance and behavior was not done is that certain
combinations of malformation probability and correlation parameter values leads to a
correlation matrix for ~ mj~ d that is not positive deﬁnite. A more thorough investigation of
what combinations are possible for using Carey’s latent normal framework to simulate
data may act as a useful guide for any future work in the ﬁeld, especially for conducting
simulations for methods not based on a full-likelihood model. A comparison of the data
patterns between data simulated from Carey’s method and Christensen’s method may
also be of interest. In particular, how much the single correlation parameter from Chris-
tensen’s model contributes to conditional dependence has not been studied, and may be
of interest to researchers considering using its latent normal framework for simulating
data.
Another research path that is potentially of great pragmatic use is to develop simple
diagnostic methods for conditional dependence. Carey’s model’s adjustment term pa-
rameter may potentially serve as as a theoretically justiﬁed diagnostic statistic. Alterna-
tively, diagnostic plots that are easily interpreted and are informative could be developed.
Variations of plotting the distribution of malformation rate and fetal weight against death
rate and dose could provide insight for toxicologists who want an intuitive understand-
144ing of how much the conditional independence assumption is violated.
Examining different approaches for BMD estimation using Carey’s model may also
be of interest. The differences between using the sum of the adjustment terms at the in-
dividual level and at the litter-level, for example, could be examined. A more formal
development of integrating out the adjustment term to obtain a marginal joint risk esti-
mate may also be possible. Since Carey’s method is not computationally intensive and
easy to implement, and had relative differences between BMDs and BMDLs that were
comparable to naive methods, being able to obtain accurate joint BMD estimates with
this model would be very useful to toxicologists.
Finally, while this thesis focused entirely on the frequentist approach to the statistical
problems present in this data, a Bayesian approach to the problem also shows promise.
Indeed, given the multiple layers of hierarchy present in the data, a Bayesian approach
may be well suited for the statistical issues present in the data. Exploring a way to model
the data that not only explicitly assumes conditional dependence, but also can estimate
the correlation parameter deﬁning the conditional dependence, under a Bayesian frame-
work could be worth pursuing.
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Supplementary material for chapter 4
A.1 Models ﬁt
For the EG data set, the models ﬁt are as follows:
logit(pd) = d0 + d1dose
ln( d) = d0
logit(pmj d) = m0 + m1dose + m2dose
2
ln( m) = m0
ln( dm) = dm0
The parameter estimates are shown in table A.1.
For the 2,4,5-T data set, the models ﬁt are as follows:
logit(pd) = d0 + d1dose + d2dose
2
ln( d) = d0 + d1dose
logit(pmj d) = m0 + m1dose
ln( m) = m0 + m1dose
ln( dm) = dm0
The parameter estimates are shown in table A.1.
146Table A.1: Parameter Estimates, Standard Errors, and 95% Conﬁdence Intervals for EG
mice data
param estimate standard error 95% conﬁdence interval
d0 -2.20 0.180 (-2.55, -1.85)
d1 0.264 0.101 (0.07, 0.46)
d0 0.521 0.139 (0.25, 0.79)
m0 -5.26 0.563 (-6.36, -4.16)
m1 4.60 0.804 (3.02, 6.18)
m2 -0.917 0.219 (-1.35, -0.49)
m0 1.23 0.219 (0.80, 1.66)
dm0 0.218 0.158 (-0.09, 0.528)
Table A.2: Parameter Estimates, Standard Errors, and 95% Conﬁdenece Intervals for 2,4,5-
T data (CD-1 strain)
param estimate standard error 95% conﬁdence interval
d0 -2.15 0.0551 (-2.26, -2.04)
d1 -3.58 3.75 (-10.9, 3.77)
d2 304.23 50.69 (204.9, 403.6)
d0 0.887 0.149 (0.596, 1.19)
d1 16.7 3.01 (10.8, 22.6)
m0 -6.33 0.174 (-6.68,-5.99)
m1 79.3 3.06 (73.3, 85.3)
m0 3.51 0.367 ( 2.79, 4.23)
m1 -18.6 5.94 (-30.2, -6.90)
dm0 0.613 0.0739 (0.468, 0.758)
147A.2 Summary statistics of adjustment covariates for EG
and 2,4,5-T data
For the EG data set, the mean adjustment covariate is -0.0506 (95% conﬁdence interval of
(-0.126, 0.0248) ) and the median adjustment covariate is -0.306 (95% conﬁdence interval
of (-0.311, -0.225)), while the mean for the 2,4,5-T data set is -.0454 (95% conﬁdence in-
terval of (-0.0669, -0.0240)) and the median is -0.509 (95% conﬁdence interval of (-0.509,
-0.482)) . Given that the distribution of the adjustment covariates are right-skewed for
both distributions, perhaps the median is the more meaningful metric for these cases.
A.3 Parameter values for the simulation scenarios
The cutoff values for death and malformation (cdk and cmk, respectively), as well as the
between-death correlation (d), between-malformation correlation (d), and hierarchical
correlation (dm), for the 8 simulation scenarios detailed from section 4.5.1 are shown in
Table A.3. The correlation parameters for the 10 simulation scenarios from section 4.5.3
are shown in Table A.3.
A.4 Estimates of mean  dm from simulation scenarios
Table A.4 shows the median  dm estimates from the model, along with the corresponding
dose and corresponding dm from the simulation scenarios presented in section 4.5.6.
A.5 Marginal probabilities for P-D method for joint risk
assessment
Using G3 to describe risk for a single fetus, and that P(H) = G3(0;0), it is possible to
derive the marginal probalities for each outcome. We know that P(D) = pd = (pd  
148Table A.3: Parameter values for the 8 simulation scenarios
Scenario 1 Scenario 2
dose cdk cmk d m dm dose cdk cmk d m dm
0 -1.175 -1.200 0.000 0.000 0.000 0 -1.200 -1.200 0.000 0.000 0.000
0.75 -1.075 -0.900 0.132 0.108 .120 0.75 -0.900 -0.900 0.066 0.054 0.060
1.5 -0.960 -0.590 0.284 0.246 .282 1.5 -0.590 -0.590 0.142 0.123 0.141
3.0 -0.725 0.110 0.600 0.600 .600 3.0 0.110 0.110 0.300 0.300 0.300
Scenario 3 Scenario 4
dose cdk cmk d m dm dose cdk cmk d m dm
0 -1.200 -1.200 0.000 0.000 0.000 0 -1.200 -1.175 0.000 0.000 0.000
0.75 -0.900 -1.150 0.132 0.108 .120 0.75 -0.900 -1.075 0.066 0.054 0.060
1.5 -0.590 -0.950 0.284 0.246 .282 1.5 -0.590 -0.960 0.142 0.123 0.141
3.0 0.110 0.400 0.600 0.600 .600 3.0 0.110 -0.725 0.300 0.300 0.300
Scenario 5 Scenario 6
dose cdk cmk d m dm dose cdk cmk d m dm
0 -1.175 -1.200 0.000 0.000 0.000 0 -1.175 -1.200 0.000 0.000 0.000
0.75 -1.075 -0.900 0.132 0.108 .120 0.75 -1.075 -0.900 0.066 0.054 0.060
1.5 -0.960 -0.590 0.284 0.246 .282 1.5 -0.960 -0.590 0.142 0.123 0.141
3.0 -0.725 0.110 0.600 0.600 .600 3.0 -0.725 0.110 0.300 0.300 0.300
Scenario 7 Scenario 8
dose cdk cmk d m dm dose cdk cmk d m dm
0 -1.175 -1.200 0.000 0.000 0.000 0 -1.200 -1.200 0.000 0.000 0.000
0.75 -1.075 -1.075 0.132 0.108 0.120 0.75 -0.900 -1.150 0.132 0.108 .120
1.5 -0.960 -0.900 0.284 0.246 0.282 1.5 -0.590 -0.950 0.284 0.246 .282
3.0 -0.725 -0.500 0.600 0.600 0.600 3.0 0.110 0.400 0.600 0.600 .600
149Table A.4:  parameters for 10 simulation scenarios for examining how the difference in
methods changes as the hierarchical correlation changes
Scenario 1* Scenario 2*
dose d m dm dose d m dm
0 0.000 0.000 0.000 0 0.000 0.000 0.000
0.75 0.000 0.000 0.000 0.75 0.0022 0.018 0.020
1.5 0.000 0.000 0.000 1.5 0.0473 0.041 0.047
3.0 0.000 0.000 0.000 3.0 0.100 0.100 0.100
Scenario 3* Scenario 4*
dose d m dm dose d m dm
0 0.000 0.000 0.000 0 0.000 0.000 0.000
0.75 0.044 0.036 0.040 0.75 0.066 0.054 0.060
1.5 0.0947 0.082 0.094 1.5 0.142 0.123 0.141
3.0 0.200 0.200 0.200 3.0 0.300 0.300 0.300
Scenario 5* Scenario 6*
dose d m dm dose d m dm
0 0.000 0.000 0.000 0 0.000 0.000 0.000
0.75 0.088 0.072 0.080 0.75 0.110 0.090 0.100
1.5 0.189 0.164 0.188 1.5 0.237 0.205 0.235
3.0 0.400 0.400 0.400 3.0 0.500 0.500 0.500
Scenario 7* Scenario 8*
dose d m dm dose d m dm
0 0.000 0.000 0.000 0 0.000 0.000 0.000
0.75 0.132 0.108 0.120 0.75 0.154 0.126 0.140
1.5 0.284 0.246 0.282 1.5 0.331 0.287 0.329
3.0 0.600 0.600 0.600 3.0 0.700 0.700 0.700
Scenario 9* Scenario 10*
dose d m dm dose d m dm
0 0.000 0.000 0.000 0 0.000 0.000 0.000
0.75 0.176 0.144 0.160 0.75 0.198 0.162 0.180
1.5 0.379 0.328 0.376 1.5 0.426 0.369 0.423
3.0 0.800 0.800 0.800 3.0 0.900 0.900 0.900
Table A.5: dm parameter values for simulation scenarios A, B, C, and D, and their corre-
sponding median  dm values by dose
dose dm median  dm
A B C D A B C D
0 0 0 0 0.197 1.002 1.028 1.052 1.848
0.75 0 0.0749 0.171 0.268 1.002 1.360 1.592 2.148
1.5 0 0.149 0.332 0.336 1.001 1.484 2.408 2.496
3.0 0 0.291 0.598 0.462 1.000 2.142 5.509 3.372
150Table A.6: Mean, median and stardard deviations for the death BMD and BMDLs, as
well as the empirical BMDL values, from all eight simulation scenarios for the P-D and
Carey/Naive method
Scenario Method mean BMD median BMD BMD SD empirical BMDL
1 P-D 0.523 0.517 0.0557 0.443
Carey/Naive 0.523 0.517 0.0561 0.443
2 P-D 0.0408 0.515 0.0401 0.458
Carey/Naive 0.519 0.515 0.0401 0.458
3 P-D 0.517 0.512 0.0517 0.441
Carey/Naive 0.521 0.516 0.0538 0.443
4 P-D 0.515 0.512 0.0383 0.456
Carey/Naive 0.517 0.514 0.0389 0.457
5 P-D 2.87 1.36 46.9 0.896
Carey/Naive 6.93e+11 1.37 4.85e+13 0.892
6 P-D 1.66 1.37 2.94 0.964
Carey/Naive 1.67 1.37 2.48 0.961
7 P-D 2.86 1.36 47.0 0.895
Carey/Naive 6.94e+11 1.36 4.86e+13 0.892
8 P-D 1.65 1.36 2.95 0.960
Carey/Naive 1.66 1.36 2.48 0.960
F3(pd;pmj d; dm)) + F3(pd;pmj d; dm) = G3(mjj  Dj = 0;Dj0 = 1) + G3(mjj  Dj = 1;Dj0 = 1) =
G3(0;1) + G3(1;1). And since we already assume P(H) = G3(0;0), this leaves us with
P(M) = G3(1;0). Thus, in our interpretation, the marignal probability for malformation
decreases as  dm increases.
A.6 Summary statistics for death and malformation BMDs
and BMDLs
Table A.6 gives summary statistics for the death BMDs and BMDLs for the 8 simulatoin
scenarios presented in section 4.5.1. Table A.6 shows the same summary statistics for
malformation BMDs and BMDLs.
151Table A.7: Mean, median and standard deviations for the malformation BMD and
BMDLs, as well as the empirical BMDL values, from all eight simulation scenarios for
all ﬁve methods
Scenario Method mean BMD median BMD BMD SD empirical BMDL
1 P-D 0.786 0.756 0.161 0.598
Carey / Naive 0.589 0.576 0.0902 0.475
Carey / Carey 0.691 0.676 0.107 0.553
Naive / Naive 0.760 0.728 0.170 0.575
2 P-D 0.616 0.515 0.0401 0.524
Carey / Naive 0.547 0.543 0.0524 0.471
Carey / Carey 0.589 0.584 0.0562 0.507
Naive / Naive 0.604 0.597 0.0635 0.514
3 P-D 9.59 2.49 246.6 1.29
Carey / Naive 7.16 1.41 348.9 0.892
Carey / Carey 8.08 1.64 388.5 1.03
Naive / Naive 5.31 2.31 24.7 1.22
4 P-D 7.64 2.73 56.5 1.39
Carey / Naive 3.97 1.93 23.1 1.12
Carey / Carey 4.26 2.07 24.9 1.20
Naive / Naive 12.3 2.64 185.5 1.36
5 P-D 0.603 0.596 0.0697 0.504
Carey / Naive 0.528 0.523 0.0574 0.444
Carey / Carey 0.597 0.591 0.0619 0.506
Naive / Naive 0.576 0.569 0.0668 0.481
6 P-D 0.560 0.557 0.0478 0.489
Carey / Naive 0.528 0.525 0.0449 0.460
Carey / Carey 0.558 0.555 0.0467 0.488
Naive / Naive 0.548 0.545 0.0462 0.479
7 P-D 1.89 1.40 4.75 0.953
Carey / Naive 1.51 1.14 8.19 0.791
Carey / Carey 1.69 1.28 8.97 0.904
Naive / Naive 1.65 1.28 3.56 0.884
8 P-D 3.61 1.84 31.8 1.15
Carey / Naive 2.33 1.63 4.59 1.05
Carey / Carey 2.46 1.72 4.82 1.11
Naive / Naive 2.63 1.73 10.5 1.10
152Table A.8: Mean joint BMD, median joint BMD, median joint BMDL, and empirical joint
BMDL for BMD calculation methods 1, 2, and 4, for simulation scenarios 5 and 6
Scenario Method Mean BMDL Median BMD Median BMDL Empirical BMDL
5 1 0.513 0.486 0.361 0.380
2 0.512 0.492 0.371 0.391
4 0.514 0.493 0.369 0.392
6 1 0.447 0.438 0.354 0.367
2 0.451 0.442 0.359 0.373
4 0.451 0.443 0.358 0.373
A.7 Summary statistics of death and malformation BMDs
and BMDLs
Table A.7 shows the mean BMD, median BMD, median BMDL, and empirical BMDL for
BMD calculation methods 1, 2, and 4, for simulation scenarios 5 and 6.
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